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Abstract 
There are three different types of opioid receptor, namely mu, delta and kappa. 
Morphine and related clinically usefull analgesics exert their actions through the mu-
opioid receptor. Such compounds represent a huge structural diversity, including both 
peptides and alkaloids. Nevertheless, there exists a common pharmacophore 
comprising two cntical features, namely an amine nitrogen and an aromatic ring, 
usually with a hydroxyl substituent; the spatial relationship between them is also vital. 
In the first part of this work the roles of the aromatic ring and hydroxyl substituent in 
opioid peptides were investigated. Twenty-five cyclic tetrapeptides with variations m 
the first amino-acid and in the size of the cyclic peptide ring were characterised for 
receptor affinity and specificity using radio ligand binding assays, and for relative 
efficacy using f 5S]-GTPyS binding assays. The data show that neither the hydroxyl 
nor the aromatic ring are critical for high affinity, potency or efficacy at the mu-
opioid receptor, but this does depend upon the ring-size of the tetrapeptide. 
In the second part, an aminosteroid (SC17599) which lacks both an aromatic ring and 
a para-hydroxyl substituent was also shown to have good affmity, selectivity and 
efficacy at the mu-opioid receptor. Molecular modeling of this compound has been 
used to investigate the relationship between SC17599 and more traditional opioid 
ligands in three ways. Firstly, the pharmacophore for mu-opioid ligands has been 
refined using GASP (Genetic Analysis of Spatial Parameters). Secondly, the docking 
interaction of SC17599 with the mu op10id receptor has been compared with the 
docking of morphine using GOLD (Genetic Optimization for Ligand Docking). 
Thirdly, QSAR (Quantitative Structure-Activity Relationships) of morphine-like 
opioid ligands and SC17599 have been investigated using FBSS (Field Based 
Similarity Search) and CoMF A (Comparative Molecular Field Analysis). 
The above findings have profound implications for the future design of mu opioid 
Jigands and for the accepted theories of the binding of such ligands to the mu opioid 
receptor. 
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Chapter 1 
GENERAL INTRODUCTION 
Chapter I: Introduction 
1.1 History of opioids and opioid receptors 
The sensation of pain is integral to human existence and is generally defined as 
comprising of separate sensory and emotional components. Pain is typically the result 
of noxious stimuli to which our bodies respond when threatened with actual or 
potential tissue damage and at least in part serves as a warning. The degree of 
sensation can range from mildly unpleasant to physically debilitating. Some of the 
earliest medicines recorded in human history are analgesics, substances which act to 
control pain by alleviating one or both components. For example, the use of opium, 
the latex obtained by cutting the unripe seed capsules of the poppy Papaver 
somniferum, predates the written word. 
In 1803 the German pharmacist Sertiimer isolated the active constituent of opium, 
which he named Morphine, after Morpheus the god of dreams from the works of 
Ovid. (Figure 1.1 ). However, it took 120 years for the chemical structure of morphine 
to be elucidated [Gulland and Robinson, 1923], and another 30 until the first total 
synthesis of the molecule was achieved [Gates and Tschudi, 1952]. 
HO 
Figure 1.1 
' 
' OH 
Morphine 
Morphine and related analgesics, collectively termed opiates, are unique in their 
ability to alleviate pain without affecting the primary sensory modalities, namely 
vision, touch, hearing, taste and smell. Opiates are also able to reduce the emotional 
components of pain, including fear, ariXiety and tension. Thus preparations containing 
morphine rapidly became the treatment of choice m cases of moderate to severe pain. 
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However, morphine is by no means an ideal analgesic agent. Patients can become 
tolerant to its effects, such that escalating doses are required to provide the same level 
of pain relief. In addition, it is liable to produce dependence, whereby the user 
(typically a recreational user) develops a psychological and/or physical need for the 
drug. In addition, morphine can cause drowsiness, respiratory depression, reduced 
gastro-intestinal motility, nausea and vomiting [Rang and Dale, 1995]. Therefore 
researchers became interested in understanding the mechanisms behind the actions of 
morphine in order to create alternative analgesics with reduced side effects, 
particularly abuse potential. As the relatively new science of pharmacology advanced, 
experiments were carried out first on whole animals, then on isolated tissue 
preparations, more recently using membranes prepared from cultured cells 
endogenously expressing opioid receptors, and in the last few years on membranes 
from cells expressing recombinant opioid receptors. 
1.1.1 Endogenous opioid peptid es 
The German pharmacologist Ehrlich proposed in the late nineteenth century that 
'corpora non agunt nisifzxata', or 'a substance will not act unless it is bound'. In the 
late 1960's Martin suggested that specific binding sites for opiates must exist in the 
brain [Martin, 1967], and in the early 1970's Goldstein and eo-workers began 
developing an assay system which used radiolabeled compounds to locate these sites 
[Goldstein et a/, 1971]. In 1973 several groups working independently were able to 
show that opiates bound to receptors in membranes from central nervous system 
tissues [Pert and Snyder, 1973; Simon et a/, 1973; Terenius, 1973; Wong and Hong, 
1973]. The only logical explanation for the existence of such receptors is that they act 
as binding sites for endogenous substances, sparking a race to discover the identity of 
these substances. In 1975 Hughes and Kosterlitz isolated two pentapeptides from 
porcine brain which had opiate-like activity in an in vitro bioassay which measures 
inhibition of the electrically stimulated contractions of smooth muscle [Hughes et a/, 
1975a; Hughes et a/, 1975b ]. The two peptides differed only in their carboxy-terminal 
amino acid and were named the Enkephalins (Figure 1.2). 
3 
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a) Tyr-Gly-Gly-Phe-Met b) Tyr-Gly-Gly-Phe-Leu 
Figure 1.2 a) [Met5]enkephalin and b) [Leu5]enkephalin. 
The [Met5]enkephalin sequence is found at the arnino-termmus of the endogenous 
peptide ~-endorphin, winch also proved to have high affmity for opiate binding sites 
[Bradbury et a/, 1976] (Figure 1.3). Just as ~-endorphin is a carboxy-terminal 
extension of [Met5]-enkephalin, the dynorphins were discovered as opioid-active 
extensions of[Leu5]-enkephalin [Goldstein et a/, 1979; Goldstein et a/, 1981] (Figure 
1.3). Other families of endogenous peptides are the dermorphins [Montecucchi et a/, 
1981], the deltorphins [Kreil et a/, 1989; Erspamer et a/, 1989] and the endomorphins 
[Zadina et a/, 1997] (Figure 1.3). All retain the Tyr1 residue and a second aromatic 
amino acid in either the 3 or 4 position. The new term opioids was coined to 
differentiate these newly discovered endogenous peptides from the morphine-like 
opiates. 
~-Endorphin 
Dynorphin 1-17 
Dermorphin 
Deltorphin 1 
Endomorphin 1 
Figure 1.3 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Glu-Lys-
Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-
Ile-Ile-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-
Lys-Trp-Asp-Asn 
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 
Tyr-o-Ala-Phe-Asp-Val-Val-Gly-NH2 
Tyr-Pro-Trp-Phe-NH2 
Structures of some endogenous opioid ligands. 
1.1.2 Opzoid receptors and lzgands 
The existence of multiple types of endogenous Iigands nicely complemented the 
proposed existence of multiple types of opioid receptor. The first experimental 
evidence for multiple receptor types came from in vivo studies by Martin [Martin et 
a/, 1976]. This pioneering group looked for the ability of various compounds to 
4 
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prevent the appearance of the withdrawal symptoms which develop after an animal is 
no longer administered a drug on which it has become dependent. The authors 
identified three groups of drugs, individual members of which would substitute only 
for compounds within the same group. Thus they proposed the existence of three 
types of opioid receptor, named after the prototypical drug in each group -mu 
@orphine ), ~appa (!etocyclazocine) and ~igma @KF 10,04 7 or N-
allylnormetazocine ). However, opioid receptors are defined by their ability to bind 
naloxone (Figure 1.4), and since many of the effects mediated by the sigma receptor 
are not naloxone reversible it is no longer considered an opioid receptor [Walker et a/, 
1990]. 
HO 0 
Figure 1.4 Naloxone 
When comparing the effects of morphine and the enkephalins in the inhibition of 
electrically stimulated contractions in guinea pig ileum and mouse vas deferens, 
Kosterlitz and colleagues found that the rank order of potency was different in the two 
tissues. Thus, they proposed the existence of a third opioid receptor, the delta 
receptor, named after the tissue in which it was discovered (mouse vas deferens) 
[Lord et a/, 1977]. 
Of the endogenous opioid peptides, [3-endorplun and the enkephalins bind to both the 
mu- and delta-receptors [Paterson et a/, 1983], the dynorphin family ofpeptides bind 
preferentially to kappa receptors, the dennorphins and the endomorphins are selective 
for the mu receptor, whilst the deltorphins are highly selective for delta receptors, as 
their name implies. The pioneering work of the 1970's on multiple opioid receptor 
5 
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types was greatly hindered by the lack ofligands with both high selectivity and 
resistance to enzymatic degradation. In the searcl! [or better research tools and 
analgesic agents, a huge number of peptide and non-peptide opioid ligands were 
synthesised and older ligands recharacterised, many of which offer high affinity, 
improved selectivity and increased stability. For example, the phenylpiperidine 
derivative fentanyl [Janssen et al, 1963] and the synthetic peptide DAMGO ([D-Aia2, 
N-Me-Phe4, Gly-ol5]enkephalin) [Handa et a!, 1981] are both excellent mu ligands. 
Commonly used delta ligands include DADLE {[D-Aia2, D-Leu5]enkephalin) [Magnan 
et al, 1982], DPDPE ([o-Pen2, D-Pen5]enkephalin) [Mosberg et al, 1983] and BW 
3 73 ,U86 ( ( + )-4-[ ( aR)-a-( (2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxy-
benzyi]-N,N-diethylbenzamide) [Chang et al, 1993]. Selective kappa ligands include 
U69,593 (5R-(5a, 7a,8l3)-N-methyi-N-[7-(1-pyrrolidinyl)-1-oxaspiro[ 4.5]dec-8-yl]-4-
benzeneacetamide) [Lahti et al, 1985] and Cl 977 (5R-(5a,7a,8(3)-N-methyl-N-[7-(1-
pyrrolidinyl)-1-oxaspiro[ 4.5]dec-8-yl]-4-benzofuranacetamide) [Hunter et al, 1990] 
(Table 1.1, Figure 1.5). A selection of high affinity compounds displaying lesser 
selectivity are also widely used, for example the kappa agonists EKC 
(ethylketocyclazocine) [Harris and Sethy, 1980] and bremazocine [Romer et at, 
1980]. 
Although excellent non-specific opioid antagonists such as naloxone [Takemori et al, 
1972] (Figure 1.4) are available, truly selective antagonists have in general proved 
more elusive than their agonist counterparts. However, the mu selective CTOP (D-
Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2) [Pelton et al, 1986], the delta antagonist 
NTI (naltrindole) [Porthogese et a!, 1988a] and the kappa antagonist nor-BNI 
(norbinaltorphimine) [Porthogese et al, 1987] are examples that are all widely used, 
and there are many others (Table 1.1, Figure 1.5). 
6 
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Receptor 
Agonists Antagonists 
Type 
mu DAM GO CTOP 
fentanyl CTAP 
morphiceptin cyprod1me 
delta DPDPE ICI 174,864 
DSLET naltrindole 
DAD LE naltrlben 
kappa U69,593 norbinaltorphimine 
CI977 
Table 1.1 Highly selective opioid ligands. 
The next logical step in opioid pham~acology was to isolate the three opioid receptors 
and determine their amino acid sequence. However, this proved difficult due to both 
the paucity of opioid receptors in most tissues and their !ability in detergent [Loh and 
Smith, 1990] which is the first step in traditional purification schemes. Indeed, it was 
not until1992 that two groups published independent descriptions of the expression 
cloning of cDNA encoding the delta receptor from the neuroblastoma x glioma 
(NG108-15) cell line [Evans et a/, 1992; Kieffer et a/, 1992]. 
In the year following this breakthrough, a multitude of reports appeared detailing the 
cloning of other opioid receptors: the rat mu-opioid receptor [Chen et a/, 1993a; 
Fukuda et a/, 1993; Wang et a/, 1993], the rat kappa-opioid receptor [Chen et a/, 
1993b; Minami et a/, 1993; Li et a/, 1993; Meng et a/, 1993], the mouse kappa-opioid 
receptor [Yasuda et a/, 1993], and the rat delta-opioid receptor [Fukuda, Kato, Mori, 
Nishi, and Takeshima, 1993]. In the next two years, all three human opioid receptors 
were cloned: mu [Wang et a/, 1994], delta [Knapp et a/, 1994; Simonin et a/, 1994], 
and kappa [Simonin et a/, 1995]. 
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Based on the differential effects of the antagonist naloxonazine on the various 
physiological actions of morphine in vzvo [Ling et al, 1985], it has been suggested that 
there may be two subtypes of the mu opioid receptor, termed Jlt and Jl2 [Pastemak and 
Wood, 1986]. Similar divisions have been proposed for both the delta and kappa 
receptors, based on pharmacology (delta) and binding data (kappa). However, there is 
only a single occurrence of each opioid receptor on the genome [Thompson et al, 
1993], and all of the receptors of each type cloned to date from different sources have 
virtually identical sequences and properties. Thus, the idea of subtypes within the mu, 
delta and kappa receptorpopulations remains controversial [Fowler and Fraser, 1994]. 
The observed discrepancies in the actions ofligands such as naloxonazine may be the 
result of splice variants or post-translational modifications of a single receptor gene 
[Rossi et al, 1995]. 
In 1994 a receptor type was discovered with an amino acid sequence very similar to 
the opioid receptors, but which did not bind naloxone and is therefore not considered 
part of the immediate opioid receptor family. Several research groups published 
details of this ORL1 (opioid-receptor-like) or Orphanin receptor almost 
simultaneously [Mollereau et al, 1994; Bunzow et al, 1994; Fukuda et al, 1994; Chen 
et al, 1994; Wang et al, 1994]. The full extent of the pharmacological and 
physiological effects mediated by the ORL1 receptor are not yet fully understood, but 
it appears to mediate certain 'anti-opioid' actions, such as the inhibition of opioid 
induced analgesia. The endogenous ligand for the _orphanin receptor was quickly 
isolated by two groups (Figure 1.6), and was named orphanin FQ by one [Reinscheid 
et al, 1995], and nociceptin by the other [Meuneir et al, 1995] due to its apparent 
ability to cause hyperalgesia. Nociceptin is unlike the endogenous opioid peptides 
since it contains Phe rather than Tyr as theN-terminal residue. Despite the similarities 
in sequence between both the ORL1 and opioid receptors and between their 
endogenous hgands, all known opioids exhibit low or negligible affinity for the ORL 1 
receptor. Likewise, all ORL1 ligands show low affinity at mu, delta and kappa opioid 
receptors. Subsequently, an endogenous antagonist with specificity for the ORL 1 
receptor has been discovered, named nocistatin [Okuda-Ashitaka et al, 1998]. 
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Phe-Giy-Giy-Phe-Thr-Giy-Aia-Arg-Lys-Ser-Aia-Arg-Lys-Leu-Aia-Asn-Gln 
Figure 1.6 The endogenous ligand for the ORLl receptor, Orphanin FQ or 
Nociceptin. 
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1.2 Structure of the opioid receptors 
The opioid receptors belong to the superfamily of seven transmembrane domain 
spanning G-protein coupled receptors [Uhl et al, 1994], currently numbenng over 200 
members. These receptors share considerable structural homology, despite the huge 
diversity of ligands with which they interact. This reflects their common mechanism 
of action, namely an ability to activate intracellular proteins (G proteins) following 
agonist occupation. To date, although many G protein coupled receptors have been 
cloned, none has been crystallised. However, much structural detail has been inferred 
from the known structure ofbacteriorhodopsin, which was isolated from bacterial 
culture and its structure resolved in 1975 [Henderson and Unwin, 1975]. Each G 
protein coupled receptor is a single polypeptide chain consisting of approximately 
350-500 amino acids which spans the cell membrane seven times via a. helical 
segments 20-28 amino acids in length. The amino-tenninus resides in the extracellular 
space whilst the carboxy-terminus lies within the cell. This general structure is shown 
schematically in Figure 1.8, using the rat mu opioid receptor as an example. 
The three opioid receptors are closely related. For example, the mouse delta, mouse 
kappa and rat mu opioid receptors have approximately 57% sequence homology 
[Reisine and Bell, 1993] (Figure 1.7). The greatest similarities in sequence are seen in 
> 
the three intracellular loops, transmembrane domains II, ill, V and VII, and the first 
extracellular loop. The remaining regions exhibit decreasing sequence homology in 
the order: transmembrane domains VI > I> IV > extracellular loops 2 > 3 (Table 1.2). 
The amino- and carboxy- terminals exhibit little similarity in sequence or even in size. 
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Figure 1.7 . Sequence alignment of the mouse delta [Evans et a/, 1992], mouse kappa [Yasuda et a/, 1993] and rat mu [Chen et a/, 
1993a] opioid receptors. Underlined regions mdicate amino acids conserved between all three receptors, adapted 
from [Reisine and Bell, 1993]. 
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Loop Sequence Transmembrane Sequence 
homology(%) domain homology(%) 
Intracellular 1 90 I 45 
Intracellular 2 91 II 84 
Intracellular 3 78 III 82 
IV 30 
Extracellular 1 67 V 71 
Extracellular 2 24 VI 50 
Extracellular 3 7 VII 71 
Table 1.2 Sequence homology amongst the three opioid receptors, by region. 
The molecular weight of the opioid receptors as predicted from their amino acid 
sequences is much lower than that observed using physiochemical techniques such as 
electrophoresis. The difference in molecular weight comes from the addition of small 
chemical groups such as palmitoyl, myristoyl or glycosyl during post-translational 
modification. The three opioid receptors have a variable nmnber of consensus sites for 
N-linked glycosylation on the extracellular amino-terminus; the mu receptor contains 
five such sites (asparagine residues 9, 12, 33, 40, 48 in the hmnan mu opioid 
receptor), whilst the delta and kappa receptors each contain two (Figure 1.8). Whilst 
there may be tissue-specific differences in the glycosylation patterns of these sites, 
they do not seem to be implicated in ligand bindmg or receptor activation [Rands et 
al, 1990). The carboxy-termmus of all three opioid receptors contain a highly 
conserved cysteine residue, as indeed do many other G protein coupled receptors. 
Palmitoylation of this residue, for example Cys353 in the hmnan mu receptor 
[O'Dowd et al, 1988], constrains the structure ofthe receptor by anchoring a part of 
the carboxy-terminus to the intracellular face of the plasma membrane, in effect 
forming a fourth intracellular loop (Figure 1.8). 
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G protein coupled receptors also contain a number of other conserved cysteine 
residues which may play an important role in constraining the structure of the receptor 
through the formation of intramolecular disulphide bridges. One such bridge links 
cysteine residues in the first and second extracellular loops, Cys 140 and Cys217 in the 
mu receptor, Cys121 and Cys198 in the delta receptor, and Cysl31 and Cys210 in the 
kappa receptor. In f3-adrenergic receptors, breaking this bridge by mutagenesis of 
either cysteme residue dramatically disrupts binding [Dixon et al, 1987]. In addition, 
opioid receptors lose the ability to bind ligands after treatment with compounds that 
destroy disulphide bonds [Smith and Simon, 1980]. Interestingly, the receptor is 
protected agrunst tlus effect in the presence of pre-bound ligand, implying that th1s 
disulphide bridge is close to the ligand binding region. 
All G protein coupled receptors possess an invariant aspartate residue in the third 
transmembrane domain. This residue, for example Asp147 in the human mu opioid 
receptor, is postulated to act as a counter-ion for the positively charged amino-group 
present in the majority ofligands for G protein coupled receptors [Dohlman et al, 
1991]. Mutation of this residue with neutral alanine or asparagine residues diminishes 
both agonist and antagonist binding [Surratt et al, 1994a]. The second transmembrane 
domain also contains a highly conserved aspartate residue (Asp 116 in the human mu 
opioid receptor) which is vital to binding of agonists but not antagonists in both mu 
and delta opioid receptors [Kong et al, 1993; Surratt et al, 1994b ]. This residue forms 
part of a binding site which can accommodate either a water molecule or aNa+ ion 
[Kong et al, 1993]. The presence ofNa +is predicted to disrupt a network of hydrogen 
bonds in this region which are vital to activation of the receptor, and hence Na+ 
decreases agorust but not antagonist binding. Mutation of Asp 116 mimics the 
presence ofNa +by disrupting the same hydrogen bonding network [Pogozheva et al, 
1998]. A histidine in transmembrane domain VI (His299 in the human mu opioid 
receptor) is implicated in ligand binding through interaction with the phenohc 
hydroxyl group moiety present in virtually all opioid peptides and many opiates. This 
residue can be protected from histidme-specific alkylating agents by the presence of 
opioid ligands [Spivak et al, 1997]. 
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A variety of other residues in the transmembrane domains have also been implicated 
in ligand binding; for example, Tyr148 [Befort et al, 1996] and Trp293 [Pogozheva et 
al, 1998], as well as Gin and Tyr in TM II, Cys, Lys, Val, Asp, Tyr and Met in TM 
III, Lys, Ile, and Phe in TM V, Trp, Ile, and His in TM VI and Cys, Ile, and Tyr in 
TMVII. 
The extracellular loops of the opioid receptors have been shown using molecular 
modelling techniques to lie across the top of the ligand binding cavity [Pogozheva et 
al, 1998]. Thus, they have been Implicated as at least partial determinants ofligand 
selectivity between the three opioid receptor subtypes [Fukuda et al, 1995; Wang et 
al, 1995]. 
The second intracellular loop of most G protein coupled receptors contains an 
extremely well conserved Asp-Arg-Tyr sequence. Point mutations in this region 
generally cause a drastic reduction in the ability of receptors to stimulate downstream 
effectors [Fraser et al, 1988; Zhu et al, 1994], indicating that this triplet of amino acid 
residues is of general Importance in the couphng of receptors to G proteins. A 
putative a-helical region near the C-terminus of the third intracellular loop is also 
implicated, since mutations which disrupt the tertiary structure of this region greatly 
diminish G protein coupling [Duerson et al, 1993]. The amino acid sequence ofthis 
region is such that one 'face' of the helix is primanly charged whilst the other is 
hydrophobic. Point mutations which disrupt this arrangement without altering tertiary 
structure also diminish G protein coupling [Bhiml et al, 1994]. 
All G protein coupled receptors contain sites which may be targets for 
phosphorylation by protein kinase enzymes. These may be important in the 
desensitisation of the receptor after occupancy by agonist, resulting in reduced 
response. In the mu opioid receptor such sites include Ser263 and Thr281 in the third 
intracellular loop and Ser3651ocated in the carboxy-terminus [Arden et al, 1995]. 
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Figure 1.8 Cartoon depicting the proposed seven membrane spanning domains of the 
rat mu opioid receptor. The single letter amino acid code has been used. 
Shaded amino acid residues are conserved in the majority of G protein 
coupled receptors (black) or between all three opioid receptors (light 
grey). Amino acid sequence and proposed topology was obtained from the 
Center for Opioid Research and Design, Department of Medicinal 
Chemistry, University of Minnesota. 
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1.3 Receptor-effector coupling via G proteins 
Activation of an opioid receptor by agonist leads to a celJular response via an 
extremely intricate signal transduction cascade. The imtial steps of this cascade 
involve interaction with, and activation of, a G protein. These are heterotrimeric 
proteins consisting of an a subumt and a tightly associated f3y dimer which separate 
only under denaturing conditions (Figure 1.9). They are called G proteins because the 
a subunit contains a site which binds a gnanine nucleotide. There are at least 20 
different known Ga, 5 Gf3 and 12 Gy subunits. Thus the number of possible distinct G 
protein trimer combinations is very large, and more than 30 have been reported. These 
are grouped into four major families according to the amino acid sequence of their a 
sub units, namely G,, G/G0 , Gq, and G12 [Hepler and Gilman, 1992]. The G protein is 
anchored to the intracelJular surface of the plasma membrane via an isoprenoid group 
attached to the y-subunit. The a-subunits of most G proteins are modified at the 
amino-terminus glycine residue by either a myristate (G1a and G1a) or palmitoyl (G,a 
and Gqa) group [Yamane andFung, 1993]. The Gprotein is thought to interact with 
the receptor through two regions of the a subunit which are in close proximity (Figure 
1.9) [Higashijima and Ross, 1991]; an a-helical area at the carboxy-terminus [Hanun 
et al, 1988; Weingarten et al, 1990] and another at the amino-terminus [Taylor et al, 
1994]. 
These G proteins, once activated, can couple in turn to a large variety of downstream 
effectors which typically regulate membrane conductance (K+ and Ca2+ ion channels) 
or levels of second messenger molecules ( adenylyl cyclase, guanylyl cyclase, 
phospholipase C and phospholipase A2) [Hille, 1992]. Until recently it was thought 
that only the a subunit coupled with downstream effector [Birnbaumer et al, 1990], 
whilst the f3y dimer acted in a regulatory role. However, it has become apparent that 
the f3y dimer can also activate a variety of effector systems [Tang and Giiman, 1991; 
Taussig et al, 1993]. 
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Ribbon model of a heterotrimeric G protein. Ga is green; G~ is yellow; and G'y is red . 
a) , view down the ax is ofG~y. b), view rotated 70 degree around the horizontal axis compared to (a). 
Adapted from [Lambright et a/, 1996]. 
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Opioid receptors have been shown to couple to and inhibit adenylyl cyclase via G,IG0 
proteins [Carter and Medzirhadsky, 1993], leading to decreased levels of the second 
messenger molecule cAMP (cyclic adenosme monophosphate). Indeed, inhibition of 
cAMP accumulation is often used as a functional measure of mu opioid agonist 
action. In addition, opioid receptors inhibit the activity of voltage gated Ca2+ channels 
[Seward et al, 1991] and activate K+ channels [Williams et al, 1988]. How does one 
particular receptor couple to a small subset of G proteins which in turn activates 
perhaps only a single effector ? Opioid receptors have been shown to activate multiple 
members of the G,IG0 families [Prather et al, 1994]. However the interaction between 
G protein and effector may be much more specific, possibly even to the extent that 
specific G protem triplets couple different receptors to the same effector. For 
example, it has been shown that in GH3 cells inhibition of calcium channels by 
muscarinic m4 receptors is mediated through aodhY4 whilst somatostatin receptors 
are coupled vm ao2~1YJ [Kleuss et al, 1993]. Additionally, G-protein activating 
proteins and/or targeting or compartmentation of signalling components may play a 
role in determining specificity of signal transduction [Neubig, 1998]. 
\ 
The exact mechanism by which G prot~ins mediate the signal from activated 
receptor to effector is largely unknown, but depends upon the kinetics of 
guanine nucleotide exchange and hydrolysis, as Illustrated in schematic form in 
Figure 1.1 0. In the basal state, G proteins exist in the trimeric form, and the a 
sub unit guanine nucleotide binding site contains a molecule of guanosine 
diphosphate (GDP). The binding of agonist results in an increase in the affinity 
of the receptor for the ~y-a-GDP complex. Interaction with the receptor causes 
the a subunit to exhibit reduced affinity for all guanine nuc1eotides. This is a 
consequence of an 'opening' of the nucleotide binding site [Boume, 1993], and 
prompts the release of the bound GDP molecule. A receptor which is complexed 
to a G protein in which the nucleotide binding site is empty has increased 
affinity for its ligand. In the absence of guanosine triphosphate (GTP) this 'high 
affinity' state of the receptor forms part of an agonist-receptor-G protein 
complex which is relatively stable. However, in the presence of relatively high 
endogenous intracellular concentrations of GTP the nucleotide 
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binding site is rapidly filled. Binding of GTP leads to a conformational change 
in three 'switch' regions of Ga that are the primary regions for contact with G~y 
[Lambright et al, 1996]. 
This activation of the G protein results in dissociation of the agonist-receptor-G 
protein complex. The a and ~y subunits show greatly reduced affinity both for 
each other and for the receptor, and are freed to act separately on downstream 
targets. This dissociation also causes the receptor to return to the basal state of 
low affinity for agonist, but before the ligand is released the receptor may 
interact with another G protein. Therefore a single activated receptor may in 
turn activate many G proteins, resulting in signal amplification. The dissociated 
G protein subunits continuously activate their target effector systems until the 
intrinsic GTPase activity of the a subunit hydrolyses bound GTP to give bound 
GDP and a free molecule of phosphate. This prompts the reassociation of the a 
and ~y subunits to form the basal state ~y-a-GDP complex. Thus the degree of 
signal amplification at the effector level is regulated by the rate of GTP 
hydrolysis, which is intrinsically relatively slow. In order to prevent excessive 
levels of effector activation, GTPase activating proteins or GAPs act to increase 
the rate of GTP hydrolysis. GAPs include effector proteins themselves, for 
example phospholipase C~ [Biddlecome et al, 1996] and the large family of 
'regulators of G protein signalling' or RGS proteins. At least 19 genes coding 
for RGS-Iike proteins have been found, defined by a 120-amino acid core 
domain. Some of the characterised RGS proteins are capable of increasing the 
rate ofGTP hydrolysis by Ga, including Ga, which couple to opioid receptors, 
by up to lOO-fold [Bennan and Gilman, 1998]. They may act by stabilising the 
transition state ofGa [Dohlman and Thomer, 1997]. 
A variety ofbiochemical tools are used probe the individual steps of the G 
protein cycle at a molecular level. Two of the most commonly used are bacterial 
toxins which target the a subunits of specific G proteins. Cholera toxin, isolated 
from Vibrio cholera, catalyses the transfer of an ADP-ribose unit from 
nicotinamide adenine dinucleotide (NADH) to an arginine residue on G,a and 
G,a. Those a subunits which have been ADP-ribosylated exhibit greatly 
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reduced GTPase activity, thus resulting in constitutive activation of the G 
protein [Ribeiro-Neto et al, 1985]. Similarly, pertussis toxin from Bordatella 
pertussis ADP-ribosylates those a. subunits which posses a cysteine residue in a 
specific position close to the carboxy terminus, namely G,a., G0a. and G1a.. This 
uncouples the G protein from the receptor, preventing any functional interaction 
[Katada et al, 1986]. The G proteins which regulate receptor-mediated 
activation of phospholipase C, namely Gq and G12, are insensitive to both 
cholera and pertussis toxin. 
The G protein cycle is the basis of the e5S]-GTPyS assay [Hilf et al, 1987; 
Traynor and Nahorski, 1995], which provides a functional measure ofreceptor 
activation [Lazareno and Birdsall, 1993]. GTPyS is an analog ofGTP which is 
much less susceptible to hydrolysis by the a. subunit. By using small amounts of 
radiolabelled e5S]-GTPyS (Figure 1.11) in the absence ofGTP, the 
accumulation of a. subunits with bound e5S]-GTPyS can be measured. This 
accumulation will be greatly increased by agonist through activation ofG 
protein. 
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Figure 1.11 Structure of e5S]-GTPyS 
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1.4 Theoretical considerations 
There are two major principles involved in ligand-receptor interactions, namely 
affinity and efficacy. 
Affinity is defined as the strength of attraction between ligand and receptor, or 
more specifically as the reciprocal of the bindmg association constant: 
"Kt= 1 
K. 
= kt X [AR] 
k2 x [A]x[R] 
where "Kt is the dissociation constant for the ligand-receptor pair, K. is the 
association constant, kt is the rate constant for the association reaction, kz is the 
rate constant for the dissociation reaction, [A] is the concentration ofligand, [R] 
is the concentration ofreceptor, and [AR] is the concentration ofligand-receptor 
complex. 
Efficacy is the ability of a ligand-receptor complex to elicit a response. For 
example, full agonists produce maximal response and thus have high efficacy, a 
pure antagonist has zero efficacy, and a partial agonist has intermediate 
efficacy. Efficacy is mdependent of affinity, since compounds with high affinity 
can exlubit low or zero efficacy, and vice versa. 
One of the earliest theories of drug-receptor interactions, Occupancy Theory, 
proposes that the magnitude of a biological response is linearly proportional to 
the fraction of receptors occupied by agonist. Thus any agonist that is present in 
a high enough concentration to occupy all available receptors will produce a 
maximal response. However, there are many drugs which do not cause a full 
tissue response even at concentrations much greater than that required for full 
receptor occupancy. Ariens [1954] proposed that these "partial agonists" could 
be accounted for in terms of occupancy theory by use of a fractional value 
which he called 'intrinsic activity'. Thus a partial agonist with an intrinsic 
activity of 0.25 would only produce a quarter of the response seen with a full 
agonist, when both occupied all receptors. 
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Later work recognised that the relationship between receptor occupancy and 
tissue response was non-linear. Stephenson [1956] introduced efficacy and the 
transducer function in an attempt to separate those factors involved in receptor 
activation which are drug dependent from those which are tissue dependent. 
Implicit in this model is the concept of receptor reserve, where a high efficacy 
agonist occupying less than 100 % of the available receptors nevertheless 
produces a maximal response. Furchgott [1966] showed that efficacy as defined 
by Stephenson is still a tissue dependent term, since a compound that acts as a 
full receptor in one tissue system may appear to be a partial agonist in another 
due to differences in receptor density [Kenakm, 1993]. He defmed the related 
term 'intrinsic efficacy' which is a strictly drug-related property. Thus for any 
given agonist-receptor interaction, intrinsic efficacy should be constant across 
all tissues and species [Kenakin, 1983]. 
The simplest model ofreceptor activation holds that a receptor can exist in 
either inactive (R) or active form (R*), Figure 1.12. An agonist has higher 
affinity for R * and is therefore able to displace the equilibrium in that direction, 
whereas an antagonist has equal affinity for both states of the receptor. This is 
the two-state model, originally proposed for the interaction of oxygen and 
haemoglobin [Monod, 1965]: 
L+R LR 
1~ 1~ 
L+R* LR* 
Figure 1.12 The two state model. L, ligand; R, inactive receptor; R*, active 
receptor; G, G protein. 
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However, this model makes no allowance for the -jnvolvement of G proteins. 
Thus De Lean et al [De Lean et al, 1980] proposed a modified version of the 
two state model called the ternary complex model, Figure 1.13. 
L+ R + G :::;;::::=:::::'!~ LR+G 
1~ 1~ 
L+R*G LR*G 
Figure 1.13 The ternary complex model. L, ligand; R, inactive receptor; R *, active 
receptor; G, G protein. 
The discovery that certain receptors which spontaneously activate in the 
absence of agonist, or 'constitutively active' receptors, exhibit affinities for 
agonists that increase not linearly, but in proportion with their eflicacies 
[Samana et al, 1993], caused Lefkowitz et al [Lefkowitz et al, 1993] to propose 
the 'allosteric ternary complex model', Figure 1.14. This model allows for 
several important concepts: 
1) receptors exist in equilibrium between inactive (R) and active (R *) states, 
only the latter of which is capable of binding to G protein; 
2) efficacy is a measure both of the ability of a ligand to convert R toR* and to 
facilitate binding ofR* to G protein; 
3) constitutive activity depends on both the ability ofR to spontaneously 
convert into R * in the absence of ligand and on the affinity ofR * for G 
protein. 
Recently it has become obvious that the same receptor can couple to multiple 
biochemical response pathways, with the same agonists showing different rank 
orders of potency at each [Spengler et al, 1993; Eason et at, 1994]. It has been 
suggested that there may be more than one active continuation of each receptor, 
each promoted by different agonists and coupling to a different effector system 
[Leff et al, 1997]. 
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L+R+G LR+G 
1~ 1~ 
L+R*+G lR*+G 
1~ 1~ 
L+R*G LR*G 
Figure 1.14 The allosteric ternary complex model. L, ligand; R, inactive receptor; 
R *, active receptor; G, G protein. 
Opioid Iigands include agonists, antagonists, and inverse agonists. The delta 
receptor has been shown to exhibit constitutive activity [Neilan and Traynor, 
1999], although this has yet to be shown for the mu and kappa receptors. 
Therefore the theoretical models of ligand actions discussed here are useful in 
the understanding of opioid pharmacology. 
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1.5 Opioid ligands and structure-activity relationships 
Since the discovery that morphine exhibits many undesirable side effects, thousands 
of analogs have been synthesised in an attempt to discover a potent analgesic without 
these drawbacks. To date, the huge amount of work dedicated to this search has led to 
many advances in opioid pharmacology and pharmacology in general, but no 'perfect' 
analgesic. 
The concept ofligand as 'key' and receptor as 'lock' is an old but still valuable one. It 
is currently impossible to directly observe the bmding of opioid ligand to receptor, so 
designing 'keys' winch fit the lock is difficult, to say the least One approach is to 
synthesise many vanations of a promising ligand, hoping to discover an even better 
one by chance. However, when searching for the perfect key to a particular lock it 
makes little sense to manufacture key after key based on an imperfect original. 
Instead, a more rational approach is to analyse the structures of all the available keys, 
including those which fit the lock well, poorly and not at all. It should then be 
possible to create a key which includes all the features conducive to fitting the lock, 
whilst simultaneously excluding the deleterious ones. Tins is the study of structure-
activity relationships (SAR), although in practice the results are rarely ideal. 
The number of discrete structural classes which are capable of interacting with the mu 
opioid receptor is perhaps greater than for any other receptor. The sheer number of 
opioids and opiates and their structural diversity makes it extremely difficult to derive 
a comprehensive set of structure-activity relationships which are predictive of binding 
affinity. An even harder task is the structural separation of agonist from antagonist. 
When compared to the broad diversity of opioids, the differences between an agonist 
and an antagonist of the same class, for example naloxone and morphine, are small. 
The vast array of mu opioid Iigands can be divided into the following five structural 
classes (Figure 1.15) : 
1) the rigid polycyclic opioids, which include 4,5-epoxymorphinans, 
morphinans, and benzomorphans; 
2) 4-arylpiperidines, 3-phenylpyrrolidines and 4-anilinopiperidines; 
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3) 3,3-diphenylpropylamines; 
4) miscellaneous compounds, mcluding benzimidazoles; 
5) endogenous and synthetic opioid peptides;. 
4.5-epoxymorphinans morphinans benzomorphinans 
_.....R 
ul> N 
I R' 
4-phenylpiperidines 3-phenylpyrrolidines 4-amlinopiperidines 
N 
_.....R 
N ~I Tyr-Giy-Giy-Phe-etc R N~ R' 
~ '\( R" 
3,3-diphenylpropylamines benzimidazoles opioid peptides 
Figure 1.15 Opioid structural classes. 
However, although these divisions are useful they are very simplistic, since within 
each of these groups there is often a huge degree of structural variation. For example, 
the endogenous and synthetic opioid peptides can vary in size from 4 amino acids to 
more than 30, with either a linear or a cyclic tertiary structure, and include a 
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staggering number ofnatura1 and synthetic amino acids ofL- and sometimes D-
stereochemistry. 
Despite these difficulties in SAR studies it is commonly acknowledged that there are 
three key features which define the vast majority of mu opioid ligands [Casy and 
Parfitt, 1986]. All references to atom or ring numbers are taken from the standard 
morphinan/epoxymorphinan scheme shown in Figure 1.16. 
2 7 
HO R' 
Figure 1.16 Numbering of atoms and rings in typical epoxymorphinan structure. 
1) A nitrogen atom. This is secondary or tertiary in alkaloid opioids, but can be 
primary in peptides. Opioids are largely protonated at physiological pH, and the 
positively charged nitrogen is thought to be involved in an ionic interaction with a 
complementary anionic centre in the receptor. The extremely well-conserved aspartate 
m the third intracellular loop, for example Asp147 in the human mu opioid receptor, 
has been implicated as the anion. In addition, the orientation of the nitrogen relative to 
the rest of the molecule may be important [Belleau et al, 1974], since this determines 
the position of both the nitrogen substituent and the lone pair. In the majority of 
opioids the lone pair is anti to the aromatic ring. 
There appears to be a causal relationship of sorts between the nature of the substituent 
on the nitrogen atom and the agonist or antagonist properties of the ligand. In the 
polycyclic opioids a small 3 to 5 carbon substituent such as propyl, allyl, 
cyclopropylmethyl or cyclobutylmethyl is traditionally associated with antagonism. It 
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has been proposed that such groups interfere wtth activation of the receptor by steric 
hindrance of the critical Aspl47 residue [Pogozheva et a!, 1998]. An N-arylalkyl 
group is necessary for activity in 4-anilinopiperidines such as fentanyl, the majority of 
which are agonists. Thts moiety can fit into the ligand binding domain in such a way 
as to Inimic the position of the second aromatic residue of many opioid peptides 
[Pogozheva et a!, 1998]. However, it may be the case that fentanyl and related 4-
anilinopiperidines occupy the bmding domain of the receptor in a manner unrelated to 
more traditional, rigid polycyclic opioids [Ferguson et a!, 1999] since in the fentanyl 
series, N-cyclopropylmethyl, N-cyclobutylmethyl and N-allyl substituents do not 
confer antagonist properties [Casy et a!, 1969]. Rather, substitution of the piperidine 
ring with methyl groups in the 3 and 4 positions results in antagonists [Zimmerman et 
at, 1993], suggesting that this class of compounds binds to the opioid receptor in a 
novel manner. 
2) An aromatic ring. This is usually phenyl, for example the 'A' ring in the rigid 
polycyclic opioids and the Tyr1 moiety of opioid peptides. It has been a long-held 
hypothesis that this aromatic ring forms van der W aals interactions with a 
complementary feature in the ligand bindmg domain of the receptor. A molecular 
modelling study has demonstrated that when a selection of opioid ligands were 
'docked' in the receptor, their aromatic rings all occupied similar positions which 
promoted interaction with a tryptophan residue in the sixth transmembrane domain 
(Trp293 in the human opioid receptor) [Pogozheva et a!, 1998]. Many highly potent 
alkaloid and peptide ligands contain two aromatic rings, suggesting that there may be 
a second such site for van der W aals bonding. In vivo, the increased lipophilicity 
conferred upon a molecule by the presence of aromatic features also aids penetration 
of the blood-bram barrier. 
The presence of substituents on the aromatic ring generally causes a decrease in 
affinity for the mu opioid receptor, with one important exception. In the polycyclic 
opioids a 3-0H substituent is generally necessary for high affinity, and the equivalent 
tyrosyl -OH moiety is considered vital in opioid peptides. In both cases the -OH group 
has been suggested to form a hydrogen bond with the same histidine residue in 
transmembrane domain VI, for example His 297 in the human opioid receptor 
[Pogozheva et a!, 1998]. Masking the 3-0H substituent of morphine by methylation 
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gives codeine, which is approximately 10 to 30-fold less active than the parent 
compound in a variety of assay systems. Acetylation of both the 3 and 6 position 
hydroxyl groups of morphine affords heroin, which is at least equipotent with the 
parent compound. The activity of heroin is due to enzymatic hydrolysis of either one 
or both acetoxy groups, and in both cases the 3-0H group is 'unmasked'. However, 
hydroxylated analogs of the fentanyl and pethidine series designed to mimic the 3-0H 
substitutent of morphine actually exhibit a decrease in affinity [Lobezzo et a/, 1981], 
further evidence for distinct binding modes of 4-anilinopiperidines and morphine-like 
ligands. 
3) The spatial arrangement of the nitrogen, aromatic ring, and (if present) the 
hydroxyl function. The distances and angles between these features comprise the 
'pharmacophore' for mu opioids, which is at present relatively simple and oflimited 
use in predicting accurate binding affinities. However, it is still useful as a basic 
screen since a molecule which does not fit the pharmacophore is unlikely to bind to 
the mu opioid receptor at all. 
More generally, the stereochemistry of the molecule is also critical. In the ngid 
polycyclic opioids the(-) absolute configuration is necessary for maintained affinity. 
For example, (-)levorphanol exhibits high affinity for mu opioid receptors, whilst its 
stereoisomer dextrorphan has the(+) configuration and almost completely abolished 
affinity. In opioid peptides the amino acids are generally of the L-configuration, 
especially the first residue which is typically L-Tyr:1 or an analogous residue. 
However, there are many examples of opioid peptides containing D-configuration 
amino acids since these are more resistant to enzymatic degradation. 
As in most things, there are exceptions to the pharmacophoric 'rules' outlined above. 
Although there are no known opioids which lack an appropriate nitrogen feature, 
there are a very few which lack an aromatic ring. One set of examples are the 
ozonolysis products of a series of very similar etorphine-like compounds (Figure 
1.17) which have analgesic potency in the rat much reduced when compared to the 
parent compounds, but still comparable to that of morphine [Bentley et a/, 1969]. In 
view of the traditional opioid SAR theory that an aromatic ring is essential for opioid 
activity, this was a surprising finding. The authors proposed that the extraordinary 
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potency afforded to the parent molecules by the inclusion of the additional cyclic ring 
and the substituent on the 7 position could compensate for the loss of the aromatic 
ring in the ozonolysis product. 
(a) 
...... rR 
OH 
OH3C 
~H3 
...... rR 
OH 
OH3C 
F1gure 1.17 Etorphine-like compounds (a) and their ozonolysis products (b), R = n-
Pr, n-Bu or n-pentyl. 
Another example with an even less typical opioid structure is the steroid SC17599 
(F1gure 1.18). In 1968 Craig [1968] reported that the steroid 17a.-acetoxy-6-
dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3,5-dien-20-one, or SC17599, 
possessed marked antinociceptive activity in three m vivo procedures, namely the rat 
trul flick, mouse writhing, and mouse hot plate assays. In addition, 1t caused 
respiratory depression in the rabbit, reduced gastrointestinal motility in mice, and the 
Straub tail response, also in mice. However, the antinociception observed in the rat 
tail flick assay was not nalorphine reversible, unlike that of morphine. Craig 
concluded that SC17599 was most likely acting in a sinlilar manner to morphine. 
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/"--.o 
F1gure 1.18 The steroid 17a-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-
pregna-3,5-dien-20-one, or SC17599. 
In addition to the nitrogen centre, aromatic ring and sterochemistry descnbed 
above, there are several other elements of opioid ligand structure that have been 
proposed to be important in binding to the opioid receptors. For example, in the 
rigid poylcyclic systems a 14-position hydroxyl or ketone group increases 
ligand binding affinity, possibly through interaction with an asparagine residue 
which is present in the mu but not delta or kappa opioid receptors, Asn230 
[Pogozheva et al, 1998]. In opioid peptides, a second aromatic ring is often 
present as part of a phenylalanine or analogous residue. This residue may be 
especially important in delta selective opioids and an analogous aromatic 
moiety is also present in several high affinity delta selective alkaloid Iigands 
[Lomize et al, 1996]. It has been shown in opioid peptides that the side chain of 
this 'second' aromatic residue occupies different well-defined orientations in 
compounds which exhibit selectivity for the mu or delta opioid receptor 
[Mosberg et al, 1996; McFadyen et a/, 1999]. 
There is a wealth of SAR information available on a huge diversity of opioids, 
and hence only a small selection has been presented here. An extremely 
thorough if slightly outdated review is given by Casy and Parfitt [1986]. The 
field of SAR study has been revolutionized by the increased availability of 
extremely powerful and relatively affordable computers in the last decade. It is 
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now possible to analyze even the largest structures in terms of minimum energy 
conformations, partial energy charges, electrostatic potential, steric bulk, and 
other physical characteristics. Custom written software can search for features 
and conformations common to all molecules in a given group, allowing for 
pharmacophore definition. It is possible to build mathematical models which 
attempt to predict the properties of novel compounds, for example ligand 
binding affinities. This last is increasingly used as a tool to help direct ligand 
synthesis programs and testing studies, and there are a variety of appropriate 
software packages available. 
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1.6 Aims 
The exact nature of the ligand binding domain of the receptor, the nature of the 
interaction of a ligand with this domain, the determinants of specificity of a ligand for 
its receptor, the mechanism by which binding of agonist causes activation of receptor, 
and the determinants of agonist/antagonist properties are some of the most 
fundamental questions concerning G protein coupled receptor pharmacology. 
These questions are still largely unanswered. In particular, elucidation of the 
relationships between the structure of a ligand and..its affinity, specificity and extent 
of agonist action is still in its infancy. 
The aim of the work reported here is to test the following hypotheses : 
1) the aromatic ring and para-hydroxyl groups of the typical Tyr1 residue are critical 
to the binding of opioid peptides; 
2) the steroid se 17599 exerts its antinociceptive actions through the mu opioid 
receptor; 
3) SC 17599 binds to the mu opioid receptor in a similar mauner to morphine and 
other traditional opiates despite lacking both the aromatic and hydroxyl moieties; 
4) molecular modelling techniques can be applied to the redefinition of the mu opioid 
pharmacophore in light of the activity of severalligands with unusual structures. 
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Radwchemicals 
eH]-DAMGO ([D-Ala2, N-MePhe4, Gly(ol)5]enk!Jlhalin) (54.5 Ci/mmol; 2.02 
TBq/mmol), and eHJ-diprenorphine (45 Cilmmol; 1.66 TBq/mmol or 58 Ci/mmol; 
2.14 TBq/mmol) were from Amersham International, Aylesbury, UK or Piscataway, 
NJ, USA. 
[3H]-CI977 (SR-(Sa, 7a,8P)-N-methyl-N-[7 -(1-pyrrolidinyl)-1-oxaspiro[ 4.5]dec-8-
yl]-4-benzofuranacetamide) (21.1 Ci/mmol; 0. 78 Thq/mmol) was a kind gift from Dr. 
J.C. Hunter, Parke-Davis Neuroscience Research Centre, Cambridge, UK. 
eH]-Nociceptin (60 Ci mmol; 2.22 TBq/mmol), eH]-triamcinolone acetonide (38 
Ci/mmol; 1.41 TBq/mmol), and e 5S]-GTPyS (guanosine-5'-0-(3-thio)triphosphate) 
(1250 Ci/mmol; 46.25 TBq/mmol) were all purchased from DuPont NEN, Hounslow, 
UK or Boston, MA, USA. 
Structures of the radioligands used are given in Figure 2.1. 
2.1.2 Chemicals 
EDTA (ethylenediaminetetraacetic acid), Folin & Ciocalteu's phenol reagent, GDP 
(guanosine diphosphate), GTP (guanosine triphosphate), HEPES (N-[2-
hydroxyethyl]-piperazine-N' -[2-ethanesulfonic acid], DL-dithiothreitol, sodium 
hydroxide, sodium potassium tartrate, magnesium chloride, magnesium sulfate, 
copper sulfate, sodium hydrogen carbonate, hydrochloric acid (sp. gr. 1.16), sodium 
molybdate, phenylmethylsulfonyl flouride, dextran, ammonia solution (specific 
gravity 0.88) and Trizma base (tris[hydroxymethyl]-arninomethane) were purchased 
from Sigma Chemical Co., Poole, UK or St. Louis, MO, USA. 
Calcium chloride, potassium chloride, potassium phosphate monobasic, and sodium 
chloride were purchased from Mallinckrodt, St. Louis, MO, USA. 
Activated charcoal and DMSO (dimethylsulfoxide) were from Fisher Scientific, 
Loughborough, UK or Pittsburgh, P A, USA. 
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Sodium bicarbonate was from Columbus Chemical Industries, Inc., Columbus, WI, 
USA. 
UltimaGold liquid scintillation fluid was from Packard Bioscience, Groningen, 
Holland. 
a) [3,5, 3H]Tyr-o-Aia-Giy-N-MePhe-NH(CH2kOH 
b) 
HO 
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OH 
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c) 0 I o o"·?J 
0 
d) Phe-Giy-Giy-Phe-Thr-Giy-Aia-Arg-Lys-Ser-Aia-Arg-Lys-[3,5,3H]Tyr-Aia-Asn-Gin 
0 
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2 
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11 11 11 
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Figure 2.1 a) [3H]-DAMGO, b) eH]- diprenorphine, c) eH]-CI 977, d) eHJ-
nociceptin, e) eHJ-triamcinolone, f) e 5S]-GTPyS. 
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2.1.3 Drugs and related compounds 
The following drugs were generous gifts from the National Institute on Drug Abuse, 
Rockville, MD, USA: fentanyl HCl, alfentanil HCl, a-prodme, profadol, SNC 80 
( ( + )-4-[ ( aR)-a-( (2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N ,N-
diethylbenzamide), naloxone HCl, and naltrexone HCI. 
BW 373,U86 ((+)-4-[(aR)-a-((2S,5R)-4-allyl-2,5-dimethyl-l-piperazinyl)-3-
hydroxy-benzyl]-N,N-diethylbenzamide) was from Burroughs Wellcome, Research 
Triangle Park, NC, USA. 
Morphine sulfate was purchased from Mallinckrodt, St. Louis, MO, USA. 
se 17599 (17a-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3,5-
dien-20-one) was a kind gift from G. D. Searle and Co., Chicago, IL, USA. 
Nociceptin, 5a-pregnan-3a-ol-20-one, 5a-pregnan-313-ol-20-one, 17a-estradiol, 1713-
estradiol, estrone, hydrocortisone, and dexamethasone were purchased from Sigma 
Chemical Co., St. Louis, MO, USA. 
Codeine sulfate, U69,593 (5a, 713,8y-(-)-N-[7-(1-pyrrolidinyl)-1-oxaspiro( 4,5)dec-8-
yl]benzeneacetamide) and etonitazene HCl were from RBI, Natick, MA, USA. 
2.1.4 Peptides 
DAMGO was from Tocris Cookson, Bristol, UK or Ballwin, MO, USA. 
All of the peptides described in Chapter 3 were supplied by Dr. Henry Mosberg, 
School of Pharmacy, University ofMichigan. 
2.1 5 Cell culture media 
Dulbecco's Modified Eagle Medium (without sodium pyruvate; with 4,500 mg L"1 
glucose), Minimum Essential Medium (with Earle's salts), foetal calf serum, 
penicillin/streptomycin, fungizone, trypsin, EDTA, and geneticin were all from Gibco 
Life Sciences, Grand Island, NY, USA. 
Sterile DMSO was from Sigma Chemical Co., St. Louis, MO, USA. 
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2.1.6 Buffers 
The composition ofBuffer A used in all ess]GTPYS assays was (mM): HEPES (20) 
MgCh.6H20 (1 0) and NaCl (1 00). The pH was adjusted to 7.4 with NaOH. 
The Tris buffer used in radioligand binding studies was Trizma base (50 mM) 
acidified with HCI to pH 7.4. 
Buffer B used in the glucocorticoid receptor binding assay was composed of (mM): 
HEPES (I 0), EDTA (0.1 ), sodium molybdate (20) and phenylmethylsulphonyl 
fluoride (3). The pH was adjusted to 7.5 with NaOH. 
2.1.7 Equipment 
Brandel Cell Harvester, model M-24, Biomedical Research and Development 
Laboratories, Gaithersburg, USA, used with Glass F1br Filter Papers, Whatman GF/C 
or #32, Schleicher and Schuell, Keene, NH. 
Liquid Scintillation Counter, model LS 6800, Beckman Scientific Instruments 
Division, Irvine, CA. 
Tissue Tearor, model985-370, Biospec Products, Bartlesville, OK. 
Ultracentrifuge, model J2-21, Beckman Scientific Instruments Division, Irvine, CA. 
Centrifuge, model Centra CL2, IEC, Needham Heights, MA. 
pH meter, Model 440, Coming, NY, USA. 
Balance, Precision Plus Model400S, Ohaus, NJ, USA. 
Microbiological Safety Cabinet, Forma Scientific, Marietta, OH. 
C02 Incubator, model3546, Forma Scientific, Marietta, OH. 
Pipet-Aid, Drummond Scientific Company, Broomall, P A. 
Tissue culture plastics, Fisher Scientific, Pittsburgh, P A. 
40 
Chapter 2: Materials and Methods 
2.2 Methods 
2.2.1 Cell culture 
The SH-SYSY human neuroblastoma cell line was kindly donated by Dr. D. Lambert, 
Department of Anaesthesia, Leicester University, UK. Cells were cultured in 
Minimum Essential Medium (MEM) supplemented with 10 % foetal calf serum, 2.5 
f!g mL-I amphotericin B (fungizone), 50 J.lg m1·I penicillin/streptomycin, and 250 f!g 
m1·I L-glutamine at 3 7 °C in a humidified 5 % C02 atmosphere. 
C6 glioma cells transfected with either the cloned rat mu- or delta-receptor were a 
kind donation from Dr. Huda Akil, Mental Health Research Institute, University of 
Miclugan, Ml, USA. Cells were cultured in Dulbecco's Modified Eagle's Medium 
supplemented with 10% foetal calf serum at 37 oc under a 5% C02 atmosphere. For 
subculture one flask from each passage was grown in the presence of 1 mg m1·I 
Geneticin. Cells used for experiments were grown in the absence of Geneticin with 
no significant reduction in receptor number. 
Chinese Hamster Ovary (CHO) cells transfected with the mouse delta-opioid receptor 
were a kind gift from Dr. C.J. Evans, Department of Psychiatry, UCLA, Los Angeles, 
California. Cells were cultured in Dulbecco's Modified Eagle Medium supplemented 
with 5 % foetal calf serum, 2.5 f!g mL-I fungizone, SOU m1·I penicillin, SOJ.lg m1·I 
streptomycin and 258 f.lg m1·I L-glutamine at 37°C in a humidified 5% C02 
atmosphere. 
All cell lines were subcultured at confluency by splitting one flask per passage, as 
follows : the medium was aspirated, and trypsin (5 mL) added. After approximately 2 
mins the cells were lifted from the flask by gentle agitation, removed, and pelleted by 
centrifugation for 3 mins at 1,600 rpm. Supematant was removed, the pellet was re-
suspended in fresh medium, and finally the cell suspension was added to fresh 
medium in new flasks. 
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2.2 2 Membrane preparation 
Once cells had reached confluency they were harvested in HEPES (20 mM pH 7.4) 
buffered saline containing 1 mM EDTA, dispersed by agitation and collected by 
centrifugation at 1,600 rpm. The cell pellet was suspended in 50 mM Tris-HCI buffer 
pH 7.4, and homogenized using a Tissue Tearor. The resultant homogenate was 
centrifuged for 15 min at 18,000 rpm at 4 oc and the pellet collected, washed, 
resuspended and recentrifuged. The final pellet was resuspended in 50 mM Tns-HCI 
buffer pH 7.4; separated into 0.5 mL aliquots (0.75 - 1.0 mg protein) and frozen at-
80°C. 
Cytosol fractions from Sf9 cells stably transfected with the glucocorticoid receptor 
were kmdly supplied by Dr. W. Pratt, Department of Pharmacology, University of 
Michigan, MI, USA. 
2.2.3 Preparation ofbram homogenates 
Male Dunkin-Hartley guinea-pigs (250-500 g) from David Hall, Newchurch, Burton-
on-Trent, were decapitated and the brain removed, weighed and homogenised in Tris-
HCI buffer for 15 sec using a Polytron homogeniser. After centrifugation (35,000 x 
g, 15 mins, 4 °C) the pellet was resuspended in 10 times the volume ofTris buffer and 
incubated at 37 °C for 30 min to enable dissociation of endogenous ligands. The 
homogenate was re-centrifuged as above and the pellet was finally resuspended in 
Tris buffer to give a known concentration of approximately 1 :60 w/w (original weight 
of wet tissue). 
2.2.4 Determination ofprotem 
Protein concentration for both cell membrane and guinea-pig brain membrane 
preparations was determined by the method ofLowry et al. [1951], using a bovine 
serum albumin standard. 
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2.2.5 Radiolzgand bmdmg assays 
2.2.5.1 Competition assays 
C6 glioma cell membranes (30- 60 Jlg protein), SH-SY5Y cell membranes (100-
150 Jlg protein), or guinea-pig brain homogenates ( 400 Jlg protein) were incubated at 
25°C in 50 mM Tris-HCl buffer, pH 7.4 for 1 hour with radio labelled ligand at the 
concentrations indicated in the text, and varying concentrations of unlabelled ligand to 
give a final volume of 1 mL. Non-specific binding was defined with 10 J.!M 
naloxone. The reaction was terminated by filtering the samples through glass fiber 
filters mounted in a Brandel 24 well harvester. The filters were subsequently washed 
3 times with ice-cold Tris-HCl, pH 7.4 and radioactivity determined by scintillation 
counting after addition of 3 mL ofliquid scintillation fluid. 
The displacement of eH]-triamcinolone in cytosol fractions from Sf9 worm ovary 
cells infected with a mouse glucocorticoid receptor baculovirus was performed as 
descnbed recently [Kanelakis et al, 1999]. Briefl:Y;" cytosol fractions (20-30 Jlg 
protein) were incubated at 4 oc in buffer B, pH 7.5 for 18 h with eH]-TA (1.0 nM) 
and varying concentrations of hgand to give a final volume of 200 J.!L. Total binding 
was determined in the absence ofunlabeled ligand, and non-specific binding was 
defined by dexamethasone (10 J.!M). Free eH]-TA was separated from bound by 
incubation with a suspension containing charcoal (1 % w/v) and dextran (0.2 % w/v) 
for 10 min followed by centrifugation at 12,000 x g for 2 min, and quantified by 
liquid scintillation counting of the supernatant. Buffer B comprised : HEPES (1 0 
mM), EDTA (100 JlM), sodium molybdate (20 mM), and phenylmethylsulfonyl 
fluoride (3 mM). 
2.2.5.2 Saturation assays 
Membrane homogenates (as described above) were incubated at 25°C for 1 hour with 
varying concentrations of tritiated ligand (10- 0.005 nM) in the presence of either 
water (control) or 10 J.!M naloxone (non-specific binding) to determine total specific 
binding. The reaction was terminated by rapid filtration and filters subjected to liquid 
scintillation counting as above. 
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2.2.6 f 5S]-GTPyS bzndzngassays 
Membrane homogenates (as described above) were incubated for I hour at 30 °C in 
the presence ofe5S]GTPyS (100 pM), GDP (10 jlM for SH-SYSY cell homogenates, 
30 J.1M for C6 glioma cell homogenates) and various concentrations ofunlabeled 
ligand. Maximal stimulation was determined using fentanyl (I 0 J.1M} for mu-receptor 
studies and BW 373,U86 (10 J.1M} for delta-receptor studies. After I hour samples 
were rapidly filtered and filters subjected to liquid scintillation counting as before. 
The amount of stimulated e 5S]GTPyS binding is given as a percentage of the 
maximal stimulation evoked by either fentanyl (10 J.1M} or BW 373,U86 (10 J.lM}. 
2.2. 7 Data analyszs 
All data were analysed using Microsoft Excel 97 (Microsoft, Seattle, WA) and 
GraphPad Prism 2.01 (GraphPad, San Diego, CA). From saturation binding assays, 
binding capacities (Bmax) and equilibrium dissociation constants (Ko) were calculated 
from non-linear regression using GraphPad Prism. For radioligand binding assays 
mean IC50 values were calculated from individuaiJC50 values from at least three 
separate experiments, which were in turn determined using GraphPad Prism. 
K, values were determined using the Cheng-Prusoff equation [Cheng and Prusoff, 
I973]: K, = ICso x Ko I (Ko + [L]) 
where K, is the equilibrium dissociation constant for the competing ligand; IC50 is the 
concentration of the competing ligand required for half-maximal inhibition of the 
binding of the radioligand; Ko is the equilibrium dissociation constant for the 
radioligand; and [L] is the free radioligand concentration, assumed to be equal to the 
total radio ligand concentration when present in large excess. 
Ko values used were determined by saturation assay and were : 0.2 nM for 
eH]diprenorphine at mu receptors in either SH-SYSY or C6J.1 cell membranes, 1.0 nM 
for eH]DAMGO at mu receptors in SH-SYSY cell membranes, O.I nM for eH]CI977 
at kappa receptors in guinea-pig brain homogenat_e_s, and I.O nM for 
eH]triamcinolone at glucocorticoid receptors m Sf9 cytosol fractions. 
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For e5S]-GTPyS binding assays, ECso values (effective concentration producing a 50 
% maximal response) were calculated from individual EC50 values from at least three 
separate experiments, which were in turn determined using GraphPad Prism. 
2.2.8 Antinociceptzve assays 
Male Nlli mice (20-30 g) were used (Harlan Sprague Dawley Inc., Indianapolis, IN, 
USA). Subjects were housed in groups in a colony maintained at 20 oc, 40-50% 
humidity with a 12 hour light/dark cycle. Food and water were available ad libitum 
until the time of the experiments. Each subject was tested only once and all 
experiments were performed between 8 a.m. and 6 p.m. 
2.2.8.1 Acetic acid induced writhing assay 
The procedure ofKoster et al. was used [Koster et al, 1959]. Briefly, mice received 
subcutaneous injections of drug prior to intraperitoneal injection of0.6% acetic acid 
(0.4 mL). Five minutes after the injection of acetic acid, the number of writhes 
occurring during a 5 min period was recorded, with a 'writhe' defmed as an extension 
of the animal's abdomen and hind legs. Inhibition of writhing was expressed as the 
percentage of writhes observed in control mice, which was determined for each new 
batch of mice: 
2.2.8.2 
% control writhes = (writhes with sterile water- writhes with drug) x 100 
writlies with sterile water 
Warm water tail withdrawal assay 
The procedure of Janssen et al. was used [Janssen et al, 1963]. Briefly, the lower third 
of the tail was immersed into a 50 °C water bath and the latency to tail withdrawal 
was measured, with a cut-off latency of20 sec. Drugs were injected i.p. at 30 min 
intervals and tail withdrawallatencies measured after 25 mins. Antinociception was 
measured as percent of maximum possible effect (% MPE) : 
% MPE = (mean latency following drug- control latency) x 100 
(cutoff time- control latency) 
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2.2.9 Molecular modelling 
All computations were carried out on either an SGI Oxygen RI 0,000 workstation or 
an SGI Octane workstation. The majority of the work was done using SYBYL 6.4.3 
form Tripos Inc., St.Louis, MO. In all calculations, parameters were as default except 
where noted. 
All molecules were constructed within Sybyl in the pharmacologically relevant 
protonated form, except where noted. Charges were added using the MOP AC 
(Molecular Orbital PACkage) module with the following parameters : MNDO 
(Modified Neglect Differential Overlap) method [Dewar and Thiel, 1977], ESP 
(ElectroStatic Potential) option, slope = 1.2, convergence = 'precise'. Structures were 
then minimised using the Tripos force field engin~ incorporating the use of charges 
(from above), and with termination by gradient at 0.001 kcaVmol. All minimisations 
were allowed to run until converged (usually< 1,000 iterations). 
2.2.9.1 Pharmacocophore generation 
The GASP (Genetic Algorithm Superposition Program) module of SYBYL was used 
to align from 2 to 4 energy minimised opioid ligands and to identifY common site 
points, hypothetical features with which those molecules may interact when bound to 
a receptor. More than four molecules could not be aligned simultaneously due to 
limitations on computation time. The ligands used were: morphine, etorphine, the 
ozonolysis product of etorphine, and SC17599. Four alignments were generated in 
each run, and distance constraints were imposed such that all amine nitrogens had to 
be located within a 0.5 A radius sphere. The alignments were scored as a weighted 
average of measures descnbing steric overlap, hyorogen bonding contribution, and 
increased internal energy m the molecules. Those pharmacophore models with the 
best 'overall' scores were selected, except when their 'internal energy' scores were 
significantly(> 10 %) higher than the model with the next best 'overall' score. This 
resulted in unfavorable distortion of the molecule which was confirmed by a visual 
assessment. 
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2.2.9.2 Structure alignment 
The FBSS (Field Based Similarity Search) module developed by David Wild at the 
University of Sheffield, Sheffield, UK [Wild and Willett, 1996] uses a genetic 
algorithm (GA) to align a set of molecules one at a time to a target. Alignments are 
determined by the GA based not on common atomic features as is the case in GASP, 
but on the similarity between the target and the test molecule calculated as a function 
of one or more of the following fields; electrostatic, hydrophobic, and shape. 
Here, FBSS was used to align a relatively small but structurally diverse database of 17 
opioid ligands as a precursor to analysis of quantitative structure-activity relationslnps 
(QSAR). The database comprised : etorphine, buprenorphine and diprenorphine 
(thebaine analogues), morphine, codeine, nalbuphine and naloxone (4,5-
epoxymorphinans), butorphanol (a morphinan), pentazocine (a benzomorphan), 
pethidine and a.-prodine (4-phenylpiperidmes), profadol (a 3-phenylpyrrolidine), 
fentanyl and alfentanil (4-anilinopiperidines), methadone (a diphenylpropyl-amine), 
etonitazene (a benzimidazole), and SC17599 (a steroid). For structures, see Figure 
5.7. 
All of the Iigands had AMI (Austin Modell) charges attached via the MOPAC 
module [Dewar et a/, 1985] rather than the MNDO charges used elsewhere, due to the 
requirements of the FBSS genetic algorithm. Two target molecules were used to align 
the set in separate runs, namely etorphine (most active) and morphine (most typical 
structure). The genetic algorithm uses a scoring function to test the 'goodness' of its 
alignment of the target and database molecule in order to determine when the analysis 
has converged. Part of the scoring function analyses the steric overlap between the 
target and database molecule, and two variations were used. In the first, full steric 
scoring (FSS), overlap between the two molecules generates a positive scoring 
contribution whilst regions of excess volume in the database molecule generate a 
negative scoring contribution. In the second, partial steric scoring (PSS), there is no 
negative contribution from excess volume in the database molecule. 
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In each case (morphine or etorphine target, full steric scoring or partial steric scoring), 
four separate analyses used the following combinations offield{s); electrostatic, 
electrostatic plus hydrophobic, electrostatic plus shape, or electrostatic, hydrophobic 
and shape. For each analysis 20 iterations were performed, each consisting of20,000 
operations at a population size of 125 with selection pressure set to 1.1 0. The target 
was held rigid whilst the database molecules were allowed to flex. 
Five sets of four alignments each were generated, and were assessed on the individual 
'similarity score' given for each molecule relative to the target and the average 
'similarity score' for allligands in the database The similarity score is an unweighted 
average of measures describing the similarity of the stenc, electrostatic, and 
hydrophobic fields. The alignments were also assessed visually, using the position of 
the amine nitrogen atom in each molecule. 
2.2.9.3 Quantitative structure-activity relationships 
The CoMFA (Comparative Molecular Field Analysis) module ofSYBYL was used, 
based on an alignment of a database of ligands by FBSS (Field Based Structural 
Similarity). The FBSS module is particularly useful in preparation for a QSAR 
(Quantitative Structure-Activity Relationships) study since it aligns molecules based 
not on their structural features but on their steric, electrostatic, and hydrophobic 
fields, which is also the basis of the CoMF A analysis. The chosen alignments from 
the FBSS analysis were used to construct separate spreadsheets which also contained 
log (1/K,), log (1/ECso) and % maximal stimulation data for each molecule as 
measures of affinity, potency and efficacy at the mu opioid receptor respectively. 
Ligands which were mis-aligned in a particular FBSS analysis were omitted from the 
corresponding spreadsheet. 
The CoMF A field for each ligand was generated using the default parameters, and 
used to derive a model describing the variance in one of the three provided measures 
of biological activity. In each case, an irutial cross-validated partial-least squares 
{PLS) analysis was used to identifY the optimal number of components for further 
analysis, where additional components increase the complexity ofthe equation which 
describes the model. Default parameters were used in all cases. The cross-validation 
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calculation is a sequential process in which one ligand at a time is removed and the 
remainder used to generate a QSAR model. The predicted biological activity of the 
'odd-man-out' is then compared to its actual activity. In addition to identifYing the 
optimal number of components, this analysis also provides a measure of the predictive 
ability of the QSAR model, and ensures that it is not reliant on any one single data 
point. 
A further PLS analysis was performed using the recommended optimal number of 
components, with no validation and column filtering turned off. The predicted regions 
of favourable and unfavourable steric and electrostatic contributions were visualised 
using the default parameters. 
2.2.9.4 Ligand docking 
Genetic Optimization for Ligand Docking (GOLD) is a joint collaboration between 
the CCDC, Cambridge, UK (Cambridge Crystalographic Data Center) and Dr. Gareth 
Jones, Sheffield University, Sheffield, UK [Jones et al, 1995; Jones et al, 1997]. 
GOLD uses a genetic algorithm to search out possible docking modes of a given 
ligand with a given receptor. Here, energy minimised structures (with charges) were 
docked with a model ofthe mu opioid receptor kindly provided by Dr. Henry 
Mosberg [Pogozheva et al, 1998] (http://www-personal.umich.edu/-him). Ten 
dockings were generated in each run, with 'set atoms types' enabled for both ligand 
and protein in order to validate atom type assignments, and 'early termination' 
disabled to ensure that the full number of dockings were produced. The active site 
was defmed by a 15.0 A radius around the a carbon (atom number 644) of the 
Asp147 residue of the receptor, since this residue-lias been consistently implicated in 
forming an ionic interaction with the positively charged amine nitrogen present in all 
opioid ligands. Individual dockings were scored as a weighted average of measures 
describing internal and external hydrogen bonding contnbutions, van der W aals 
interactions, and torsion energies. Those docking models with the best 'overall' scores 
were selected. 
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CYCLIC TETRAPEPTIDES 
Chapter 3: Cyclic Tetrapeptides 
3.1 Introduction 
As discussed in Chapter 1, extensive study of the interactions ofhundreds if not 
thousands of structurally diverse Iigands with the opioid receptors has led to the 
identification of phannacophore models which detail the spatial arrangement of 
structural features common to all Iigands of a particular opioid receptor. The main 
focus of these efforts has been the mu receptor, for which the largest number of 
Iigands are available and which has the greatest clinical relevance. These models are 
constantly being refined, commonly through the design and study of conformationally 
restricted Iigands, many of which display selectivity in binding to one or other opioid 
receptor. This study examines the mu opioid phannacophore by characterising the 
binding affmity, potency and relative efficacy of a series of tetrapeptldes in which 
such restriction is achieved via cyclisation between the second and fourth amino 
acids. 
The endogenous opioid pentapeptides lend themselves well to this approach. For 
example, DPDPE, [o-Pen2, D-Pen5]-enkephalin, is a cyclic disulfide containing 
analogue ofLeu-enkephalin, Figure 3.1. This compound displays such high affinity 
( 4.0 nM) and selectivity (200-fold) for the delta opioid receptor that it is considered 
the standard delta ligand [Mosberg et al, 1983; Mosberg et al, 1988]. 
Figure 3.1 
Tyr-c[D-Pen-Gly-Phe-D-Pen]OH 
Structure ofDPDPE, [D-Pen2, D-Pen5]-enkephalin 
(cyclised via a disulfide bond between D-Pen2 and D-Pen5). 
A large number of conformationally restricted disulfide- or dithioether-containing 
tetrapeptides related to DPDPE have been studied, with the focus on refining the delta 
opioid receptorphannacophore [Mosberg et al, 1994a; Mosberg et al, 1994b; 
Mosberg et a/, 1996; Lomize et a/, 1996]. These compounds can be thought of as des-
Glr analogues ofDPDPE and have the general structure depicted in Figure 3.2. 
When cyclization is via a disulfide bond (i.e. n = 0), giving a ring size of 11 atoms 
and the C-terminal group is carboxylic acid, these peptides typically show selectivity 
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for the delta receptor. For example, H-Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13), shows 
higher affinity for the delta receptor than DPDPE at 0. 75 nM, and at the same time 
displays a similar selectivity ratio as DPDPE (70-fold) over the mu receptor [Mosberg 
et a/, 1988]. However, when the C-terminus ofJOM-13 is modified to carboxamide, 
giving H-Tyr-c[o-Cys-Phe-D-Pen]NH2 (JOM-5), delta receptor affinity is diminished 
by 80-fold whilst mu receptor affinity is concurrently enhanced by 7.5-fold to give an 
affinity of7.0 nM, such that JOM-5 actually shows moderate, 8-fold, mu receptor 
selectivity [Mosberg et a/, 1988]. Increasmg the ring size of JOM-5 from 11 to 13 
atoms by incorporating a dithioethane linkage (i.e. -S(CH2)2S-) gives H-Tyr-c[D-
Cys-Phe-D-Pen]NH2 (Et) (JOM-6), which exhibits greatly increased mu receptor 
affinity (0.3 nM) when compared to JOM-5, resulting in a correspondingly higher 
selectivity (80-fold) for the mu opioid receptor [Mosberg et a/, 1988]. 
OH 
D1th1oethane bridging group 
o-Cysteine 
(o-Cys2) 
(Et) 
o-Pemcillamine 
(o-Pen4) 
Figure 3.2 
Phenylalamne 
(Phe3) 
Tyrosine 
(Tyr1) 
General structure of cyclic tetrapeptides, using JOM-6 as an example. 
Analogues reported include variations in the first and third residues 
and alterations to the bridging group. 
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The extensive work carried out on these and related peptides has determined that three 
of the key ph~acophore elements that govern binding to both the mu and delta 
opioid receptor are contained within the Tyr1 residue, namely the amino function, and 
the phenolic aromatic and hydroxyl groups [Casy and Parfitt, 1986; Mosberg et a/, 
1987]. In opioid peptides, replacement of the Tyr1 residue with an aromatic amino 
acid Jacking a para-hydroxyl group almost invanably results in a drastic, if not 
complete, loss of affinity for both the mu and delta opioid receptors [M organ et a/, 
1976; Chang et a/, 1976; Chang et a/, 1976]. Two exceptions are the cyclic 
octapeptides CTAP and CTOP, which are related to a short stretch of the cyclic 
tetradecapeptide Somatostatin rather then the enkephalins [Pelton et a/, 1985; Pelton 
et a/, 1986]. The general structure ofthese compounds is D-Phe-c[Cys-Tyr-D-Trp-x-
Thr-Pen]-Thr-NH2, where x =Ornithine (CTOP) or Arginine (CTAP). Both exhibit 
high affinity for the mu opioid receptor (approximately 2.8 nM and 3.5 nM 
respectively) with extremely low affinity for both delta opioid and somatostatin 
receptors, but both are antagonists at the mu opioid receptor. The ab1hty of these 
peptides to bind to the mu opioid receptor is especially surprising, since not only does 
the o-Phe1 residue Jack the tyrosyl hydroxyl group, it also has D- stereochemistry, 
which traditionally abolishes mu receptor binding [Coy et a/, 1976; Casy and Parfitt, 
1986]. 
In addition, the aromatic ring of the Phe3 residue, cyclic peptide ring size and C-
terminal substitution play important roles particularly as determinants of mu/delta 
selectivity, as seen above with the conversion from JOM-13 (C-terminal -COOH) to 
JOM-5 (C-terminal -CONH2) [Heyl et a/, 1991; Heyl and Mosberg, 1992; Ho et a/, 
1999]. The relative positions of the aromatic rings of the first and third amino acids 
has been shown to be crucial for both bmding and selectivity. One of the main 
determinants of this relative position is the orientation of the Phe3 side chain phenyl 
group, which must be gauche for high delta receptor affinity [Mosberg et a/, 1994b J 
and trans for optimal mu opioid binding [Mosberg et a/, 1996]. Changes to the cyclic 
peptide ring size also directly affect the relative positions of the first and third 
aromatic side chains [Wang et a/, 1998]. 
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In the first part of this chapter the influence of affiiflo acids substitutions and changes 
to the cyclic ring system have been examined whilst retaining the para-hydroxyl 
group considered to be crucial in binding to both mu and delta opioid receptors. In the 
second section, characterisation of a larger series of peptides lacking any para-
substituent highlights a possible reduced role for this group in certain mu opioid 
receptor selective peptides. Finally, several compounds are considered in which the 
Tyr1 residue is replaced by aromatic amino acids containing nitrogen. These 
experiments were designed to examine the mu opioid receptor pharmacophore for 
peptide ligands but also to determine if the structural features requrred for binding 
affinity are the same as those necessary for agonist potency and efficacy. The general 
structure of these peptides is shown in Figure 3 .2, and the amino acid substitutions 
and numbering of the peptides is shown in Table 3.1. 
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Peptide structure Analogue 
Amino acid sequence Bridge 1 Number 
Tyr-c[o-Cys-Phe-o-Pen]NH2 8-Et-S JOM-6 
t-Hpp-c[o-Cys-Phe-o-Pen]NH2 S-Et-8 1 
Hat-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 2 
Tyr-c[o-Cys-A E -Phe-o-Pen ]NH2 s-s 3 
Tyr-c[o-Cys-Phe-o-Pen]NH2 S-cis-Ey-S 4 
p-F-Phe-c[D-Cys-Phe-o-Pen]NH2 S-Et-s 5 
Phe-c[o-Cys-Phe-o-Pen ]NH2 S-Et-S 6 
Phe-c[o-Cys-Phe-o-Pen]NH2 S-S 7 
Phe-c[o-Cys-Phe-o-Pen]NH2 S-czs-Ey-S 8 
pheny1Gly-c[o-Cys-Phe-o-Pen]NH2 8-Et-8 9 
homoPhe-c[o-Cys-Phe-D-Pen]NH2 8-Et-8 10 
diphenyWa-c[o-Cys-Phe-o-Pen]NH2 S-Et-8 11 
1-naphthyWa-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 12 
2-naphthyWa-c[o-Cys-Phe-D-Pen]NH2 - S-Et-S 13 
trans-pheny1Pro-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 14 
czs-phenylPro-c[o-Cys-Phe-D-Pen ]NH2 S-Et-8 15 
isoquinoline-c[o-Cys-Ph e-o-Pen ]NH2 S-Et-s 16 
tetralin-c[D-Cys-Phe-o-Pen ]NH2 S-Et-S 17 
cyclohexyWa-c[o-Cys-Phe-D-Pen ]NH2 S-Et-8 18 
pyridyl-c[o-Cys-Phe-o-Pen]NH2 S-Et-8 19 
His-c[o-Cys-Phe-D-Pen]NH2 S-Et-8 20 
Trp-c[D-Cys-Phe-o-Pen]NH2 S-Et-S 21 
indan-c[o-Cys-Phe-D-Pen]NH2 S-Et-8 22 
Table 3.1 Structures of cyclic tetrapeptides studied 
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3.2 Peptides retaining a para-hydroxyl subsituent 
Five analogues of JOM-6 (Tyr-c[o-Cys-Phe-o-Pen]NH2 (Et}}, were characterised to 
examine the effects of conformational restriction of Tyri or Phe3 or alterations in 
peptide ring size, in addition to one para-fluoro analogue. The residue 1 substituted 
analogues contain: L-trans-hydroxyphenylproline (L-t-Hppi) (la), D-trans-
hydroxyphenylproline (D-t-Hppi) (lb), L-hydroxyaminotetralin (L-Hati) (2a}, orD-
hydroxyaminotetralm (o-Hati) (2b). The peptide 3 retains tyrosine m position 1 but 
contains the Phe3 analogue dehydro(E)phenylalanine (~E-Phe3) and a disulfide bndge, 
whilst 4 differs from JOM-6 only in its altered nng closure, namely cis-ethene (-
S(CHhS-). Finally, 5 contains para-fluorophenylalanine (p-F-Phei). The structures of 
the amino acids and bridging groups used are shown in Figures 3.3, 3.4, and 3.5. 
peptides: 
peptides: 
Figure 3.3 
0 
tyrosine 
JOM-6, 3, and 4 
OH 
OH 
0 
trans-hydroxyphenylproline 
1a (L, shown) and 1b (D) 
F 
6-hydroxy-2-amino-2 para-fluorophenylalanine 
-carboxytetralin 
2a (L) and 2b (D) 5 
Structure of theN-terminal portion of the cyclic tetrapeptldes. The 
general structure is as shown in Figure 3.1. 
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peptides: 
Figure 3.4 
_......s--s......._ 
direct d1sulfide 
linkage 
3 
H H 
~ 
-s s-
~ 
-s s-
dithioethane 
(Et) 
JOM-6, 1a, 1b, 2a, 2b and 5 
cis-dithioethene 
(cis-Ey) 
4 
Structure of bridging groups used to close cyclic peptide system. The 
general structure is as shown in Figure 3.1. 
OH 
0 
peptides: 
phenylalanine 
JOM-6, 1a, 1b, 2a, 2b, 
4 and 5 
dehydro(E)phenylalanine 
3 
F1gure 3.5 
3.2.1 Results 
Structure of the third residues of the cyclic tetrapeptides. The general 
structure is as shown in Figure 3.1. 
3.2.l.l RadJohgand bindJng assays 
Radioligand binding data for the peptides at mu, delta and kappa opioid receptors in 
gum ea-pig brain were provided by Dr. Henry Mosberg of the School of Pharmacy and 
are shown in Table 3.2, along with values for the standard ligands for the delta 
(DPDPE) and mu (DAMGO) receptors. 
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Peptide structure Analogue Binding K, (nM) Selectivity 
Amino acid sequence Bndge 1 Name mu delta kappa KI(a) t Ki(!l) 
Tyr-n-Aia-Giy-N-MePhe-Giy-ol None DAMG0 2 4.13 ±0.84 2,540± 155 > 10,000 615 
Tyr-c[D-Pen-Giy-Phe-D-Pen]OH S-S DPDPE 810 ± 66 40±0.5 > 10,000 0.005 
Tyr-c[D-Cys-Phe-n-Pen]NH2 S-S JOM-5 3 7.0±0.5 57.7±4.7 > 10,000 8.23 
Tyr-c[n-Cys-Phe-n-Pen]NH2 S-Et-S JOM-6 3 0.29±004 24.8 ± 1.5 2,000± 235 83.3 
L-t-Hpp-c[n-Cys-Phe-D-Pen]NH2 S-Et-S la 0.32±0.03 27.3 ± 1.0 615 ± 187 85.6 
D-t-Hpp-c[D-Cys-Phe-D-Pen]NH2 S-Et-S lb 31.3 ± 4.2 4,163 ± 99.4 > 10,000 133 
L-Hat-c[D-Cys-Phe-D-Pen]NH2 S-Et-S 2a 0.40±0.08 23.7 ± 1.3 933 ±237 59.1 
D-Hat-c[D-Cys-Phe-D-Pen]NH2 S-Et-S 2b 0.39 ± 0.04 57.9±3.8 281 ±45.2 148 
Tyr-c[D-Cys-aE-Phe-D-Pen]NH2 S-S 3 8.7 ± 1.2 161 ± 19.7 2,270±320 18.4 
Tyr-c[D-Cys-Phe-D-Pen]NH2 S--cis-Ey-S 4 4.1 ±0.7 61.2 ± 13.3 3,357 ±430 14.9 
p-F-Phe-c[D-Cys-Phe-D-Pen]NH2 S-Et-S 5 12.3 ± 1.8 "'1,000 > 10,000 "' 100 
Table3.2 Opwid receptor bmding profiles of cyclic tetrapeptides. Displacement of eHJ-DAMGO (0.6 nM, mu), eH]-DPDPE (1.8 nM, 
delta), or eH]-U69,593 (0.9 nM, kappa) from guinea pig brain homogenates. Data represent mean± standard error of the mean 
from 3 or more separate experiments. Data provided by Dr. Henry Mosberg of the School of Pharmacy, University of Michigan 
1 Bndge between the second and fourth ammo acids (second and fifth amino acids in DPDPE) 
S-Et-S denotes -S--CH~H~-, and S--cis-Ey-S denotes -S--CH=CH-S-
2 Determined m rat brain membranes 3 Taken from Mosberg et al [1988] 
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Chapter 3: Cyclic Tetrapeptides 
As described above, JOM-5 exhibits good affinity for the mu opioid receptor and 
moderate selectivity for the mu over delta receptor. This selectivity is increased 10-
fold when the disulfide bond of JOM-5 is altered to a dithioethane bond, giving JOM-
6, as a consequence of greatly increased mu receptor affinity (Table 3 .2). 
The L-trans-hydroxyphenylproline (L-t-Hpp1) derivative la exhibited affinity for both 
mu and delta receptors equivalent to that of the parent compound JOM-6. However, 
its diastereomer lb (D-t-Hpp1) had 108- and 168-fold reduced affmity at mu and delta 
receptors respectively. In contrast, both of the diastereomeric Hat1 containing 
analogues 2a (L) and 2b (D) showed affinities at th_e mu opioid receptor identical to 
that of the parent peptide JOM-6. As a consequence of its slightly reduced affinity for 
the delta receptor, 2b had improved selectivity for the mu opioid receptor when 
compared to JOM-6, and at approximately 150-fold was the most selective of the 
peptides tested here. The peptide 3 (Tyr-c[D-Cys-ilEPhe-D-Pen]NH2 (Et)), is the 
dehydro(E)-phenylalanine analogue of the disulfide-bridged JOM-5. This peptide 
exhibited affinity for the mu opioid receptor similar to that of JOM-5, but with almost 
3-fold decreased delta receptor affinity. The czs-ethene linked analogue of JOM-6 is 
the peptide 4, which exhibited 10-fold reduced affmity for the mu opioid receptor but 
unchanged affinity at delta. Finally, the p-F-Phe1 containing peptide 5 showed 40-fold 
reduced affinities at both the mu and delta opioid receptors. 
All of the cyclic tetrapeptides tested showed very low affinity for the kappa opioid 
receptor as measured by displacement of fHJU6!),593, with the exception of the 
peptide 2b which exhibited moderate to low affinity at approximately 280 nM. 
Consequently, all of the peptides possessed selectivity for mu and delta over kappa 
opioid receptors. For example, JOM-6 exhibited almost 7,000-fold selectivity for the 
mu over the kappa opioid receptor, and 80-fold selectivity for delta over kappa. 
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Peptide structure Analogue mu Delta 
Amino ac1d sequence Bndge 1 Name ECso(nM) max (%) 2 ECso(nM) Max (%) 2 
Tyr-D-Ala-Gly-N-MePhe-Gly-ol none DAM GO 6 4 ± 145 110.0±4.6 > 10,000 
Tyr-c[D-Pen-Gly-Phe-D-Pen]OH S-S DPDPE n.d. 3 n.d. 3 1.87 ± 0.52 99.7 ±0.58 
Tyr-c[o-Cys-Phe-o-Pen]NH2 S-S JOM-5 17.8 ± 3.56 98.2 ±2.3 n.d. 3 n.d. 3 
Tyr-c[D-Cys-Phe-D-Pen]NH2 S-Et-S JOM-6 2.93±0.83 125.8 ±6.0 4 337.7 ±72.6 72.6 ± 1.9 4 
L-t-Hpp-c[D-Cys-Phe-D-Pen]NH2 S-Et-S la 8.76± 1.99 125.7 ± 5.1 4 57.5 ±3.9 40.9 ± 1.0 4 
D-t-Hpp-c[D-Cys-Phe-D-Pen]NH2 S-Et-S lb n.d. 3 n.d. 3 nd. 3 n d. 3 
L-Hat-c[D-Cys-Phe-D-Pen]NH2 S-Et-S 2a 0.40±0.21 102.1 ± 5.5 247.7 ± 37.8 696±5.1 4 
D-Hat-c[D-Cys-Phe-D-Pen]NH2 S-Et-S 2b 1.44 ±0.36 109.6±5.4 1,550 ± 117.2 73.9 ± 3.2 4 
Tyr-c[D-Cys-~ 8-Phe-D-Pen]NH2 S-S 3 1,060 ± 69.1 117.4 ± 5.6 4 567.6 ± 61.7 35.4 ± 8.8 4 
Tyr-c[D-Cys-Phe-D-Pen]NH2 cis-Ey 4 1.41 ± 0.44 105.1 ±7.0 56.9 ± 19.2 65.8 ± 11.8 4 
p-F-Phe-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 5 41.3 ± 2.73 105.6±4.4 n.d. n.d. 
Table 3.3 Potency and relative efficacy of cyclic tetrapeptides. Stimulation of e5S]-GTPyS bmdmg m membranes of either C6~-t (mu) or C6o 
(delta) cells, as descnbed in Methods. Data represent mean ± standard error of the mean from 3 or more separate experiments. 
1 Bridge between the second and fourth amino acids (second and fifth amino acids in DPDPE). 
S-Et-S denotes -S-CHr.CH2-S-, and S-cis-Ey-S denotes -S-CH=CH-S- 3 n.d., not determined 
2 Values represent percentage of the maximal response to 10 !lM fentanyl (mu) or BW 373,U86 (delta) 
4 Significantly different to the maximal response to 10 ~tM fentanyl (mu) or BW 373,U86 (delta), p < 0.05 (Student's t test) 
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Chapter 3: Cyclic Tetrapeptides 
3.2.1.2 GTPyS binding assays 
The e5S]-GTPyS assay provides a functional measure of the efficacy of a ligand 
interacting with a G protein-coupled receptor [Hilf et al, 1987; Traynor and Nahorski, 
1995]. Potencies and relative efficacies of the cyclic peptides for the mu opioid 
receptors are shown in Table 3.3 and compared to values for DPDPE and DAM GO. 
The mu opioid full agonist fentanyl was used as a control in the e5s)-GTPyS assay, 
and it displayed a potency of 10.3 ± 0.9 nM. The mu opioid receptor selective 
DAM GO exhibits high potency, 6.4 ± 1.5 nM, and stimulation equal to that produced 
by a maximal concentration of fentanyl. Of the cyclic tetrapeptides reported here, la, 
2a, 2b and 3 showed potencies comparable to or greater than DAM GO, and all 
showed maximal response at least equal to those of DAM GO and fentanyl. Indeed, as 
shown in Table 3.3, the peptides JOM-6, la and 3 produced sigruficantly greater 
stimulatiOn than fentanyl, suggesting very high efficacy. The analogues 2a, 2b and 4 
exlubited potencies approximately 7-, 2- and 2-fold higher than JOM-6, respectively. 
The peptides la and 5 showed 3- and 14-fold lower potencies than JOM-6, whilst 3 
exhibited very low potency (Figure 3 6) 
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Figure 3.6 Stimulation of [35S]-GTPyS bmding in C6Jl cell membranes by DAM GO 
(+), JOM-6 (11), 3 (_.)or 5 (T). Data represent percentage of the 
maximal response to 10 J.!M fentanyl, means± standard error of the 
mean from three or more separate experiments, as described in Methods. 
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At the delta receptor, maximal stimulation was defined using the non-peptide delta 
receptor full agonist BW 373,U86. DPDPE had high potency, 1.87 ± 0.52 nM and 
produced maximal stimulation equal to that seen with BW 373,U86. None of the 
pep tides tested here were able to produce stimulation of e5S]-GTPyS binding 
equivalent to that ofBW 373,U86, instead ranging from 35.4% for 3 to 73.9% for 
2b. Potencies were also more varied, and lower, than found in the same assay at the 
mu receptor, ranging from 56.9 nM (4) to 1,550 nM (2b) (Figure 3.7). All of the 
peptides but 3 exhibited greater potency and efficacy in the e5S]-GTPyS assay at the 
mu receptor than at the delta receptor, with functional selectivity ranging from 7-fold 
(la) to more than 1,000-fold (2b). 
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Stimulation of e5s]-GTPyS binding in C61l cell membranes by 
DPDPE (+), JOM-6 ~. 2b (T) or 4 (..&.).Data represent percentage 
of the maximal response to 10 J.1M BW 373,U86, means± standard 
error of the mean from three or more separate experiments, as 
described in Methods. 
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3.2.2 Dzscussion 
3.2.2.1 Radioligand binding assays 
Conformational restriction ofthe N-terminal residue was achieved in two ways. 
Firstly, when compared with the Tyr1 residue in JOM-6, L-trans-
hydroxyphenylproline {L-t-Hpp1) restricts rotation about the Ca-CJ3 but not CJ3-Cy 
bonds, thus reducing the conformational space accessible to the phenolic ring (Figure 
3.3). However, the fact that la maintained the binding profile of JOM-6 despite Ca-
CJ3 rotational restriction implies that the required conformation(s) for binding to the 
opioid receptors lies within the limited accessible conformational space of the L-t-
Hpp 1 residue. This has been seen previously for delta selective cyclic tetrapeptides 
containing the L-t-Hpp1 residue [Mosberg and Kroona, 1992]. In contrast, the D-t-
Hpp1 containing peptide lb had approximately lOO-fold reduced affinity, indicating 
that tins residue is much less compatible with the required binding conformation at 
the mu opimd receptor. Delta receptor affinity was likewise affected. 
Compared to hydroxyphenylproline, the hydroxyaminotetralin residue (Hat1) restricts 
rotation about both the Ca-CJ3 and CJ3-Cy bonds through formation of a bicyclic 
structure spiro to the a-carbon, greatly restricting the number of possible conformers 
(Figure 3.3). Delta selective D- and L-Hat analogues of the peptide JOM-13 have 
previously been shown to exhibit similar binding affinities which are reduced, but not 
abolished, when compared to the parent compound [Mosberg et al, 1994a], and this is 
also the case at the mu receptor. This ability ofboth the o- and L-Hat1 containing 
peptides 2a and 2b to bind with high affinity to the mu, and indeed the delta receptor 
is intriguing, since they can never be configured in such a way as to allow 
superimposition of the phenolic rings and primary amine groups of the L-and D-Hati 
residues, two of the essential pharmacophoric elements for binding to both the mu and 
delta receptors. However, the stereoisomeric amino acids can be configured such that 
both the primary amine and backbone amide groups, and hence the cyclic peptide 
system of both molecules, are superimposed (Figure 3.8). The cyclohexyl rings of 
both are also overlapped, although in slightly different conformations, and there is a 
difference in the position of the tyrosyl phenyl rings. These are in the same plane but 
approximately 2.5 A apart, and as a consequence there is also a difference in the 
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position of the hydroxyl groups. One model for the binding of ligands to the mu 
opioid receptor [Pogozheva et a /, 1998] proposes that the quaternary nitrogen of the 
primary amine group of the peptide forms an ion pair with the carboxylic acid group 
of the Asp 147 residue in the third transmembrane domain, whilst the oxygen atom of 
the tyramine hydroxyl group forms a hydrogen bond interaction with the hydrogen 
attached to the secondary nitrogen of the imidazole moiety of the Hi 297 residue in 
the sixth transmembrane domain. Assuming that both peptides occupy the binding site 
in broadly the same orientation, this difference in position of the tyramine phenolic 
rings of2a and 2b requ ires that the hydroxyl groups of both can form hydrogen bonds 
with His297. This is certainly feasible, as shown in Figure 3.8. 
Figure 3. Overlap of L- and o-H at isomer and their hypothetical interaction with 
the His297 residue. Nitrogens are shown in blue; oxygens, red; 
hydrogens, cyan; and carbons in either orange (L-Hat), magenta (o-
Hat) or white (His). Dashed yellow lines indicate hydrogen bonds. 
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In addition, the hydrophobic residues comprising the binding pocket, namely well 
conserved hydrophobic residues in the fifth (Ile234), sixth (Ile296 and V al300) and 
seventh (Cys321) transmembrane domains, must be flexible enough to be able to 
accommodate both L-and D-Hat in pos1tion 1 of these tetrapeptides. Thus, the 
phenolic ring of the first residue of opioid peptides may have a degree of positional 
flexibility without detriment to binding at the opioid receptors. 
The D.E-Phe3 residue as in peptide 3 introduces a double bond between the a and~ 
carbons, restricting rotation of the Co.-C~ but not C~-Cy bonds (Figure 3.5). The 
reduced affinity of 3 for the delta but not mu receptor suggests that the required 
binding conformation IS energetically unfavorable in the former case but not the latter, 
showing that the side chain of the Phe3 residue must be in the gauche conformation in 
order to bind with high affinity to the mu receptor. This also implies that bmding to 
the delta receptor requires the trans conformation. Indeed, it has previously been 
shown in a tetrapeptide series based on JOM-13 (Tyr-c[D-Cys-Phe-D-Pen]OH) that 
binding to the delta opioid receptor requires a gauche orientation of the Phe3 
sidechain, as in the D.z-Phe3 analogue [Ho et a/, 1999] and in a group of four~­
methylphenylalanine isomers [Mosberg et a/, 1994b ]. In contrast, bmding to the mu 
receptor requires a trans orientation of the Phe3 sidechain, as seen in the .6.E-Phe3 
analogue [Mosberg et al, 1996]. 
Alteration of the bridging group of JOM-6 from -S(CH2) 2S- to -S(CH) 2S-, as in 4 
{Tyr-c[D-Cys-Phe-D-Pen]NH2 (cis-Ey)) resulted in a 10-fold reduction in affiruty for 
the mu opioid receptor but no change in delta affinity. Thus, the reduction in 
flexibility of the cyclic peptide system upon introduction of a double bond affects the 
ability of the peptide to assume the binding conformation necessary at the mu, but not 
delta, receptor. However, it should be noticed that affinity for the delta receptor was 
extremely low, and this finding may not translate to higher affinity analogues. 
Substitution of a para-fluorophenylalanine residue in position I of JOM-6 gives 5, 
which exhibited parallel 40-fold reductions in affmity at the mu and delta receptors. 
However, affinity for the mu receptor was still 12.3 nM, implying that the para-
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hydroxyl substituent of tyrosine is not cntical for bmding of these peptides to the mu 
opioid receptor, but does contribute to binding. 
Peptidergic opioids related to enkephalin traditionally exhibit very low affinity for the 
kappa opioid receptor, and this is the case in this series. It is apparent that those 
peptides containing the -S(CH2) 2s- ring closure exhibit higher affinity for the kappa 
opioid receptor than those with the disulfide linkage, implying that conformational 
freedom of the peptide ring system is important m allowing for correct orientation 
within the binding pocket of the kappa opioid receptor. 
3.2.2.2 GTPyS binding assays 
The cyclic tetrapeptide JOM-6 compares favourably with fentanyl and DAMGO in 
the e5S]-GTPyS binding assay, exhibiting maximal response even greater than these 
highly efficacious mu opioid agonists. Likewise, the L-t-Hpp1 analogue la exhibited 
relative efficacy equal to that of JOM -6, whilst the remaining peptides exhibited 
maximal response equal to fentanyl, suggesting very high efficacy. Thus in the L-t-
Hpp residue the tyrosyl residue may be constrained in the correct position for optimal 
efficacy. 
The conformational restrictions imposed on the aromatic moiety of residue 1 in the 
peptides 1 a, 2a and 2b had a greater effect on relative potency in the e5s]-GTPyS 
assay than on affinity as measured by the ligand binding assay. For example, the L-
Hat analogue 2a exhibited a 7-fold higher potency than JOM-6 and the L-t-Hpp1 
peptide la showed a 3-fold lower potency in the e5S]-GTPyS assay, whilst both had 
equal affinity to JOM-6 in the ligand binding assay. The disulfide linked peptide 3 
with a ~E-Phe3 residue was 60-fold less potent at the mu opioid receptor than JOM-5, 
but still gave a full maximal response. However, 3 displayed almost equivalent 
affinity to JOM-5, suggesting that although all of the peptides tested produced 
maximal stimulation in this assay, their true efficacies at the mu opioid receptor are 
different. The L-and o-Hat isomers 2a and 2b produced a similar maximal effect and 
only 3-fold differing potency in the e5S]-GTPyS assay, confinning that the features 
within the opioid binding site have the degree of conformational freedom necessary to 
bind both L- and D-isomers of this conformationally restricted amino acid. 
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As with the mu receptor, the relationship between affinity and potency at the delta 
receptor is not parallel for all ofthe compounds in this series. For example, the 
peptide la exhibited higher potency than JOM-6 at the delta receptor, despite showing 
equivalent affinity. Also, 2a and 2b had similar affinities at the delta opioid receptor, 
but 6-fold different potencies in the [35S]-GTPyS assay. This differentiation resulted 
m the D-Hat1 containing peptide 2b becoming functionally very selective for the mu 
over delta opioid receptors, with a greater than 1,000-fold preference for mu as 
measured by the e5S]-GTPyS assay. 
In conclusion, the peptide 2b (D-Hat-c[D-Cys-Phe-D-Pen]NH2 (Et)), has high potency 
and more than I ,000-fold functional selectivity for the mu over delta opioid receptor, 
comparable to the greater than 1,500-fold selectivity of DAM GO. The structural 
requirements for binding to the mu or delta opioid receptor are not necessarily the 
same as the structural requirements for activation of the receptor. Thus, variations in 
afflruty are not matched by parallel changes in potency. This is perhaps most 
graphically illustrated by the L-trans-hydroxyphenylproline derivative 1 a and the L-
Hat analogue 2a, which displayed comparable affinities at the mu receptor but 20-fold 
different potencies. This highlights the need to measure relative efficacy in SAR 
studies. Finally, the retained high affinity of the p-F-Phe1 analogue 5 for the mu 
opioid receptor suggests a reduced role for the tyrosyl para-hydroxyl substituent 
common to opioid peptides in this series of cyclic tetrapeptides. 
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3.3 Peptides lackingpara-hydroxyl subsituents 
As shown above, the cyclic tetrapeptide containingpara-fluorophenylalanine in 
position I maintains high affinity for the mu opioid receptor despite lacking a para-
hydroxy! substituent, implicatmg a reduced role for this moiety in the binding of this 
series of cyclic tetrapeptides to the mu opioid receptor. Indeed, a recent publication 
has reported that a phenylalanine containing peptide is also capable of high affinity 
mu receptor binding [Mosberg et a/, I998]. To test this hypothesis, thirteen analogues 
of JOM-6 (Tyr-c[D-Cys-Phe-o-Pen]NH2 (Et)) in which the tyrosine in position I was 
replaced by various aromatic residues lacking a para-hydroxy! substituent, as well as 
one peptide containing cyclohexylalanine, were characterised for their ligand binding 
affinities and potencies and relative efficacies in the e5S]-GTPyS binding assay. 
Replacement of the Tyr1 residue of JOM-6 with phenylalanine gave Phe-c[o-Cys-Phe-
D-Pen]NH2 (Et) (6), whilst the same substitution in JOM-5 gave Phe-c[o-Cys-Phe-o-
Pen ]NH2 (7). Retaining the Phe1 residue of 6 and 7 but altering the ring closure to a 
cis-ethene bridge gave Phe-c[o-Cys-Phe-o-Pen]NH2 (cis-Ey) (8). The bridging groups 
used are the same as in the previous section, but are shown again here for convemence 
(Figure 3.9). 
peptides: 
Figure 3.9 
H H 
/s--s, ~ 
-s s-
~ 
-s s-
direct disulfide dithioethane cis-dithioethene 
linkage (Et) (cis-Ey) 
7 JOM-6, 6,and 9 to 18 8 
Structure ofbridging groups used to close cyclic peptide system. The 
general structure is as shown in Figure 3.2. 
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OH 
.... H 
OH 
0 
tyros1ne 
JOM-6 
phenylalanine phenylglyc1ne (L or D) 
peptides: 
homophenylalamne 
peptides : 10 
\ 
H, 
~ 
H 0 
3-(2-naphthylalanine) 
peptides : 13 
OH 
6, 7 and 8 9a and 9b 
diphenylalanine 
11 
trans-phenylprohne 
(L, shown or D) 
14a and 14b 
3-(1-naphthyl-alanine) 
12 
cts-phenylproline 
(L, shown or D) 
15a and 15b 
1 ,2,3,4-tetrahydroisoqUinollne 2-amino-2-carboxy cyclohexylalanine 
-3-carboxyhc acid -tetralin (L or D) 
peptides: 16 17aand 17b 18 
Figure 3.10 Structure of the N-tenninal residues of the cyclic tetrapeptides. The 
general structure is as shown in Figure 3.2. 
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The following modified amino acids were also incorporated in JOM-6 as substitutions 
in place ofTyr1; phenylglycine (pheny!Giy) (9), homophenylalanine (homoPhe) (10), 
diphenylalanine (dtpheny!Ala) (11), 3-(1-naphthylalanine) (1-naphthy!Ala) (12), 3-(2-
naphthylalanine) (2-naphthy!Ala) (13), trans-phenylproline 
(trans-pheny!Pro) (14), cis-phenylproline (cis-pheny!Pro) (15), 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (isoquinoline) (16), 2-amino-2-
carboxytetralin (tetralin) (17), and cyclohexylalanine (cyclohexy!Ala) (18). The 
structures of the amino acids used are shown in Figure 3.10. 
3.3.1 Results 
3.3.1.1 Radioligand bindmg assays 
The Phe1 analogue of the dithioethane containing JOM-6, 6, retained affinity at the 
mu receptor only 5-fold less than the parent peptide but exhibited 40-fold reduced 
affinity for the delta receptor, resulting in a 750-fold selectivity for mu over delta 
receptors. However, the Phe1 analogue of JOM-5 (cyclized via a disulfide bond), 7, 
had 50-fold reduced affiruty for the mu receptor and extremely low affinity for the 
delta receptor. Peptide 8, cyclized vza a czs-ethene bond, exhtbited intermediate 
affinity for the mu opioid receptor and very low affinity for the delta receptor. 
Varying the a carbon to phenyl ring chain length as in the phenylglycine analogues 
9a and 9b and the homophenylalanine peptide I 0 resulted in greatly reduced affinity 
for the mu opioid receptor, by a minimum of 50-fold. Addttional steric bulk in theN-
terminal residue was however tolerated in the 3-(1-naphthylalanine) (12) and 3-(2-
naphthylalanine) (13) analogues which displayed only 10-fold reduced affinities when 
compared to the Phe1 compound 6, but not m the diphenylalanine containing peptide 
(11) which had lOO-fold reduced affinity (Table 3.4). 
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Peptide structure Analogue Binding K. (nM) SelectiVIty 
Amino acid sequence Bridge 1 Name mu delta Ki(ll) I Ki(J.l) 
Tyr-o-Aia-Gly-N-MePhe-Giy-ol None DAMG0 2 4.13 ±0.84 2,540 ± 155 615 
Tyr-c[o-Pen-Giy-Phe-0-Pen]OH S-S DPDPE 810 ± 66 3.98±0.46 0.005 
Tyr-c[o-Cys-Phe-o-Pen]NHz S-S JOM-5 3 7.01 ±0.45 57.7±4.7 8.23 
Tyr-c[o-Cys-Phe-o-Pen]NHz S-Et-S JOM-6 3 0.29±0.04 24.8 ± 1.46 83.3 
Phe-c[o-Cys-Phe-o-Pen]NHz S-Et-S 6 1.36 ± 0.4 1,021 ± 91 750 
Phe-c[o-Cys-Phe-o-Pen]NHz S-S 7 352±37 > 10,000 >28 
Phe-c[o-Cys-Phe-o-Pen]NH2 S-cis-Ey-S 8 16.4 ±4.2 > 10,000 >610 
pheny!Giy-c[o-Cys-Phe-o-Pen]NHz S-Et-S 9a 361 ±47.2 > 10,000 >27 
pheny!Gly-c[o-Cys-Phe-o-Pen]NHz S-Et-S 9b 754±53.9 > 10,000 >13 
homoPhe-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 10 1,956 ±249 > 10,000 >5.1 
Table 3.4 Opioid receptor binding profiles of cychc tetrapepttdes. Displacement of eH]-DAMGO (0.6 nM, mu), eHJ-DPDPE (1.8 nM, 
delta), or eHJ-U69,593 (0.9 nM, kappa) from guinea pig brain homogenates. Data represent mean± standard error of the mean 
from three or more separate expenments. Data proVIded by Dr. Henry Mosberg of the School of Pharmacy, University of 
Michigan. Continued on next page. 
() 
::r 
.§ 
~ 
<> 
... 
w 
() g_ 
(')" 
;;' 
~ 
Cl> 
"' :;:l'. 0. 
Cl> 
"' 
-.l 
N 
Peptide structure Analogue Binding K, (nM) 
Amino acid sequence Bridge 1 Name mu delta 
diphenylAla-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 11 146 ± 18.8 > 10,000 
1-naphthylAla-c [D-Cys-Phe-D-Pen ]NH2 S-Et-S 12 15.5 ± 1.6 4,268 ±446 
2-naphthy1Ala-c[D-Cys-Phe-D-Pen]NH2 S-Et-S 13 12.2 ± 3.5 4,243 ±526 
trans-pheny1Pro-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 14a 1,079 ± 51.1 > 10,000 
trans-pheny1Pro-c[D-Cys-Phe-D-Pen]NH2 S-Et-S 14b 14.3 ± 2.1 1,369 ± 39.2 
cis-pheny1Pro-c[o-Cys-Phe-D-Pen]NH2 S-Et-S 15a 2,645 ±574 > 10,000 
cis-phenylPro-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 15b 11.8 ± 2.8 2,260 
1soquinoline-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 16 979 ± 117 > 10,000 
tetrahn-c[o-Cys-Phe-D-Pen]NH2 S-Et-S 17a 7.2 ± 1.0 > 10,000 
tetrahn-c[o-Cys-Phe-D-Pen]NH2 S-Et-S 17b 44.5 ± 12.5 > 10,000 
cyclohexylAla-c[D-Cys-Phe-o-PenJNH2 S-Et-S 18 32.5 ± 7.4 > 10,000 
Table 3.4 Opioid receptor binding profiles of cychc tetrapeptides. Contmued from previous page. 
1 Bridge between the second and fourth amino acids (second and fifth amino acids in DPDPE) 
S-Et-S denotes -S-CHrCH~-. and S-cis-Ey-S denotes -S-CH=CH-S-
2 Deternuned in rat brain membranes 3 Taken from Mosberg et al [1988] 
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Chapter 3: Cyclic Tetrapeptides 
The peptides 14 to 17 contain analogues of phenylalanine which are conformationally 
restricted about the Ca-CJ3 bond. The peptides 14, 15 and 17 were each prepared 
using a racemic mixture of the starting material for the N-terminal residue, resulting 
in a pair of stereoisomers in each case. One of the pair of trans-phenylproline 
stereoisomers (14b ), one of the Cls-phenylproline peptides (15b) and both of the 2-
amino-2-carboxytetralin stereoisomers (17a and 17b) exhibited high affinity for the 
mu opioid receptor (Table 3.4). The remainder, namely the phenylproline 
stereoisomers 14a and 15a and the 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
peptide (16), each showed low affinity. 
Surprisingly, when the phenylalanine of 6 is replaced by cylcohexylalanine as in the 
analogue 18 (cyclohexyiAla-c[D-Cys-Phe-o-Pen]NH2 (Et)), moderate affinity for the 
mu opioid receptor of 58.8 nM is retained. 
The majority of the peptides examined showed low affinity for the delta receptor with 
K, values> 10,000 nM, but the peptides 7, 12, 13, 14b and 15b showed affinity for the 
delta receptor of 1,000 nM to 4,500 nM. Selectivities of the individual compounds for 
the mu over delta receptors were difficult to determine in those cases where delta 
receptor affinities were greater than 10,000 nM, but in some cases were extremely 
high. For example, the tetralin analogue 17a exhibited a mu over delta opioid receptor 
selectivity of almost 1,400-fold. 
3.3.1.2 e5s]-GTPyS binding assays 
Analogues with affinity for the mu opioid receptor of< 500 nM were examined in the 
e5S]-GTPyS binding assay, in order to determine their efficacy relative to the full mu 
agonists fentanyl and DAMGO (Table 3.5 and Figures 3.11 and 3.12). All of the 
analogues tested gave ECso values between 1.0 and 4.2 times higher than their 
affinities (K,) measured in the ligand binding assay, with the exception of JOM-6, 6, 7 
and 15b, winch were approximately 9 to 13-fold higher. 
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Table 3.5 
Peptide structure Analogue mu 
Amino acid sequence Bridge 1 ECso(nM) max (%) 2 
Tyr-n-Ala-Gly-N-MePhe-Gly-ol None DAM GO 6.4 ± 1.45 108.9 ± 12.0 
Tyr-c[D-Pen-Gly-Phe-D-Pen]OH S-S DPDPE n.d. 4 nd. 4 
Tyr-c[n-Cys-Phe-n-Pen]NH2 S-S JOM-5 17.8 ± 3.56 98.2±2.3 
Tyr-c[D-Cys-Phe-D-Pen]NH2 S-Et-S JOM-6 2.93±0.83 125.8 ± 6.0 3 
Phe-c[D-Cys-Phe-n-Pen]NH2 S-Et-S 6 18.1 ±4.72 98.1 ± 2.2 
Phe-c[n-Cys-Phe-n-Pen]NH2 S-S 7 4,465 ± 210 45.1 ± 1.8 3 
Phe-[n-Cys-Phe-n-Pen]NH2 S-cis-Ey-S 8 52.0±6.19 84.5 ± 1.8 3 
diphenylAla-c[n-Cys-Phe-n-Pen]NH2 S-Et-S 9 286.5 ± 19.4 101.7 ± 1.9 
Potency and relative efficacy of cyclic tetrapeptides. StimulatiOn of e5S]-GTPyS binding in membranes of C6Jl cells, as descnbed 
m Methods. Data represent mean± standard error of the mean from 3 or more separate experiments. Only those peptides 
exhibitmg affinity at the mu opioid receptor < 500 nM were tested. Continued on next page. 
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Table 3.5 
Peptide structure Analogue 
Amino acid sequence Bridge 1 ECso(nM) 
1-naphthylAla-c[o-Cys-Phe-o-Pen]Nlh S-Et-S 12 36.9 ± 1.75 
2-naphthy1Ala-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 13 12.7 ± 2.71 
trans-pheny!Pro-c[n-Cys-Phe-D-Pen]NH2 S-Et-S 14b 44.2±3.56 
cis-phenylPro-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 15b 105.8 ±6.26 
tetralin-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 17a 23.3±2.00 
tetralin-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 17b 73.5 ± 11.3 
cyclohexylAla-c[D-Cys-Phe-n-Pen]NH2 S-Et-S 18 58.8 ± 11.1 
Potency and relative efficacy of cyclic tetrapepttdes. Continued from previOus page. 
1 Bridge between the second and fourth arruno acids (second and fifth amino ac1ds in DPDPE) 
S-Et-S denotes -S-CHrCH~-. and S-cis-Ey-S denotes -S-CH=CH-S-
2 Values represent percentage of the maximal response to 10 !.IM fentanyl 
3 Significantly different to the response to 10 !.IM fentanyl, p < 0.05 (Student's t test) 
4 n.d., not determined 
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Chapter 3: Cyclic Tetrapeptides 
Of the Phe1 peptides containing dithioethane bridging groups, only 13 was capable of 
stimulating [35S]-GTPyS binding comparable to that produced by a maximal 
concentration ofJOM-6, approximately 115% and 126% respectively of that 
produced the mu full agonist fentanyl. The remainder, namely 7, 11,12, 14b, 15b, 
17b, and including the cyclohexyiAia1 derivative 18, all exhibited maximal 
stimulation equivalent to that of fentanyl. However, the cis-d1thioethene analogue 8 
and the dithioethane analogue 17a produced maximal stimulation significantly less 
than that of fentanyl, approximately 85 % and 86 %respectively, while the disulfide 
analogue 7 produced only 45 % stimulation at 10 J!M, the highest concentration 
tested. 
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Figure 3.11 Stimulation ofe5S]-GTPyS binding in C6J.! cell membranes by 
DAM GO(+), JOM-6 (11), 6 (.A.) or 18 (T). Data represent percentage 
of the maximal response to 10 J.!M fentanyl, means± standard error of 
the mean from three or more separate experiments, as described in 
Methods. 
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Stimulation of e5S]-GTPyS binding in C6).1 cell membranes by 
DAMGO (+), 6 (11), 14b {A) or 15b (T). Data represent percentage 
of the maximal response to 10 ).IM fentanyl, means± standard error of 
the mean from three or more separate experiments, as described in 
Methods. 
3.3.2 Discussion 
The results reported here indicate that the tyrosyl hydroxyl moiety is not an absolute 
requirement for the binding of opioid peptides with agonist properties to the mu 
opioid receptor, as has previously been believed [Morgan et al, 1976; Chang et al, 
1976], since the Phe1 analogue of JOM-6, 6, showed only 4-fold and 6-fold reduced 
affinity and potency respectively when compared to the parent peptide. This modest 
decrease in affinity and potency is presumably due to the loss of the favorable 
contribution from the hydrogen bond which is believed to exist between the tyrosyl 
hydroxyl group and the His297 residue in transmembrane domain VI of the human 
mu opioid receptor [Pogozheva et al, 1998]. However, 6 did exhibit affinity and 
potency 10- and 5.8-fold higher respectively than the para-flurorophenylalanine 
analog 5, indicating that the electron withdrawing characteristics of the para-fluoro 
substituent are undesirable for mu opioid receptor binding. The ring present in the 
first residue, traditionally tyrosine, need not even be aromatic in nature since the 
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peptide 18 exhibited reasonable affinity and potency and was a full agonist in the 
e5S]GTPyS assay despite possessing a cyclohexyl nng. 
As discussed earlier, the relative position of the aromatic rings of the first and third 
residues has been shown to play a crucial role in the binding of peptides to the opimd 
receptors [Mosberg et a/, 1996; Wang et a/, 1998]. In this series, the Tyr1 containing 
and dithioethane bridged peptide JOM-6 showed approximately 25-fold higher 
affimty than the corresponding disulfide analogue JOM-5. Replacement of the Tyr1 
residue of JOM-6 with Phe1, giving 6, resulted in only a 5-fold reduction in affinity 
and potency at the mu opioid receptor. In contrast, loss of the tyrosyl hydroxyl group 
of JOM-5, giving 7, caused a drastic reduction in mu receptor binding affinity and 
potency. Thus, only when cyclization was via a dithioether bridging group as in JOM-
6, and not when cyclization was via a disulfide bond as in JOM-5, can the Tyr1 
residue be replaced with Phe1 without abolishing affinity. 
The crs-ethene containing analogue of 6 and 7 is the peptide 8, which exlubits 
intermediate affinity and potency at the mu opioid receptor. The cis-ethene bridging 
group of 8 limits flexibility of the ring compared to the ethane group of 6 since the 
double bond IS rotationally restricted, and yet still allows greater flexibility than the 
direct disulfide bond of7. Thus the pharmacophoric elements of the analogue 8 may 
be able to assume the required conformation for binding to the mu opioid receptor, 
less readily than in 6 due to unfavorable energy barriers imposed by the rotational 
restriction of the double bond, but more readily than in 7. This confirms similar 
fmdings with the related Tyr1 analogues. 
At the delta receptor, inclusion of a Phe1 residue is extremely deleterious to binding 
regardless of the nature of the bridging group joining the D-Cys2 and D-Pen2 residues. 
Both 7 and 8 exhibited affinities> 10,000 nM whilst 7 had an affinity of 1,000 nM, 
40-fold lower than its Tyr1 analogue JOM-6. Consequently, 6 showed greatly 
increased selectivity over JOM-6. Thus the tyrosyl hydroxyl group appears to be vital 
to interactions of peptides with the delta receptor. 
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In the homologous series of analogues 6, 9, and 10, optimal affinity for the mu opioid 
receptor occurs when the chain length linking the a carbon and the aromatic ring of 
the first residue is 1 carbon atom, as in phenylalanme. When the chain length is zero, 
as in phenylglycine (9a and 9b ), or two, as in homophenylalanine (1 0), affiruty is 
reduced at least 250-fold. Affinity at the delta receptor is similarly affected. Thus in 
the analogues 9 and 10, the conformational space accessible to the N-temiinal residue 
phenyl ring does not allow it to assume a favorable position relative to that of the third 
residue, and therefore to fit into an appropriate hydrophobic bindmg pocket in the 
receptor. 
Additional bulk in the aromatic portion ofthe N-terminal amino acid can be 
accommodated without adverse steric interactions. When naphthalene is incorporated 
into the first residue via attachment at either the 1 or 2 position giving increased steric 
bulk fused to the aromatic ring, as in 12 and 13, mu receptor binding is reduced only 
10-fold relative to the analogue 6. Potency at the mu opioid receptor is either 
unaffected, in 13, or reduced 2-fold, in 12. However, when the first residue 
incorporates an additional phenyl ring as a substitution at the J3 carbon, as in 11, mu 
receptor binding affinity is reduced 100-fold, indicating that the tolerance of 
additional steric bulk depends upon 1ts position. 
The czs and trans isomers ofphenylproline (14 and 15) were used to examine the 
effects of conformational restriction of the first amino acid about the Ca-CJ3 but not 
CJ3-Cy bonds. Since a racemic mixture of each phenylproline isomer was used in the 
synthesis, four analogues resulted - a pair of trans-phenylprolines (L and D) and a pair 
of czs-phenylprolines (L and D). Within each pair, one isomer showed high affinity for 
the mu opioid receptor (14b and 15b), but the complementary pair exhibited low 
affinity (14a and 15a). The difference in affinities between diastereomers was 
approximately 75-fold for the trans-phenylprolines and almost 225-fold for the cis-
phenylprolines. The high affinity analogues also exhibited moderate potencies in the 
e5S]-GTPyS assay. This suggests that the first residues ofboth high affinity analogues 
are able to assume a common arrangement of the first residue which is suitable for 
bindmg to and activation of the mu opioid receptor, but which is outside the 
conformational space accessible to the peptides which exhibit low affinity. Since the 
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L-trans and L-c1s-phenylprolines are stereoisomers, they can pever assume a 
conformation in which the primary nitrogen and aromatic rings are overlapped. 
However, the L-trans and D-c1s phenylprolines can assume a common conformation, 
as can the D-trans and L-cis isomers (Figure 3.13). Generally, in a pair of peptides 
containing the same N-terrninal amino acid in both L and D forms, the L-analogue 
exhibits far greater affinity for the mu opioid receptor. However, since in each pair of 
phenyl pro lines which can assume a common conformation there is an L- and aD-
isomer, it is impossible without further stereochemical characterization to predict 
which pair corresponds to the high affinity analogues 14b and 15b and which to the 
low affinity 14a and 15a. 
Restriction of rotation about the Ca.-CJ3 and CJ3-Cy bonds has been examined in two 
ways. Firstly, formation of a bicyclic structure via cyclization to the amide nitrogen 
gives theN-terminal 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid analogue 16, 
which had drastically reduced affinity for both the mu and delta opioid receptors. In 
contrast, formation of a bicyclic structure sp1ro to the a. carbon gives the 2-amino-2-
carboxytetralin analogue 17. Synthesis of 17 used a racemic mixture of the 2-
aminotetralin-2-carboxylic acid hydrobrornide starting material, giving rise to the two 
stereoisomers 17a and 17b. Both bound to the mu opioid receptor with affinities of 
5.6 nM and 44.5 nM respectively, although this represents almost 20-fold and !50-
fold decrease when compared to JOM-6. Potency at the mu opioid receptor as 
determined in the e5s]-GTPyS binding assay was only reduced approximately 10-fold 
and 20-fold respectively when compared to JOM-6, but the higher potency analogue 
17a showed significantly lower efficacy than either JOM-6. Binding to the delta 
opioid receptor was completely abolished. The analogue 17a is tentatively assigned as 
L-2-amino-2-carboxytetralin-n-Cys-Phe-n-PenNH2 (Et) and therefore 17b is assigned 
as D-2-amino-2-carboxytetralin-n-Cys-Phe-n-PenNH2 (Et) on the basis that the higher 
affinity analogue of a pair of stereoisomers is generally the L-isomer. As seen above, 
the related L-and n-2-arnino-2-carboxy-6-hydroxytetralin analogues exhibited 
affimty, potency and efficacy at both mu and delta opioid receptors identical to that of 
their parent compound JOM-6. In contrast, conformational restriction does cause a 
reduction of affinity in the tetralin-containing analogues 17a and 17b when compared 
to the Phe1 peptide 6. 
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Figure 3. 13 Overlap offour phenylproline isomers: L-trans (green); L-cis 
(magenta); D-lrans (white); and D-ei (orange). Nitrogen i shown in 
blue; oxygens, red; and hydrogen , cyan. 
Perhaps the most surprising find ing in thi s group of peptides was that the 
cyclohexy1Aia1 containing analogue 18 exhibited approximately lOO-fo ld reduced, 
but sti ll good, affinity for the mu opioid receptor when compared to JOM-6. Potency 
in the e5S]-GTPyS assay was decreased a lmost 20-fold, but 18 still produced max imal 
stimulation, ind icating good effi cacy. Loss of aromaticity in the first residue wou ld be 
expected to cause a complete loss of affinity and potency for both the mu and de lta 
opioid receptor, since an aromatic ring i traditionally considered a crucial 
pharmacophoric element [Casy and Parfitt, 19 6]. However, binding to the mu 
receptor was decreased but not abolished. In contrast, aromatic ity in the -terminal 
res idue was critica l for binding to the delta receptor in this series. 
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In conclusion, it has been shown here that the Tyr1 residue in this series of cyclic 
tertrapeptides can be replaced with Phe1 and a variety of related residues lacking a 
hydroxyl group without drastic reductions in affinity, potency and relative efficacy at 
the mu opioid receptor, suggesting that although the tyrosyl hydroxyl group is 
important in interactions wtth the mu opioid receptor It is not critical. Indeed, even 
aromaticity of the N-terminal residue is not vttal, since the cyclohexylalanine 
analogue 18 exhibited moderate affinity and potency and full maximal response in the 
e5s)-GTPyS assay. Consequently, it is possible that at theN-terminus any relatively 
planar, hydrophobic group may be able partially to substitute for the tyrosyl aromatic 
ring in these cyclic tetrapeptides by forming suitable van der Waals interaction(s) with 
the appropriate region of the mu receptor, although it must be located in the correct 
position relative to the a-carbon and IS subject to steric restrictions in fitting into the 
binding pocket, which comprises at least in part ofhydrophobic residues in the fifth 
(Ile234), sixth (Ile296 and V a1300) and seventh (Cys321) transmembrane domains. 
As discussed earlier, there are several peptides related to somatostatin which are high 
affinity mu opioid ligands despite lacking a para-hydroxyl substituent in the initial 
residue. However, CT AP and CTOP are antagonists, whilst the cyclic tetrapeptides 
are fully efficacious agonists, many with high potency at the mu opioid receptor. In 
transmembrane domain VII of the mu receptor there is a tryptophan residue that is 
substituted for a leucine found in the same position in the delta receptor. It has been 
proposed [Mosberg et a/, 1998] that the interaction of the tryptophan with the cyclic 
peptide system of a related series ofpeptides causes a shift in the docking mode such 
that the oxygen of the Tyr1 residue is shifted approximately 0. 7 A away from its 
proposed hydrogen bonding partner, the His of transmembrane domain VI. This 
increased separation may explain the reduced role of the tyrosine para-hydroxyl 
substituent in the binding of these peptides to the mu opioid receptor. Note however 
that the role of the hydroxyl group is not totally abolished, since JOM-6 is more 
efficacious and has higher affinity than the phenylalanine analogue 6. 
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3.4 Peptides containing nitrogen in the N-terminal residue 
As a consequence of the dtscovery that affinity for the mu opioid receptor is retamed 
in certain cyclic tetrapeptides incorporatmg initial residues lacking a para-hydroxy! 
substituent, four analogues of JOM-6 (Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et)) were 
characterised to examine the influence of aromatic rings containing nitrogen in the 
first residue. Effects were measured on ligand binding affinities, as well as potencies 
and relative efficacies in the e5s]-GTPyS binding assay. 
The following natural and modified arruno acids were incorporated in JOM-6 as 
residue 1 substitutions; 3-(3-pyridyl)alanine (pyridy!Ala) (19), histidine (His) (20), 
tryptophan (Trp) (21), and 2-amino-2-carboxyazamdan (indan) (22). These peptides 
were compared with the phenylalanine containing 6 and the tyrosine containing JOM-
6. The structures of the amino acids used are shown in Figure 3.14. 
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Figure 3.14 Structure of theN-terminal residues of the cyclic tetrapeptides. The 
general structure is as shown in Figure 3.2. 
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Peptide structure Analogue Bmding K. (nM) Selectivity 
Amino acid sequence Bridge 1 Name mu delta Ki(o) I Ki(!l) 
Tyr-D-Ala-Gly-N-MePhe-Gly-ol None DAMG0 2 4.13 ±0.84 2,540 ± 155 615 
Tyr-c[D-Pen-Gly-Phe-D-Pen]OH S-S DPDPE 810 ± 66 3.98 ±0.46 0005 
Tyr-c[D-Cys-Phe-D-Pen]NH2 S-Et-S JOM-6 3 0.29±0.04 24.8 ± 1.46 83.3 
Phe-c[n-Cys-Phe-D-Pen]NH2 S-Et-S 6 1.36 ±0 38 1,021 ± 91 750 
pyndy1Ala-c[D-Cys-Phe-D-Pen]NH2 S-Et-S 19 8.7±0.3 > 10,000 > 1,150 
His-c[n-Cys-Phe-n-Pen]NH2 S-Et-S 20 1,535 ± 246 > 10,000 >6.5 
Trp-c[n-Cys-Phe-n-Pen]NH2 S-Et-S 21 93.4± 13.3 > 10,000 > 107 
indan-c[n-Cys-Phe-n-Pen]NH2 S-Et-S 22 137 ± 20.5 > 10,000 >73.0 
Table 3.6 Opioid receptor binding profiles of cyclic tetrapeptides. Displacement of eH]-DAMGO (0.6 nM, mu), eH]-DPDPE (1.8 nM, 
delta), or eHJ-U69,593 (0.9 nM, kappa) from guinea pig brrun homogenates. Data represent mean± standard error of the mean 
from 3 or more separate experiments. Data provided by Dr. Henry Mosberg of the School of Pharmacy, University of Michigan. 
1 Bridge between the second and fourth amino acids (second and fifth arruno acids m DPDPE) 
S-Et-S denotes -S-CH:z-CH~-. and S-cis-Ey-S denotes -S-CH=CH-S-
2 Deterrruned m rat brain membranes 
3 Taken from Mosberg et al [1988] 
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3.4.1 Results 
3.4.1.1 Radioligand binding assays 
The pyridy1Ala1 analogue of the dithioethane containing JOM-6, 19, retained good 
affinity (K. 8.7 nM) at the mu opioid receptor, only 6-fold reduced compared to the 
phenylalanine1 containing peptide 6. In addition, 19 exhibited a complete loss of 
affinity for the delta receptor, resulting in an extremely high selectivity (greater than 
1,150-fold) for mu over delta opioid receptors. Replacement ofPhe1 with His\ as in 
the analogue 20, was greatly detrimental to binding at both mu and delta opioid 
receptors. Indeed, at the mu receptor affinity was reduced more than 1,000-fold 
compared to the Phe1 containing 6. The Trp1 and indan1 containing peptides 21 and 22 
showed very similar moderate to poor affinities at the mu opioid receptor, 
approximately lOO-fold reduced when compared to 6, and very poor affinities at the 
delta receptor. 
3.4.1.2 e5S]-GTPyS binding assay 
Analogues with affinity for the mu opioid receptor of< 500 nM were examined in the 
e5S]-GTPyS binding assay, in order to determine their efficacy relative to the full mu 
agonists fentanyl and DAMGO. These resnlts are shown in Table 3.7 and Figure 3.15. 
The pyridy1Ala1 analogue 19 exhibited maximal stimulation greater than fentanyl and 
comparable to JOM-6, even though potency was much lower at approximately 588 
nM. The difference between affinity and potency in 19 was very large, approximately 
67-fold. The tryptophan peptide 21 displayed maximal stimulation of 87 %, 
significantly less than seen for fentanyl, but potency only about 3-fold lower than Its 
affinity. The indan analogue 22 gave maximal stimulation equivalent to that of 
fentanyl and 4-fold reduced potency relative to its binding affinity. 
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Table3.7 
Peptide structure Analogue mu 
Amino acid sequence Bridge 1 ECso(nM) max (%) 2 
Tyr-o-Ala-Gly-N-MePhe-Gly-ol None DAM GO 6.4 ± 1.45 110.0±4.6 
Tyr-c[o-Cys-Phe-D-Pen]NH2 S-S JOM-5 17.8 ±3.56 98.2±2.3 
Tyr-c[D-Cys-Phe-o-Pen]NH2 S-Et-S JOM-6 2.93 ±0.83 125.8 ±6.0 3 
Phe-c[o-Cys-Phe-D-Pen]NH2 S-Et-S 6 18.1 ± 4.72 98.1 ±2.2 
pyridylAla-c[o-Cys-Phe-o-Pen]NH2 S-Et-S 19 587.8±34.7 117.8 ± 2.8 3 
Trp-c[o-Cys-Phe-D-Pen]NH2 S-Et-S 21 248.7 ± 22.1 86.5 ± 3.4 3 
mdan-c[o-Cys-Phe-D-Pen]NH2 S-Et-S 22 529.7±43.8 101.1 ± 0.2 
Potency and relative efficacy of cyclic tetrapepttdes. Stimulation of e5S]-GTPyS binding in membranes of C6j.1. cells, as described 
in Methods. Data represent mean± standard error of the mean from 3 or more separate experiments. Only those peptides 
exhibiting affimty at the mu opioid receptor < 500 nM were tested (see Table 3.6). 
1 Bridge between the second and fourth amino acids (second and fifth amino acids m DPDPE) 
S-Et-S denotes -S-CHrCH~-. and S-cis-Ey-S denotes -S-CH=CH-S-
2 Values represent percentage of the maximal response to 10 jl.M fentanyl 
3 Sigmficantly different to the response to 10 jl.M fentanyl, p < 0.05 (Student's t test) 
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Stimulation of e5S]-GTPyS binding in C6J.1 cells membranes by 
DAMGO (+), 6 (e), 19 ~. 21 (A) or 22 (T). Data represent 
percentage of the maximal response to I 0 J.1M fentanyl, means± 
standard error of the mean from three or more separate experiments, 
as described in Methods. 
3.4.2 Discussion 
The introduction of a nitrogen atom into the aromatic moiety of the first residue 
reduced mu opioid receptor binding in the analogues tested. However, the close 
analogue of the Phe1 peptide 6, the 3-(3-pyridyl)alanine containing 19, retained good 
affinity and exhibited good relative efficacy at the mu receptor. However, 19 
displayed much reduced potency, with a much larger difference between potency and 
2 
affinity than was seen with other cyclic tetrapeptides. The ECso/K1 ratio for 19 was 
67.5 compared to 3.9 for 22, 13.3 for 6, or 10.1 for JOM-6. This may indicate that the 
structural requirements for binding to the mu opioid receptor are different to those for 
activation. 
The indan analogue 22 displayed moderate affinity and low potency, although it 
produced a full maximal response. As with the tetralin and hydroxytetralin analogues 
discussed above, in the 2-amino-2-carboxyindan residue rotation about the Ca.-Cf3 
and Cf3-Cy bonds is restricted by the formation of a bicyclic structure spiro to the a. 
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carbon. The reduction in potency of the indan analogue 22 compared to the 
pyridylAia-containing 19 ( 15-fold) is much greater than was seen with the 
hydroxyamjnotetralin peptides 2a and 2b compared to the tyrosine containing JOM-6 
(only 1.4-fold), or the tetra I in I analogue 17a compared to the phenylalanine peptide 6 
(5.3-fo ld) . Thus the low affinity of 22 is not the result of conformational restrict ion, 
since similarly constrained peptides have retained high affinity. either is it a result of 
the inclusion of a nitrogen atom, since the pyridy1Ala1 peptide exhibited good affinity. 
Therefore it must be a result of the di fference in the nature of the ring spiro to the a.-
carbon, which is 6-membered in the case of the hydroxyaminotetralin and 
aminotetralin analogues 2a, 2b, and 17a but 5-membered in the indan peptide 22. This 
change forces the pyridyl ring of 22 to assume a different position in space than the 
phenyl ring of 17a and the pyridyl ring of 19, which can overlap, by approximately 
half the diameter of the ring (Figure 3. 16). 
Figure 3. 16 Overlap of the initial res idues of the peptides 19 (pyridylalanine, 
white), 22 (2-amino-2-carboxy-indan, orange) and 17a (2-amino-2-
carboxy-tetralin, magenta). Nitrogen is shown in blue; oxygens, red; 
and hydrogens, cyan. 
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This shift in position of the aromatic ring also moves the nitrogen of the pyridyl ring 
of22 relative to that of19, by approximately 1.7 A within the plane of the ring. It is 
unclear whether the cause of the large decrease in affinity seen with 22 is the shift in 
position of the aromatic ring, the nitrogen, or bot!!: 
The His1 analogue 20 displayed a 5,000 and 1,125-fold decrease in affinity at the mu 
opioid receptor as compared to the peptides JOM-6 and 7 respectively. The side chain 
imidazole moiety of histidine has a pKa value of 6.2, and therefore will only be 6.3 % 
protonated at physiological pH [Tandford, 1962]. Thus the decrease in affinity is 
likely to be due to either the altered size electronic characteristics of the aromatic ring, 
rather than protonation of the histidine. 
There are three possibilities that explain the moderate binding affinity and potency, 
and reduced maximal response of the tryptophan containing peptide 21 at the mu 
opioid receptor. In the first, the presence of the indole group causes the phenyl ring to 
be incorrectly positioned within the binding domain of the receptor and thus unable to 
interact efficiently with its complementary featur~: Secondly, the additional steric 
bulk of tryptophan compared to the simple phenyl ring of more traditional peptides 
may cause unfavourable steric interactions with the residues comprising the binding 
pocket. Lastly, the electronic characteristics of the tryptophan group compared to 
those of phenylalanine or tyrosine may be incompatible with mu opioid receptor 
binding. 
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In conclusion, the results reported here confirm that binding to the mu opioid receptor 
can be maintained in the absence of a tyrosyl hydroxyl substituent, and furthermore 
that the aromatic ring may be heterocyclic. However, affmity for the delta receptor is 
reduced, as a consequence of which a peptide 19 has been identified with greater than 
1,150-fold selectivity for mu over delta opioid receptors. As seen previously, changes 
in affinity are not matched by parallel changes in potency, in particular with the 
analogues 19 and 22 which exhibited EC5o/K, ratios of 67.5 and 3.9 respectively. This 
highlights the possibility that structural requirements for binding to the mu opioid 
receptor are not necessarily the same as those for activation. 
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Chapter 4: The Steroid SC17599 
4.1 Introduction 
The traditional pharmacophore for mu opioid ligands highlights the importance of the 
amine nitrogen, aromatic ring, and hydroxyl group, as discussed in the introduction 
[Casy and Parfitt, 1986]. In the previous chapter, members of a series of cyclic opioid 
tetrapeptides lackmg any suitable para-hydroxyl feature have been shown to retain 
high affinity for the mu opioid receptor. Likewise, a single example of a tetrapeptide 
lacking both the hydroxyl group and the aromatic feature was shown to exhibit good 
affinity and potency and to be a full agonist. Thus, the stress placed on the importance 
of the aromatic and hydroxyl moieties in the traditional mu opioid pharmacophore is 
called into question, at least in this series of opioid tetrapeptides. In this chapter, the 
role of the same features in the binding of non-peptide ligands to the opioid receptors 
is examined through the characterisation of a steroid, 17a-acetoxy-6-
dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3,5-dien-20-one (SC 17 599) which 
has been reported to possess opioid actions zn vzvo [Craig, 1968]. 
It has been shown that the majority of steroids are incapable of interacting with high 
affinity with the three opioid receptor subtypes, namely mu, delta and kappa. For 
example, steroids from the androgen, glucocorticoid, mineralocorticoid, and gestagen 
families were ineffective at displacing bound radio ligand from rat brain homogenates 
at concentrations up to 100 J.1M [LaBella et al, 1978; Schwarz and Pohl, 1994]. Of the 
hundreds of endogenous and synthetic steroids tested, the highest affmity for the mu 
opioid receptor has consistently been shown to belong to members of the oestrogen 
family, including diethylstJlbestrol, 17a-estradiol, and 17a-dihydroequilienine, 
presumably due to the presence of an aromatic A ring and suitably placed hydroxyl 
group. However, even these steroids only display affmities in the micromolar range, 
200-fold or more lower than that shown by morphine [LaBella et al, 1978; LaBella, 
1985; Schwarz and Pohl, 1994]. 
That steroids should exhibit such uniformly low affiruty for the opioid receptors is 
only to be expected from the pharmacophore detailed above. Although the role of the 
aromatic ring has been questioned in the previous chapter, the importance of the 
amine nitrogen is still undisputed [Casy and Parfitt, 1986]. There are no known 
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examples ofligands with high affinity for any of the three opioid receptors that lack 
such a feature, which is almost invariably tertiary in alkaloid opioid Iigands, and 
either primary or less commonly secondary in peptide Iigands. All of the steroids that 
have been investigated to date with regard to opioid receptor binding have lacked an 
amine moiety, thus explaining their low affinity. 
There is one exception; the steroid 17a.-acetoxy-6-dimethylarninomethyl-21-fluoro-3-
ethoxy-pregna-3,5-dien-20-one (SC17599) contains a tertiary nitrogen (Figure 4.1) 
and has been shown to possess marked antinociceptive potency m vivo as measured 
by the mouse writhing test, the mouse hot plate, and the rat tail flick assay [Craig, 
1968]. In addition, SC17599 markedly depressed the respiratory rate and increased 
pC02 in rabbits, and caused a reduction m gastrointestinal motility and afforded the 
Straub tail response in mice [Craig, 1968]. Potency in all cases was less than that of 
morphine. Although the respiratory depressive effects of SC17599 were reversed by 
pretreatment with nalorphine, the antinociceptive effects ofSC17599 in the rat tail 
flick assay were unaffected [Craig, 1968]. 
Figure 4.1 
0 
.... o--y--
o 
/"'-.o 
The steroid 17 a.-acetoxy-6-dimethylarninomethyl-21-fluoro-3-ethoxy-
pregna-3,5-dien-20-one, or SC17599. 
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Thus, with this one exception SC17599 presents the typical m vivo action profile of a 
mu opioid agonist. However, it is possible that SC17599 could be exerting its in vivo 
effects indirectly through stimulation of the release of endogenous peptides, rather 
than by acting directly at mu opioid receptors, although a closely related analogue of 
SC17599lacking a methyl subshtuent m the 10-position, SC22000, has been reported 
to bind to opioid receptors in mouse brain with affinity 30-fold less than morphine 
[LaBella et al, 1978]. 
IfSC17599 is indeed exerting its antinociceptive actions through a direct action at the 
mu opioid receptor, it represents a highly novel structure for a mu opioid ligand. 
Although SC17599 possesses a tertiary nitrogen, it lacks both the aromatic and 
hydroxyl features stressed by the traditional mu opioid pharmacophore (Figure 4.1) 
[Morgan et al, 1976; Casy and Parfitt, 1986; Lomize et al, 1996]. The characterisation 
of the direct interaction ofSC17599 with the mu receptor directly addresses the 
importance of these moieties. 
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4.2 Results 
4.2.1 Antznociceptive assays 
In order to confirm the finding that SC17599 exhibits antinociceptive actions zn vivo 
[Craig, 1968], the effects of the steroid in the mouse acetic acid induced writhing and 
mouse warm-water tail withdrawal procedures were evaluated (see Methods) and 
compared to those of morphine. 
In the warm water tail (50 °C} withdrawal assay, SC17599 and morphine both 
produced dose-dependent antinociception (Figure 4.2). SC17599 was approximately 
2.5-fold less potent than morphine, ED50 values of25.1 mglk:g and 10.5 mglk:g 
respectively. 
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Figure 4.2 Antinociceptive effects of cumulative doses of either morphine (•) or 
SC17599 (.A.) in the warm water (50 °C} tail withdrawal assay, as 
described in Materials and Methods. Poznts, mean± standard error of the 
mean from five separate experiments performed in duplicate. 
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In the acetic acid mduced writlnng assay, SC17599 produced a significant and dose-
dependent suppression of writhing (Figure 4.3a) with potency approximately 1 0-fold 
less than that shown by morphine (Figure 4.3b ). The actions of both ligands were 
reversed by pretreatment with both the non-selective opioid antagonist na1trexone (1.0 
mg!kg, 15 min) and the mu selective antagonist M-CAM (1.8 mg!kg, I hour). 
Figure 4.3 Antagonism of the antinociceptive effects of SC17599 (a) and morphine 
(b) by naltrexone (NTX) (l.Omg/kg, 15 min) and methocinnamox (M-
CAM) (1.8 mg!kg, 1 hour) in the mouse acetic acid induced writhing 
assay, as described in Materials and Methods. Points, mean± standard 
error of the mean from 6-12 separate experiments performed in duplicate. 
*,significantly different to control (100 %),p < 0.05 (Student's t test) 
**, significantly different to agonist treatment (10 mg!kg), p < 0.05 
(Student's t test) 
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4.2.2 Radzobgand bznding studies 
Having confirmed the na1trexone reversible antinociceptive effects of SC 17599 in 
vivo, the direct interaction of the steroid with the opioid receptors was examined. In 
membranes from SH-SY5Y cells endogenously expressing mu opioid receptors 
SC17599 dtsplaced both the selective mu agonist fH]-DAMGO and the non-selective 
antagonist fH]-diprenorphine (DPN) in a concentration-dependent manner, giving 
affinities of 16.3 and 19.1 nM respectively (Figure 4.4 and Table 4.1). 
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Figure 4.4 Displacement by SC17599 of the binding of either fH]-DPN (0.2 nM) 
(A) or fH]-DAMGO (1.0 nM) (T) from membranes ofSH-SY5Y cells 
in Tris buffer, as described in Materials and Methods. Points, mean± 
standard error of the mean from three or more separate experiments 
performed m duplicate. 
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Table4.1 
fH]- Membranes 
Ligand 
DAM GO 
DPN 
DPN 
DPN 
DPN 
DPN 
CI977 
SH-SY5Y 
SH-SY5Y 
SH-SY5Y 
C6J.1. 
C6!1 
CH Oil 
GPBH 2 
Conditions Receptor 
in Tris J.l. 
in Tris J.l. 
in Buffer A 11 
in Tris J.l. 
in Buffer A J.l. 
in Tris ll 
in Tris 1C 
K,(nM) Selectivity over : 
ll 1C 
16.3 ±2.6 143.7 120.0 
19.1 ± 3.9 122.9 102.5 
146.3 ±20.9 
62.3 ± 5.4 37.7 31.5 
434.0±43.5 
2,348 ± 509.5 0.83 
1,959 ± 927.5 1.20 
Opioid receptor binding profile ofSC17599. Displacement ofradioligands from membranes as described in Methods; eHJ-DPN 
h 'l (0.2 nM), eHJ-DAMGO (1.0 nM), e:HJ-CI977 (1.0 nM). Data represent mean± standard error of the mean from three or more 
separate experiments. Buffer composition as described in Methods; briefly, Buffer A contains 100 mM Na+ and 10 mM Mi+, 
whilst Tris buffer is Na + and Mg2+ free. 
I Morphine displaced eHJ-DPN (0.2 nM) from membranes ofC6J.1. cells in Tris buffer with aK. value of1.90 ± 0.11 nM 
2 Guinea pig brain homogenate, see Methods. 
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Similarly, SC17599 displaced eH]-diprenorplune from membranes ofC6~t cells with 
a K, of 62.3 nM, approximately 5-fold lower than that shown by morphine in the same 
cell line (K, 11.7 nM) (Figure 4.5 and Table 4.1). 
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Figure 4.5 Displacement of the binding of eH]-DPN (0.2 nM) from membranes of 
C6!! cells by morphine (•) or SC17599 (A) in Tris buffer, as described m 
Materials and Methods. Points, mean± standard error of the mean from 
three or more separate experiments performed in duplicate. 
When the buffer system was changed from Tris buffer to buffer A which contains 100 
mM Na+ and 10mM Mg2+ ions (see Methods), the dose response curve for the 
displacement of eH]-diprenorphine in C6!l cell membranes was shifted to the right in 
parallel fashion by approximately 7. 7-fold, affording a K, of 434.0 nM (Figure 4.6 and 
Table 4.1). Similarly, a 7.0-fold rightward parallel shift was seen in the displacement 
of eH]-diprenorphine in SH-SY5Y cell membranes, such that the K, m buffer A was 
146.3nM. 
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Figure 4.6 Displacement of the binding ofeH]-DPN (0.2 nM) from membranes of 
C6!1 cells by SC17599 in the absence (..6.) (Tris-HCl buffer) or presence 
(+)(buffer A) of lOO mM Na+ and 10 mM Mg2+, as described in 
Materials and Methods. Poznts, mean ± standard error of the mean from 
three or more separate experiments performed in duplicate. 
A small selection of other steroids were tested for their ability to displace eH]-
DAMGO in SH-SY5Y cell membranes. Three estrogens (17a-estradiol, 17~-estradiol 
and estrone) were chosen since this class of steroids has been reported to exhibit some 
affinity for the 11 opioid receptor [LaBella et a!, 1978; LaBella, 1985; Schwarz and 
Pohl, 1994]. In addition, three glucocorticoids (hydrocortisone, dexamethasone and 
tnamcinolone) and two pregnanolones (a-pregnanalone and ~-pregnanalone) were 
tested. Of these, only 17a-estradiol was able to bind significantly to the mu opioid 
receptor, but even at a relatively high concentration (1 0 11M) only approximately 40% 
of the bound eH]-DAMGO was displaced (Figure 4.7 and Table 4.2). In contrast, 
SC17599 displaced virtually all bound radioligand at the same concentration. 
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Figure 4.7 Displacement by I 0 J.lM of the specified steroids of bound eHJ-DAMGO 
(1.0 nM) from membranes ofSH-SY5Y cells. Assays were performed as 
described in Materials and Methods. Points, mean± standard error of the 
mean from three or more separate experiments performed in duplicate. 
*,significantly different to control (100 %),p < 0.05 (Student's t test) 
Steroid Specific bindmg Steroid Specific binding 
remaining(%) remaining(%) 
a-pregnanolone 102.5 ± 5.5 Triamcinolone 95.1 ± 3.3 
~-pregnanolone 99.6±2.9 Dexamethasone 94.8±3.7 
17a-estradiol 59.2±3.8 * Hydrocortisone 99.6 ±4.3 
17~-estradiol 94.0±2.2 
Estrone 
Tab1e4.2 
84.4± 3.6 SC17599 2.1±3.7* 
Binding of steroids to the mu opioid receptor. Displacement of eH]-
DAMGO (1.0 nM) from SH-SY5Y cell membranes by 10 J.tM each of 
the various steroids, as described in Methods. Data represent mean± 
standard error of the mean from three or more separate experiments. 
* Significantly different to 100 %, p < 0.05 (Student's t test) 
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SC17599 also produced dose-dependent displacement ofboth [3H)-diprenorphine 
from CHOo cell membranes and of the kappa selective agonist eH]-CI977 from 
guinea pig brain homogenates but with very low affinity, giving K, values of2,348 
nM and 1,950 nM respectively (Figure 4 8 and Table 4.1). 
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Figure 4.8 Displacement by SC17599 of either bound eH]-DPN (0.2 nM) from 
membranes of CHOo cells (.A) or bound eH]-CI977 (0 2 nM) from 
guinea pig brain homogenates (T). Assays were performed as descnbed 
in Materials and Methods. Points, mean± standard error of the mean 
from three or more separate experiments performed in duplicate. 
In cystosolic fractions from Sf9 cells infected with a mouse glucocorticoid receptor 
baculovirus, SC17599 was unable to displace eH]-triamcinolone (TA) at 
concentrations up to 100 J.!M. In contrast, dexamethasone exhibited a K, of 0.17 ± 
0.04 nM under the same conditions (Figure 4 9). 
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Figure 4.9 Displacement of the binding of [3H]-TA (1.0 nM) from cytosolic fractions 
ofSf9 cells by SC17599 (•) or dexamethasone (A). Assays were 
performed as described in Materials and Methods. Points, mean ± 
standard error of the mean from three or more separate experiments 
performed in duplicate. 
4.2.3 f 5S]-GTPyS bznding studies 
The shift in the affinity ofSC17599 for the mu opioid receptor induced by the 
presence of 100 mM Na+ and 10 mM M!(+ ions indicates agonist properties, which 
was confirmed by the results of e 5S]-GTPyS binding assays. In C6J1 cell membranes 
the mu selective agonist fentanyl stimulated the binding of e 5S]-GTPyS with a 
potency (EC50) of10.3 ± 0.9 nM. A high concentration of fentanyl (10 JlM) was used 
to define maximal stimulation in all e 5S]-GTPyS binding studies. In the same cell line 
morphine stimulated binding ofe5S]-GTPyS cells with potency of21.1 ± 1.8 nM and 
gave an equivalent maximal response. 
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In C6!l cell membranes SC17599 stimulated f 5S]-GTPyS binding with an ECso of 
248.3 ± 63.2 nM and maximal stimulation equivalent to that ofboth morphine and 
fentanyl (Figure 4.1 0). 
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Figure 4.10 Stimulation of f 5S]-GTPyS (1 00 pM) binding to membranes of C611 cells 
by morphine (11) or SC17599 (A). Assays were performed as described 
in Materials and Methods. Points, mean± standard error of the mean 
from three or more separate experiments performed in duplicate. 
In membranes from SH-SYSY cells SC17599 stimulated the binding of e5S]-GTPyS 
with an ECso of 282.3 ± 42.4 nM and maximal response equivalent to that of fentanyl. 
This effect was antagonized by naloxone (1 0 nM), which shifted the dose-response 
curve to the right by approximately 5.6 fold, allowing an apparent affinity for 
naloxone of2.2 nM (Figure 4.11 ). 
In wild type C6 cells, SC17599 like fentanyl, the delta agonist BW 373,U86 and the 
kappa agonist U69,593 did not significantly stimulate ess]-GTPyS binding at 
concentrations up to 10 JlM (data not shown). 
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Figure 4.11 Stimulation of e 5S]-GTPyS (1 00 pM) binding to membranes of SH-
SY5Y cells by SC17599 in the absence (.A.) and presence (T) of 
naloxone (10 nM). Assays were performed as described in Materials and 
Methods. Points, mean± standard error of the mean from three or more 
separate experiments performed in duplicate. 
L1gand 
Morphine 
Morphine 
SC17599 
SC17599 
SC17599 
Table4.3 
Membranes ECso(nM) Max1mal(%) 
C6)! 23.4±3.7 95.6±2.11 
SH-SY5Y 31.8 ± 3.2 98.7±3.5 
C6fl 248.3 ± 64.2 93.9 ±2.3 
SH-SY5Y 282.3 ±42.4 100.5 ±2.4 
SH-SY5Y (10nMNX) 1,570± 175.7 96.5 ± 5.0 
Potency and relative efficacy of SC17599 and morphine. Stimulation 
ofe5s]-GTPyS binding in membranes of either C6)! or SH-SY5Y cells, 
as described in Methods. Data represent mean ± standard error of the 
mean from 3 or more separate experiments. 
1 maximal stimulation (100 %) defined by 10 )!M fentanyl 
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4.3 Discussion 
4.3.1 Antinociceptive assays 
The results reported here confirm the previous finding that SC17599 exhibits 
antinociceptive actions in vivo [Craig, 1968]. In both the acetic acid induced writhing 
and warm water tail withdrawal procedures in mice, SC17599 was fully effective at 
dose-dependently producing antinociception. In both assays the steroid was less 
potent than morphine; 2.5-fold in the tail withdrawal assay, and 10-fold in the 
writhing assay. 
The antinociceptive effects ofSC17599 in the acetic acid induced writhing assay were 
reversed by both the non-selective opioid antagonist naltrexone and the mu selective 
antagonist M-CAM. Taken together, these data suggest that SC17599 is acting via mu 
opioid receptors to produce its antinociceptive effects. Further work on the m vivo 
actions ofSC17599 in this laboratory by Hani Houshyar has shown that pretreatment 
with naltrexone shifts the dose-response curve for both SC17599 and morphine in the 
mouse warm water tail withdrawal assay to the right in parallel fashion, whilst 
pretreatment with M-CAM completely abolishes the ability ofSC17599 to exert its 
antinociceptive effects. Additionally, both morphine and SC17599 produced the 
Straub tail response in mice [Houshyar et a/, 1999]. However, some interesting 
differences between the actions of SC17599 and morphine were highlighted in this 
study. In a mouse tail withdrawal time course assay, SC17599 was shown to possess a 
significantly longer duration of action than morphine, with full antinociceptive effects 
lasting up to 4 hours after injection, compared to 2 Y. hours for morphine. In a 
locomotor activity assay in mice, morphine significantly enhanced activity whereas 
SC17599 did not. 
Thus, SC17599 appears to be a mu opioid agonist in several in vivo preparations, 
longer acting than morphine but less potent. 
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4.3.2 Radioligand bindzng studies 
SC17599 displaced two radioligands, namely eH]-diprenorphine and eH]-DAMGO, 
from mu opioid receptors in SH-SY5Y cell membranes with almost identical 
affinities, approximately 18 nM. In C6J.l cell membranes affinity was lower by about 
3.5-fold at 62.3 nM as measured by displacement ofeH]-diprenorphine, but still 
good. In this cell line SC17599 exhibited approximately 5-fold lower affinity for the 
mu opioid receptor than morphine (K. 11.7 nM). SC17599 bound with greatly reduced 
affinity to the delta and kappa opioid receptors, exhibiting between 38- and 145-fold 
and 32- and 120-fold selectivity respectively. In cytosolic fractions from Sf9 cells, 
dexamethasone displayed high affinity for the glucocorticoid receptor (K. 0.17 ± 0.04 
nM), whereas SC17599 did not bind significantly at concentrations up to 10 J.tM 
suggesting that the steroid is not a glucocorticoid receptor ligand. 
The ability of SC17599 to bind with good affinity to the mu opioid receptor is not 
shared by any of the other steroids tested. Dexamethasone, a-pregnanolone, ~­
pregnanolone, triamcinolone, hydrocortisone, 17~-estradiol, and estrone were all 
unable to displace eH]-DAMGO from SH-SY5Y cell membranes. 17a-estradiol was 
able to bind to the mu opioid receptor, but with very low affinity. This is consistent 
with previous data [LaBella et al, 1978; LaBella, 1985; Schwarz and Pohl, 1994]. The 
ability of 17a-estradiol but not 17~-estradiol to bind to the mu opioid receptor 
indicates a role for the 17-hydroxyl group in the interaction of these steroids with the 
mu receptor. This substituent is unlikely to correspond to the para-hydroxyl group of 
traditional opioids, a role which would be more logically assigned to the hydroxyl 
substituent of the phenolic A ring of the steroid. Rather, the 17-hydroxyl moiety 
provides a favourable interaction which does not correspond to any feature in the 
more traditional opioid structures. 
Displacement of fH]-diprenorphine from the mu opioid receptor in both SH-SY5Y 
and C6J.t cell membranes was shifted to the right in the presence of 100 mM Na + and 
10 mM M!(+. The presence of sodium ions causes a shift in the equilibrium of the 
high and low affinity states of the receptor in favor of the low affinity state. The 
'Allosteric Ternary Complex Model' (Figure 1.14 in the Introduction) [De Lean et al, 
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1980] predicts that agonists bind preferentially to the high affinity state of the 
receptor, whilst antagonists exhibit no preference. Therefore, the nghtward shift in the 
concentration-effect curve for displacement of bound radioligand by SC17599 in the 
presence ofNa+ ions implies that SC17599 possesses agonist properties. 
4.3 3 f 5S]-GTPyS bznding studies 
The e5S]-GTPyS binding assay provides a functional measure of agonist occupation 
of mu opioid receptors, allowing for detennination of the potency and relative 
efficacy of a ligand [Hilf et al, 1987; Traynor and Nal10rski, 1995]. For example, 
morphine stimulates binding of e5S]-GTPyS in membranes from SH-SY5Y cells with 
high potency, only 2-fold lower than fentanyl at approximately 20 nM, and equivalent 
maximal response. 
The agorust properties of SC17599 suggested by the rightward shifts in the binding 
curves in the presence ofNa+ and MJi+ ions were confirmed by the stimulation of 
e5S]-GTPyS binding in membranes from two cell lines. In both cases ECso values 
were approximately 12-fold lower than shown by morphme, with a maximal 
stimulation equivalent to that afforded by fentanyl. In SH-SY5Y cell membranes and 
in the presence of naloxone (10 nM), the concentration-effect curve for SC17599 in 
the e5S]-GTPyS binding assay was shifted to the right by 5.6-fold. The apparent pA2 
value afforded was 8.66, indicating that SC17599 stimulates binding ofe5s]-GTPyS 
under these conditions vza mu opioid receptor activation [Traynor and Nahorski, 
1995]. This naloxone-induced rightward shift in the concentration effect curve did not 
cause any change in maximal stimulation, showing that SC17599 interacts with the 
mu opioid receptor. The low potency ofSC17599 relative to its binding affinity is due 
to the use in the e5S]-GTPyS binding assay ofbuffer A, which contains 100 mM Na+ 
and 10 mM Mlf+ ions, causing a shift in the equilibrium state of the receptor as 
described above. The K, value from the ligand binding assay (434 nM) and the ECso 
value from the e5S]-GTPyS binding assay (248 nM) were comparable when the same 
sodium containing buffer system was used. 
In C6 wild type cell membranes lacking any opioid receptors, high concentrations of 
SC17599 and the traditional op10id ligands fentanyl (mu), BW373,U86 (delta) and 
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U69,593 (kappa) were all unable to stimulate e5s]-GTPyS binding above baseline, 
indicating that the agonist activity of SC17599 described above Is indeed due to an 
op10id receptor mediated mechanism of action. 
Thus, SC17599 is a full agonist at the mu opioid receptor, and exhibits good affinity 
and potency both in vivo and zn vztro. It is selective for the mu over the delta and 
kappa receptors, and is unable to bind to the glucocorticoid receptor. The activity of 
the steroid brings into question traditional structure-activity findings for mu opioid 
agonists. It lacks both the aromatic and phenolic hydroxyl moieties which are thought 
to be crucial to the activity of morphine-like and peptide opioid ligands. SC17599 is 
extremely unusual in its ability to bind to mu opioid receptors whilst lacking any 
aromatic feature. Aside from the close analog SC22000 [LaBella et al, 1978], the only 
other reported example known to us is a set of ozonolysis products of etorphine-like 
compounds which exhibited antinociceptive actions with potencies similar to 
morphine [Bentley et al, 1969] (Figure 1.17 in the Introduction). In these molecules it 
has been suggested that the loss of the aromatic ring is compensated for by the 
contributions of features in other areas of the molecule. A simple manual overlap of 
SC17599 with morphine and etorphine based on the position of the quaternary 
nitrogen and the orientation of theW -H bond suggests that this may be possible for 
the steroid (Figure 4.11). The delocalised electron system of the A and Brings maybe 
able to substitute for the aromatic A ring of more traditional opioids. A redefined 
model of the mu opioid pharmacophore based on this simple alignment is shown in 
Figure 4.12. 
These results, taken together with those reported in the previous chapter, indicate that 
the aromatic and hydroxyl groups play a less important role in the binding ofboth 
peptides and smallligands to the mu opioid receptor than was previously believed. 
Therefore a more extensive structure-activity relationship study of mu opioid ligands 
forms the basis of the next chapter. 
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Figure 4 . 12 Manual overlap of morphine (orange), etorphine (magenta) and 
SC I 7599 (white). itrogens are shown in blue; oxygens, red; 
hydrogens, cyan and fluorine in green. 
Electron rich , 
relatively planar region 
HO 
quaternary nitrogen 
relatively planar, electron rich region 
(typically an aromatic ring) 
with optional 3-0H substituent 
R 
\ + N-H 
0 
1.4 A 
above plane of 
aromatic ring 
Figure 4. 13 Modified pharmacophore for the mu opioid receptor based on the 
manual overlap shown in Figure 4 . 12. 
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5.1 Introduction 
The use of computers to visualise the three dimensional shape of molecules, their 
properties and their interactions has only become possible through the revolutionary 
advances in processing power in the late 1980's and throughout the 1990's. As 
available computing power increases, modelling software can approach the level of 
complexity necessary to accurately reproduce experimental results. 1n pharmacology, 
this has allowed molecular modelling techniques to be applied to the generation of 
pharmacophores, the quantitative investigation of structure-activity relationships, the 
docking ofligands to receptors and even the tracking of the motion of entire receptor 
proteins in simulated membrane environments. 
5.1.1 Pharmacophore modellmg 
The number of known ligands which bind to opioid receptors is huge, and they 
represent perhaps more structural classes than ligands for any other type of receptor, 
making opioids particularly well suited to pharmacophore generation. However, 
although it is logical to assume that allligands of similar structure bind to the opi01d 
receptors in the same manner, it is possible that this is not the case for largely 
unrelated structures. For example, the sheer difference in size between the morphine-
like ligands and large endogenous peptides such as ~-endorphin suggests at the very 
least that the latter accesses parts of the bindmg pocket untouched by the former. This 
leads to the concept of 'message' and 'address', whereby certain structural features 
form a core element common to all opioid ligands (the message) whilst other 
molecule-specific moieties determine selectivity and potency (the address) 
[Porthogese et al, 1988b; Metzger et al, 1996]. Similarly, it has it has been noted that 
the structure-activity relationships in fentanyl and related analogues do not follow the 
same patterns seen in morphine-like ligands [Casy et al, 1969; Casy and Parfitt, 
1986], raising the possibility that the 4-anilino-piperidines bind to the mu opioid 
receptor in a different manner than the tyramine containing peptides and alkaloids 
[Ferguson et al, 1999]. 
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There have been many attempts to identifY opioid_pharmacophores using various sets 
of candidate ligands and different modelling packages [Cometta-Morini et al, 1991; 
Froimowitz, 1993; Huang et al, 1997]. To date, the majority have identified a single 
binding mode common to all opioid ligands, stressing the importance of the amine 
nitrogen, aromatic feature, and hydroxyl substituent. However, as seen in the previous 
chapters, these moieties may play a lesser role in the binding ofligands to the mu 
opioid receptor than has previously been believed. Therefore in this work the mu 
· opioid pharmacophore has been re-examined, using a genetic algorithm (GA) based 
package. 
5.1.2 Quantztative structure-activity relationships 
A parallel approach to pharmacophore generation is the study of quantitative 
structure-activity relationships (QSAR), whereby a 'training set' ofligand structures 
together with corresponding biological activity data is used to predict the steric and 
electronic structural characteristics which enhance or decrease that activity. This 
approach has several advantages; firstly, it can pinpoint small contributing factors 
which are missed in more gross analyses such as pharmacophore generation. 
Secondly, the accuracy of the model can be validated by generating predictions of 
activity for well characterised ligands. Finally, the predictions of a QSAR study can 
be used to identifY new candidate ligands and hence drive design and synthesis 
initiatives. 
The greatest limitations of the technique lie in the selection of the training set and the 
manner in which the chemical features of each molecule are aligned. Since all QSAR 
programs use the spatial co-ordinates of the molecules to compare and contrast their 
structures and activities, the starting alignment is crucial. Also, the inclusion of an 
excessive number of ligands from one structural class or the exclusion of more 
structurally varied compounds can bias the results by effectively 'weighting' the 
calculations. In this work a genetic algorithm has been used to align a diverse set of 
mu selective opioid ligands with no preset constraints. The package used generates 
alignments based not on individual atoms or functional groups, but by considering the 
similarities between the electrostatic, steric, and/or hydrophobic fields of the entire 
molecule. The resulting alignment has been used to quantifY the structure-activity 
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relationships of opioid ligands using COrnparitive Molecular Field Analysis 
(CoMFA). 
5.1.3 Receptor models and ligand docking 
A particularly powerful application of molecular modelling is the docking ofligands 
to receptors, which can highlight important residues in the binding pocket and the 
manner in which they interact with the ligand. The predicted docking modes can be 
validated by previously known structure-activity relationship and mutagenesis data. 
However, the construction of the receptor model is obviously critical [Bikker et a!, 
1998] and in this case extremely difficult, since high resolution experimental 
structures of the three opioid receptors are currently unavailable. When this is the 
case, 'homology modelling' techniques are often applied, whereby a model is 
generated based upon the crystal structures of closely related proteins. In the case of 
the opioid receptors this is again impossible since no G-protein coupled receptor 
structure is available at sufficiently high resolution. 
However, structural data is available for bacteriorhodopsin. This is a light sensing 
protein found in bacteria which contains seven transmembrane domains and a 
covalently bound ligand. Bacteriorhodopsin does not couple to G-proteins; instead, it 
acts as a proton pump. One common approach to modelling the opioid receptors is to 
'thread' the amino acid sequence of the target receptor onto a scaffold based on the 
structure ofbacteriorhodopsin, taken from either the original x-ray resolution 
[Henderson and Unwin, 1975] or one of the more recent images [Grigorieff et al, 
1996; Pebay-Peyroula et a!, 1997]. 
Manunalian rhodopsin is a closer analogue of G-protein coupled receptors than 
bacteriorhodopsin. It is the light sensing protein found in the retina, and although it 
consists of seven transmembrane domains and couples to a G-protein it is not truly a 
receptor since, like bacteriorhodopsin, it contains its own ligand. An alternative to the 
approach described above using bacteriorhodopsin is to construct a model by using 
the low resolution electron cryo-microscopic structure of manunalian rhodpsin 
[Schertler et al, 1993; Schertler and Hargrave, 1995; Unger et al, 1997] as a guide to 
the orientation ofhelices built de novo, using hydrophobicity data, sequence analysis 
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of many similar receptors, or dtstance constraints based upon hydrogen bonding 
networks. Both methods benefit from the large quantities of mutagenesis data 
available for G protein coupled receptors, either as initial design constraints or as 
independent validation. 
Within the transmembrane helices are invariant residues common to all G protein 
coupled receptors which serve as common anchor points when modelling these 
regions [Btkker et a/, 1998]. However, the extracellular and intracellular loops vary 
greatly between receptors, not only in terms of amino actd sequence but also in 
length. In addition, the loops have much greater conformational flexibility than the 
highly structured helices. Due to these difficulties, these regions are omitted entirely 
from many models as being inherently speculative. However, the loops are thought to 
play important roles in both ligand recognition (extracellular) and G-protein coupling 
(intracellular) and therefore more recent models have tended to include the smaller 
loops. Modelling of theN- and C-terminus portions ofreceptors, which are often very 
large, is still impossible with any degree of certainty. 
It is important to note that all receptor models provide only a single, static 
conformation, whereas these proteins are predicted to possess a great deal of 
flexibility in vzvo. Indeed, both ligand docking and receptor activation are predicted to 
involve the movement of individual residues, small regions, or whole helices. 
However, molecular dynamics of G-protein coupled receptors is unfortunately still 
unrealistic, since the starting models are of uncertain accuracy. Therefore, for the 
moment at least, static models are the norm, although there is a great deal of work 
being done in this area [Fanelli et a/, 1995; Ferguson et a/, 1999). 
Only a few attempts have been made to model the opioid receptors. One such mapped 
the mu opioid receptor onto a consensus model generated from the sequence of ahnost 
500 G-protein coupled receptors [Ferguson et a/, 1999], and examined the docking of 
a number of fentanyl analogues. Another model was derived from distance geometry 
calculations using hydrogen bonding constraints [Pogozheva et a/, 1998]. In previous 
work this latter group used the sequence of over 400 G-protein coupled receptors to 
generate a set of distance constraints between pairs of residues which participate in H-
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bonds within the a-helical bundle. Application of these distance constraints in 
iterative calculations gave a template for the position and orientation of the seven a-
helical transmembrane domains in an 'average' G-protein coupled receptor. This was 
initially used as the basis for a model of bovine rhodopsin [Pogozheva et al, 1997], 
and later extended to the opioid receptors [Pogozheva et al, 1998] and used to 
examine the docking of a selection of peptide and non-peptide opioid Iigands. 
In this study, the latter model was kindly provided by Dr. Henry Mosberg of the 
School of Pharmacy, University of Michigan and used to dock a small selection of mu 
opioid ligands, including the steroid SC17599. A ribbon representation of the model is 
shown in Figure 5.1. The first intracellular loops as well as the first, second and third 
extracellular loops are included in the model. However, the second and third 
intracellular loops are omitted, as are both terminii. The binding pocket as identified 
by the authors [Pogozheva et al, 1998] occnrs towards the extracellular surface, near 
to transmembrane domains Ill, IV, V, VI and VII, and directly underneath the large 
second extracellular loop. 
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Figure 5. 1 Ribbon representation of the mu opioid receptor model kindly 
provided by Dr. Henry Mosberg of the School ofPharmacy, U nivers ity 
of Michigan. Morphine is shown docked. 
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5.2 Results 
5.2.1 Automated pharmacophore generatzon 
The mu opioid pharmacophore has been re-examined in light of the activity of the 
unusual opioid ligands discussed in previous chapters, namely the steroid SC17599, 
the cyclic tetrapeptides and the ozonolysis product of etorphine. SC17599 does not fit 
the traditional mu opioid pharmacophore since it lacks a suitable hydroxyl substituent 
(Figure 1.18). There are very few examples of peptide (with the exception of the 
cyclic tetrapeptides discussed earlier) or morphine-like opioid ligands which lack such 
a group, although it is more common amongst less traditiona1ligands such as the 4-
arylpiperidines (e.g. fentanyl) and 3,3-diphenylpropylamines (e.g. methadone). In 
addition, SC17599 lacks an aromatic ring, and in this regard is almost unique amongst 
opioid ligands. The only other examples known to us are the cyclohexylalanine 
containing cyclic tetrapeptide 18 described in this thesis, and several ozonolysis 
products of etorphine-hke compounds (see Figure 1.17). Due to the complexity and 
flexibility of the cyclic tetrapeptides this work has focused on SC17599 and the 
ozonolysis product of etorphine. 
Automated pharmacophore generation using the GASP (Genetic Algorithm 
Superposition Program) module of SYBYL gave poor steric overlap between the 
quaternary forms of morphine and SC17599 (Figure 5.2). The overlap shown is a 
result of the emphasis placed by the algorithm on the creation of shared 'site points', 
hypothetical features with which both molecules can interact. For example, the 
nitrogen groups ofboth morphine and SC17599 can act as hydrogen bond donors 
interacting with the same theoretical feature within the receptor. Both molecules have 
several oxygen functionalities which biases the algorithm in favour of any aligrunent 
which allows the inclusion of multiple shared site points created by oxygen atoms 
acting as hydrogen acceptors. For example, the highest ranked solution to the overlap 
of morphine and SC17599 (of the four generated by GASP) contains 4 such site 
points (Figure 5.2). The positive contribution to the aligrunent score from these points 
far outweighs the negative contribution from poor steric overlap. 
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This analysis seems unrealistic in light of available structure-activ ity relationship data 
which indicates that the 6-hydroxyl and 4,5-epoxy moieties of morphine-like ligands 
are not required in order to maintain high binding affmity at the mu opioid receptor. 
For example, levorphanol is a high affinity mu opioid ligand which lacks these 
moieties [Randall and Lehmann, 1950]. It is possible to adjust the weighting factors 
ass igned to the s ite po ints and steric factors in order to calculate an overlap score. 
However, satisfactory steric overlap of morphine and SC 17599 is impossible since the 
steroid skeleton is much larger, with van der Waals volume of 439.1 compared to 
242.8, as measured by SYBYL (arbitrary units). 
Figure 5.2 Overlap of morphine (orange) and SC 17599 (magenta) generated by 
GASP. Nitrogens are shown in blue; oxygens, red; hydrogens, cyan; 
fluorine, green, and hypothetical si te points in green-blue. 
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Consequently, etorphine was included in the study since it is a high affinity opioid 
ligand with a volume comparable to that ofSC 17599 (368.0 and 439. 1 respectively). 
An initial analys is of morphine and etorphine gave excellent overlap of the morphinan 
skeletons and close spatial superposition of the quaternary nitrogen and the interacting 
site point (Figure 5.3) in all four solutions. In a ll cases GASP also identified six 
additiona l site points, interacting with the 3-hydroxyl substituents (three site points), 
the 6-hydroxyl groups (two site points), and the aromatic A rings (one point) common 
to both molecules (Figure 5.3). Comparison of etorphine and its ozonolysis product 
gave the logical result, with the morphinan skeletons and 7-substituents being closely 
overlapped (Figure 5.4). There are a total of seven site points which interact with the 
quaternary nitrogen (one), the 6-methoxy group (two), the 19-hydroxyl ubstituent 
(three). and the 3-hydroxy group of etorphine and the ketone groups of the ozonolysis 
product (two). 
Figure 5.3 Overlap of morphine (orange) and etorphine (magenta) generated by 
GASP. itrogens are shown in blue; oxygens, red; hydrogens cyan, 
and hypothetical site points in green-blue. 
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Figure 5.4 Overlap of etorphine (orange) and its ozonolys is product (magenta) 
generated by GASP. itrogens are shown in blue; oxygen , red; 
hydrogens, cyan; and hypothetical site points in green-blue. 
The four analyses ofthe alignment ofSCI7599 and etorphine were remarkably 
similar, with the top ranked solution being hown in Figure 5.5. The A, Band C rings 
of the steroid coincide with, and are broadly eo-planar with, the etorphine rings A, B 
and E. The overlap of the A ring of the ste roid with the aromat ic A ring of etorphine 
suggests that the electron rich, relatively planar feature of the former may be able to 
substitute for the aromatic moiety of the latter in binding to the mu opioid receptor. 
The quaternary nitrogen are in close prox imity and interact with the same site point. 
The steroid 0 ring and its subsituents project beyond the volume occupied by the 
morphinan skeleton, into the space corresponding to the etorph ine 7-substituents. 
Here there is another si te point which interacts with the oxygens of the 19-hydroxyl 
substituent of etorphine and the carbonyl of the 17a.-acetoxyl group of SC 17599. The 
increa ed steric bulk of etorphine allows fo r a more complete steric overlap. Only a 
few substituents lie outside the shared volume, namely the 19-methyl substituent of 
etorphine and the 1 7~-tluoroacetone and 3-ethoxy group of se 17599. 
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Figure 5.5 Overlap of Se i7599 (orange) and etorphine (magenta) generated by 
GASP. itrogen are hown in blue; oxygens, red; hydrogens, cyan; 
fluorine, green, and hypothetica l site points in green-blue. 
Finally, morphine, etorphine, the ozonolys i product of etorphine and Se 17599 were 
analy ed together (Figure 5.6). As shown, the four molecules aligned in manner 
consistent with the results of the previous three anal yses (i.e. morphine/etorphine, 
etorphine/ozonol ysis product and etorphine/SC 17599). The net result is that the 
overlap of morphine and se 17599 in thi s case is similar to that of etorphine and 
se 17599, and in complete contrast to that een when se 17599 and morphine were 
analysed alone. When all four molecules a re present there is only one identified site 
point, which interacts with the amine nitrogen in all cases. 
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The amine nitrogen has a lways been considered the single most crucial 
pharmacophoric element, and of the many thousands of opioid I igands reported to 
date, none has lacked such a feature. As the single pharrnacophoric element whose 
role has remained unchallenged to date, the amine nitrogen must be assumed to play a 
central role in any new opioid pharmacophore or docking mode. This has been 
confirmed by the results presented here, which show the amine ni trogen as the single 
pharmacophoric point common to all ofthe ligands anal ysed. The abi lity ofSC17599 
to bind with high affin ity at the mu opioid receptor can be exp la ined by its unexpected 
abi li ty to mimic more traditional mu ligands such as morphine and etorphine, despite 
lacking any aromatic ring or para-hydroxyl substituent. However, as seen in prev ious 
chapters, these moietie may play reduced roles in the binding of ligands to the mu 
opioid receptor. The A ring of SC 17599 is relatively planar and electron rich, which 
may enable it to substitute for an aromatic ring in interactions with the mu opioid 
receptor. 
Figure 5.6 Overlap ofSC 17599 (white), morphine (orange), etorphine (magenta) 
and its ozonolys is product (purple) generated by GASP. N itrogens are 
shown in blue; oxygens, red ; hydrogens, cyan; fluorine, green, and 
hypothetical s ite points in green-blue. 
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5.2.2 Strncture alignment 
As described previously, GASP performs automated pharmacophore generation using 
atomic features to align molecules. In order to confirm the results seen with GASP, a 
set of 17 opioid ligands was aligned using a genetic algorithm (FBSS) which searches 
for similarity in the steric, hydrophobic and/or electrostatic fields surrounding the 
molecules. The ligands were chosen to represent a wide range of structural classes, 
and comprised : 
etorphine, buprenorphine, diprenorphine (thebaine analogues); morphine, codeine, 
nalbuphine, naloxone (4,5-epoxymorphinans); butorphanol (a morphinan); 
pentazocine (a benzomorphan); pethidine and a-prodine (4-phenylpiperidines); 
profadol (a 3-phenylpyrrolidine); fentanyl and alfentanil (4-anilinopiperidines); 
methadone (a diphenylpropylamine); etonitazene~a bezimidazole); and SC17599 (a 
steroid). See Figure 5. 7 for structures. 
No constraints were imposed on the nature of the overlap. Either morphine or 
etorphine were used as the target, the molecule to which the remainder of the ligands 
were aligned. Five runs were performed, as follows : 
A) protonated form ofligands, full steric scoring, etorphine target 
B) tertiary form ofligands, full steric scoring, etorphine target 
C) tertiary form ofligands, full steric scoring, morphine target 
D) tertiary form ofligands, partial steric scoring, morphine target 
E) tertiary form ofligands, partial steric scoring, etorphine target 
Within each run, the following analyses were used : 
1) electrostatics + shape 
2) electrostatics + hydrophobics + shape 
3) electrostatics 
4) electrostatics+ hydrophobics 
Thus, 20 alignments and associated scores were generated, as shown in Table 5.1. 
Note that the average similarity scores for the 17 ligands in the database cannot be 
used for comparison purposes between runs, since in each case either the database 
ligands, the target molecule, or the scoring function used was different. The scores 
can however be used to compare analyses within a run where the parameters are 
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consistent and the only variable is the combination of fields used to generate the 
alignment. The spatial position of the amine nitrogens of each of the I 7 Iigands was 
used as an additional measure of the goodness of the fit, since this feature has been 
highlighted in every examination of the mu opioid'receptor pharmacophore to date. 
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Structures of mu opioid Iigands us_:.d in the QSAR study. From left to 
right : Top row; etorphine, buprenorphine, and diprenorphine; 
2"d row; morphine, codeine, nalbuphine, and naloxone; 
3rd row; butorphanol, pentazocine, pethidine, a.-prodine and profadol; 
and 4th row; fentanyl, alfentanil, methadone, and etonitazene. 
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Run 1 
A 
B 
c 
D 
E 
Table 5.1 
For the structure ofSC17599 see Figure 1.18. 
Analysis Average Average Mis-aligned Score 3 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
convergence similarity ligands 2 
3893 0.90 4 **** 
4913 0.85 6 ** 
1386 0.89 5 *** 
-2569 0.92 7 * 
6323 0.78 5 **** 
5745 0.76 6 ** 
6713 0.79 6 ** 
3595 0.77 7 * 
6570 0.79 4 **** 
6442 0.72 5 ** 
6625 0.80 4 *** 
3554 0.71 5 ** 
6431 0.87 3 **** 
5990 0.83 4 *** 
8127 0.76 5 ** 
7398 0.85 5 *** 
4988 0.89- 4 **** 
6212 0.79 5 ** 
8153 0.77 5 *** 
5742 0.77 7 * 
Scoring of the twenty FBSS alignments. 
1 For the parameters used in each run see text. 
2 A 'mis-aligned' ligand is defined as one whose amine nitrogen is not 
within 1 A of the corresponding feature in the target molecule 
3 Qualitative score based on average s1milarity score, number of 
misaligned ligands and a visual assessment. 
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The initial run using the quaternary, protonated form of each of the 171igands (run A) 
did not give good alignment in any of the four analyses due to the presence of the 
large charge on the amine nitrogen. Any alignment of a database molecule to the 
etorphine target which included close overlap of the amine nitrogens generated such a 
large positive electrostatic scoring contribution that any negative scores based on poor 
steric overlap were almost negligible in comparison. Although coincidence of the 
crucial amine nitrogens is the one remaining unequivocal criteria available for the 
generation of a new opioid pharmacophore, the alignment of other charge 
concentrations and of steric bulk is nonetheless important. Inclusion of the formal 
positive charge on the amine nitrogen inevitably biases the genetic algorithms 
calculations. 
Using a database of the same ligands in uncharged, tertiary form (run B) produced 
much more balanced alignments. Within the run, analysis B 1 scored highest on the 
qualitative scale, containing only 4 mismatches, i.e. molecules in which the amine 
nitrogens are not within 1 A of the corresponding featilre of the target. The lowest 
scoring analyses were those which did not include the steric field, namely B3 and B4. 
Inclusion of the hydophobicity field as in B2 and B4 actually decreases the 
'goodness' ofthe alignment. 
This pattern holds true for the remaining runs C, D and E also. Thus, within each run 
the same rank order of goodness of fit is seen : 
electrostatic + shape > electrostatic+ shape + hydrophobicity"' electrostatics alone> 
electrostatic + hydrophobiCity i.e. 1 > 2 "' 3 > 4 
Use of the full steric scoring (FSS) function, as in runs A, B and C, had a tendency to 
produce overlaps in which ligands with large nitrogen substituents were mis-aligned, 
for example pentazocine, nalbuphine and butorphanol. This was due to the negative 
scoring contribution generated by poor steric overlap of the large N-substituent of the 
database molecule with the much smaller N-methyl of the target (morphine or 
etorphine). The partial steric scoring (PSS) function corrects this problem by 
removing the negative scoring contribution that results from excess steric bulk of the 
database molecule compared to the target. One alternative would have been to choose 
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a target molecule with a large N-substituent with high affinity, such as buprenorphine 
or diprenorphine. However, the alignments generated by FBSS were used to create a 
quantitative-structure activity model not just of affini ty but also of potency and 
efficacy, which necess itates using a full agonist as the target. 
Figure 5.8 Alignment D I generated by FB S. Ni trogens are hown in blue; 
oxygens, red; fluorine, green and carbons in either magenta (SC 17599) 
or white (etorphine, buprenorphine, diprenorphine, morphine, codeine, 
nalbuphine, naloxone, pethidine, butorphanol, a -prodine, pentazocine 
and profadol). 
128 
Chapter 5: Molecular Modelling 
In addition to ligands with large N-substituents, some other molecules were also 
commonly mis-aligned. For example, FBSS was unable to correctly align the 4-
amhnopiperidines, namely fentanyl and alfentanil, in any of the twenty analyses. This 
might be considered as indirect evidence that these ligands may interact with the mu 
opioid receptor in a different manner than the more traditionalligands, and indeed 
there is evidence in the literature for a separate binding mode for 4-anilinopiperidines 
[Ferguson et a/, 1999]. This may also be the case for other commonly mis-aligned 
ligands, including etonitazene (incorrect in 14 of the 20 alignments), SC17599 (12), 
pentazocine (11), and methadone (10). However, in the case of the steroid the mis-
alignment may simply be the result of the extreme difference in its structure from 
those of the more traditional opioid ligands. More traditional morpine-like ligands 
were rarely mis-aligned; for example, morphine and etorphine were correct m all 20 
alignments. 
There was little difference between the four high scoring analyses Bl, Cl, Dl, and 
El, since all have between 3 and 5 mismatched ligands. There is some variance in 
which ligands these are; for example, only runs Dl and El aligned SC17599 in a 
manner similar to that found above m the automated pharmacophore generation, 
although both involved mis-alignment of fentanyl, alfentanil and methadone. Other 
commonly mis-aligned ligands within this sub-set were etonitazene and methadone. 
Selected ligands within the 17 strong data set are shown for alignments D I (Figure 
5.8) and El (Figure 5.9). 
The best alignment as measured on both quantitative and qualitative scores was El 
(Figure 5.9), which used an etorphine target with the PSS function. It is notable that in 
this alignment SCI7599 had almost exactly the same orientation relative to morphine 
and etorphine as was seen with analysis by GASP, confirming the probable role of the 
A ring of SC17599 in compensating for the lack of an aromatic ring. 
129 
Chapter 5: Molecular Modelling 
Figure 5.9 Alignment E I generated by FBSS. Nitrogens are shown in blue; 
oxygens, red· fluorine, green; and carbons in either magenta 
(SC 17599) or white ( etorphine, buprenorphine, diprenorphine, 
morphine, codeine, nalbuphine, naloxone, pethidine, butorphanol, a.-
prodine, pentazocine and profadol) . 
5.2.2 Quantitative structure-activity relationships 
The FBSS-generated alignments D I and El were used as the basis for a CoMFA 
tudy on the tructural basis of affinity, potency and efficacy. The mis-aligned ligands 
were removed from each data set, namely fentanyl , alfentanil , etonitazene and 
methadone in E l and fentanyl, alfentani l, and methadone in 01. Since the aim ofthe 
study was to validate the FBSS alignment by generating a prediction of the acti vity of 
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SC17599, the steroid was also omitted. The remaining ligands constituted two 
separate data sets for the QSAR analysis. Both Dl and El therefore included a-
prodine, buprenorphine, butorphanol, codeine, diprenorphine, etorphine, pethidine, 
morphine, nalbuphine, naloxone, pentazocine and profadol, and D 1 also included 
etonitazene. The biological activity data used included ligand binding affinity (log 
(1/K,)), potency (log (1/ECso)) and efficacy(% maximal stimulation), as shown in 
Table 5.2. 
These data were generated as described in the Methods. Affinity values of the ligands 
in this study were determined by the displacement of fH]diprenorphine from 
membranes of C6!l cells, as described in Methods. The ligands used were chosen to 
represent a variety of structural classes, and they possessed a wide range of affinities 
for the mu opioid receptor, for example 0.15 nM for the thebaine analogue 
diprenorphine, 21 nM for the benzomorphan pentazocine, approximately 400 nM for 
the 4-phenylpiperidines a-prodine and pethidine, and 3,439 nM for codeine. In all 
cases displacement curves with slope of unity indicated simple competitive binding. 
In the f 5S]GTPyS assay in membranes ofC6J.! cells, a similarly wide range of 
potencies and relative efficacies were seen. Maximal stimulations as compared to 
fentanyl ranged from 0 % for the pure antagonists diprenorphine and naloxone, to 
approximately 8-12% for the weak partial agonists pentazocme, butorphanol and 
nalbuphine, to 64 % and 71 % for the strong partial agonists pethidine and profadol 
respectively, to roughly 100% for the full agonists etorphine and SC17599. In those 
cases where maximal stimulation was less than 10% the potency (EC50) could not be 
accurately determined. In the remainmg ligands, potency ranged from 0.21 nM for the 
thebaine analogue buprenorphine to 5,476 nM for the 4-phenylpiperidine pethidine. 
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Ligand K, log (IlK,) ECso log (l/ECso) Max. Stim. 
(nM) (nM) (%)I 
Etorphine 0.22 9.66 0.31 9.51 109 
Buprenorphine 0.74 9.13 0.21 9.68 51 
Diprenorphine 0.15 9.82 NA 3 NA 3 0 
Morphine 
Codeine 
Nalbuphine 
Naloxone 
Butorphanol 
Pentazocine 
Pethidine 
a-Prodine 
Profadol 
SC17599 
Table 5.2 
11.2 7.95 28.3 7.55 83 
3,439 5.46 -2 n.d. n.d. 2 n.d. 2 
8.6 8.07 1.86 8.73 12 
6.1 8.21 NA 3 NA 3 0 
2.6 8.59 3.56 8.45 12 
21.9 7.66 NA 3 NA 3 8 
381 6.42 5,476 5.26 64 
430 6.37 n.d. 2 n.d. 2 n.d. 2 
67.5 7.17 234 6.63 71 
62.3 7.21 248 6.61 94 
Affinity (K,), potency (ECso) and relative efficacy (% maximal 
stimulation) in C6J.1 cell membranes of the mu opioid ligands used in 
the CoMFA analysis. Affinities were determined by displacement of 
eHJDPN from membranes of C6fl cells whilst potency and efficacy 
were determined by e5S]-GTPyS binding assays, as described in 
Methods. All data represent the mean of three or more individual 
experiments, and s.e.m. were within 10% of the given value in all 
cases. 
1 
maximal stimulation, defined as the percentage of the stimulation of 
e5S]-GTPyS binding by 10 J.1M fentanyl 2 not determined 
3 NA - EC5o values could not be accurately determined for those 
ligands with maximal stimulation less than 10 % 
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Generally, the thebaine analogues possessed the highest affinity and potency, whilst 
those ligands with less traditional structures typically displayed lower affinity and 
potency. The steroid SC17599 had affinity and potency approximately in the middle 
of the observed range, although it was one of only two full mu agonists in the dataset, 
the other being etorphine (fentanyl and alfentanil were removed from the dataset due 
to mis-alignment). 
A total of six analyses were performed, using affinity, potency and efficacy measures 
in conjunction with two starting alignments, namely Dl and El. Analysis of variance 
of relative efficacy (maximal stimulation) and potency (EC50) failed to produce a 
useful QSAR model with either starting alignments. In all cases, cross-validated?-
were below 0.5, and non-validated?- were less than 0.85. Predicted potencies of2.2 
nM and 1.6 nM for the steroid SC17599 were inaccurate by at least lOO-fold when 
compared to the experimentally observed value of248 nM. Similarly, relative 
efficacy predictions of 46.7% and 34.8 %, i.e. partial agonism, were ~-stant from the 
observed full agonist (94 %) value. Thus, it would appear that use of alignments 
generated by FBSS in conjunction With QSAR analysis by CoMF A is incapable of 
accurately modelling the structural basis of potency and efficacy, at least with this 
selection ofligands. Indeed, this is a problem that has thwarted opioid pharmacology 
for decades, and one that seems to be no closer to resolution at the current time. 
The model of affinity based on the Dl alignment was also inaccurate, with a predicted 
K, for SC17599 of 0.32 nM, 200-fold higher than the observed value of 62.4 nM. 
However, a QSAR model based on the FBSS alignment El was more promising. 
Initial cross-validated partial least squares (PLS) analysis gave an?- of0.514, 
implying that this initial model was able to predict slightly more than half of the 
variance in affinity for the mu opioid receptor based on the differences in the steric 
and electrostatic fields of the molecules. It should be noted that this is an inherently 
conservative estimate since the cross-validation analysis is based on the omission of 
data points. This initial analysis also indicated that the optimal number of components 
to be included in the algorithm was 3, since the inclusion of further components did 
not significantly increase the cross-validated ?-. 
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Further analysis using three components without validation gave~= 0.957, 
explaining over 95 % of the variance in affinities. The correlation between predicted 
and actual affinity for the compounds within the data-set is shown in Figure 5.1 0. 
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Figure 5.10 Actual versus predicted binding affinity for the dataset of 121igands 
used in the CoMFA study(..&.) and SC17599 (+). 
Using this model to predict the binding affinity of the steroid SC17599 gave a K, 
value of7.19 nM which compared reasonably well with the experimentally-observed 
62.3 ± 5.4 nM. The ability to predict the binding affinity of such an unusual opioid 
ligand to within 10-fold of the actual value suggests that quantitative prediction of 
affinity as a function of structure is possible. It is also a testament to the advantages of 
field-based alignment (FBSS) and QSAR (CoMF A) modules over more traditional 
atom-based methods. The predicted regions of favourable and unfavourable steric and 
electrostatic influences are shown in Figure 5.11. The fact that the structure-affinity 
model reported here predicts higher affinity for SC17599 than the observed value 
suggests that there may be unfavourable steric interactions between the steroid and the 
mu opioid receptor binding pocket which have not been recognised by the CoMF A 
algorithm. Indeed there are features ofSC17599 which project beyond the shared 
volume occupied by the remainder of the dataset ligands, for example the 3-ethoxy 
and 17-substituents. 
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Figure 5. 11 Quantitative structure analysis of a database of opioid ligands using the 
CoMF A module of SYBYL. Nitrogen are shown in blue; oxygen , 
red; fluorine, green; and carbons in ei ther white (SC 17599), magenta 
(etorphine), or orange (morphine). CoMFA regions - positive steric 
influence, green; negative steric influence, yellow; positive 
electrostatic influence, blue and negative electrostatic influence, red . 
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5.2.4 Ligand docking 
The GOLD program (Genetic Optimisation of Ligand Docking) was used in order to 
explore the docking of morphjne and SC 17599 to the mu opioid receptor model. The 
Asp 147 residue in transmembrane domain III has been implicated in forming an ionic 
interaction with the quaternary nitrogen of mu opioid ligands [Dohlman et a/, 1991]. 
Analysis of the area within a 15 A radius of the a carbon of Aspl47 revealed onl y 
two possible cavity regions (Figure 5. 12). The larger cavity extends diagona lly from 
its lower end buried approximately 12 A within the membrane close to TMD Vl, 
passes between TMDs V and VII, and has its upper end at the extracellular surface of 
the membrane where it i closest to TMD Ill and lies directly beneath the large second 
extracellular loop. The second cavity is small, and lies between the upper end of the 
fi rst cavity and TMD V. The size of the two cavities suggests that only the larger is 
likely to be involved in ligand docking. 
Figure 5. 12 Ribbon representation of the mu opioid receptor model (green) 
showing the cavity regions identified by GOLD (magenta). 
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Figure 5.13 Morphine (magenta) docked to the mu opioid receptor model. Only 
selected residues in the binding pocket are shown for clarity (white). 
itrogens are shown in blue; oxygens, red; hydrogens, cyan. The 
dashed yellow line indicates a hydrogen bond between the quaternary 
nitrogen of morphine and Aspl47 in TMD IlL 
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When docked to the mu opioid receptor, morphine lies close to TMD Ill, IV, V, VI 
and VII with the A and B rings parallel to the membrane and the C and D rings 
parallel to the helix bundle (Figure 5.13). The bulk of the morphine molecule is 
surrounded by largely hydrophobic residues, including Ile234, Trp293, lle296, V al 
300, Cys321 (ring A ofmorplune), Tyrl48, Met151, Ile322 (ring D), Lys233, Tyr 
148, Asn230, and Trp318 (ring C). The quaternary nitrogen lies close to and is 
involved in hydrogen bonding to Asp147, whilst the tyrosyl hydroxyl group lies close 
to His297. This alignment (generated using GOLD) is almost identical to that reported 
earlier using the same receptor model and performed using QUANTA, a different 
molecular modelling package [Pogozheva et al, 1998]. 
Docking ofSC17599 to the mu opioid receptor shows that the quaternary nitrogen is 
also involved in a hydrogen bond with Asp147 (Figure 5.14). The remainder of the 
molecule extends diagonally upward towards the extracellular end ofTM m, with the 
17-subsituents located at the extracellular surface of the membrane directly beneath 
the second extracellular loop. The binding pocket for SC17599 is therefore larger than 
that for morphine, and includes residues Gln124, Cys 140, Lysl41, Ile144, Ala206, 
Thr207, Gln212, lle 215, Gln229. 
Both morphine and the steroid lie almost entirely within the larger cavity region 
identified by GOLD (Figure 5.15). The only projecting groups are the D ring and 6-
hydroxyl group of morphine, and the 17a.-acetoxy and 6-dimethylamino substituents 
ofSC17599. Therefore the quaternary nitrogens of both molecules lie outside the 
identified binding cavity in order to form the hydrogen bond to Asp147. 
Comparison of the docked alignments of the two molecules shows only partial steric 
overlap. In the analysis of morphine and SC17599 by GASP and FBSS the A ring of 
the steroid was broadly eo-planar and overlapped with the A ring of morphine. Here, 
the A ring ofSC17599 is shifted approximately 3.25 A within the plane ofboth 
ligands such that it now overlaps the Bring of morphine. This shift of the relative 
positions of the two molecules when compared to earlier alignments by GASP and 
FBSS may explain the results of the CoMF A analysis. The binding affinity of 
SC17599 as predicted by CoMF A based on an alignment by FBSS was 1 0-fold too 
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high, possibly as a resull of a more complete and advantageous overlap of the A ring 
of the two molecule than is seen here. Otherwise the alignments were very similar. 
Figure 5. 14 SC17599 (orange) docked to the mu opioid receptor model. Only 
selected residues in the binding pocket are shown for clarity (white). 
itrogens are shown in blue; oxygens, red; hydrogen , cyan. The 
dashed yellow line indicates a hydrogen bond between the quaternary 
nitrogen ofSCJ7599 and Aspl47 in TMD Ill. 
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Figure 5. 15 Comparison of the docked conformations of SC 17599 (white) and 
morphine (orange). The mu opioid receptor model is represented in 
ribbon fom1 (green). The binding cavities identified by GOLD are 
shown in magenta. Nitrogen are shown in blue; oxygens, red; 
hydrogen , cyan. 
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In conclusion, the ability ofSC17599 to bind to the mu opioid receptor despite its 
unusual structure has been explained by the results of two structural analyses and one 
docking study. In a pharmacophore analysis by GASP, SC17599 gave excellent 
overlap With morphine, etorphine and its ozonolysis product. The lack of an aromatic 
ring in both the steroid and the ozonolysis product are compensated for by relatively 
planar areas of electron density. The GASP module compares atomic features, 
whereas FBSS compares various combinations of whole molecule fields. Use of 
FBSS analysis with no imposed constraints was successful in reproducing the 
alignment seen in GASP with a much larger number of opioid ligands of various 
structural classes. A quantitative structure-activity relationship study based on the 
FBSS alignment was able to predict the ligand binding affinity ofSC17599 to within 
10-fold, but was unable to accurately predict either potency or efficacy. Finally, 
docking of morphine to a model of the mu opioid receptor reproduced the previously 
reported binding mode. SC17599 was also successfully docked to the model. Both 
molecules fit within an identified binding cavity located towards the extracellular 
surface of the membrane and between helices Ill, N, V, VI and VII. Comparison of 
the binding modes of morphine and the steroid was in close but not complete 
agreement with the alignments produced earlier, possibly explaining the 10-fold error 
in the affinity estimate produced by CoMF A for SC17599. 
The tentative pharmacophore shown in Figure 4.13 has been broadly validated by the 
results presented here. In all cases show the critical amine nitrogens. were very closely 
overlapped, whilst the aromatic A rings or appropriate relatively planar and electron 
rich region are also close, although there may be some freedom in the exact position 
of this last moiety. The para-hydroxyl substituent has again been shown to play a 
reduced but not abolished role in the binding ofligands to the mu opioid receptor. 
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Chapter 6: Overview 
One of the fundamental questions in pharmacology is the nature of the recognition 
process that allows a receptor to recognise and bind its ligands. In opioid 
pharmacology a pharmacophore detailing the elements crucial to recognition by the 
mu opioid receptor has been available and has remained essentially unchanged for 
many years. In the work presented here, this traditional mu opioid pharmacophore has 
been challenged, with important implications for the future design of mu opioid 
ligands. 
Initially, a series of cyclic tetrapeptides related to DPDPE were investigated, several 
of which exhibited exceptional selectivity for the mu over the delta and kappa opioid 
receptors in either radio ligand or e5S]GTPyS binding assays. Moreover, 
characterisation of peptides containing conformationally restricted amino acids has 
indirectly revealed details of the mu opioid receptor binding pocket. Importantly, it 
has been shown that high affinity for the mu opioid receptor can be maintained 
despite the loss of the tyrosyl hydroxyl group, in direct contradiction of the traditional 
pharmacophore. However, it must be emphasised that the role of this substituent is 
only reduced, not abolished. Even more surprisingly, affinity for the mu opioid 
receptor is maintained despite a loss of aromaticity in the initial residue. Again, this is 
traditionally considered to be a critical pharmacophoric element, which is shown here 
to play a reduced, but not abolished, role. 
Thus, two of the critical features of the traditional mu opioid pharmacophore are 
shown to play reduced roles in the binding of certain cyclic tetrapeptides to the mu 
opioid receptor. Characterisation of the recognition by the opioid receptors of the 
steroid SC17599 (17a-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-
3,5-dien-20-one) has shown this to also be the case in at least one non-peptide ligand. 
The ability of SC17599 to bind with high affinity and selectivity to mu opioid 
receptors, upon which it acts as an agonist with good potency and high relative 
efficacy, confirms that in certain mu ligands the para-hydroxyl and aromatic 
functionalities play a reduced role. 
Automated pharmacophore generation using a small selection of mu opioid ligands 
' has revealed that the traditional pharmacophore is largely correct, but must be 
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modified to account for the activity of the unusual opioid Iigands detailed here. The 
spatial position and lone pair orientation of the amine nitrogen are indeed as critical as 
has previously been believed. Although an aromatic ring is not strictly necessary, it 
can only be replaced by relatively planar, electron rich moieties and some loss of 
affinity is still involved. The presence of a para-hydroxyl group promotes affinity, but 
is not critical. These results have been confirmed by field-based similarity searches in 
a larger set of mu opioid ligands, which produced very similar alignments and 
allowed accurate prediction of the binding affinity of SC17599. Data presented here 
suggest that whilst the steroid may bind to the mu opioid receptor in a manner similar 
to morphine, fentanyl does not. 
However, accurate prediction of the potency or efficacy ofSC17599 was not possible 
with this model. In the study of cyclic tetrapeptides shifts in affinity were not always 
matched by parallel shifts in potency; that is, the EC5o/K, ratio differed greatly within 
the series. Thus, the structural requirements for high affinity at the mu opioid receptor 
are not necessarily the same as for potency. This provides some evidence that affinity 
and potency are separable characteristics from a ligand design stand-point, with 
different structure-activity relationships. 
SC17599 was docked successfully to a model of the mu opioid receptor, and 
comparison of the binding modes of morphine and SC17599 was largely compatible 
with the previous alignments produced by either atomic- or field-based analysis. Both 
molecules docked inside a binding pocket located towards the extracellular surface of 
the membrane and in contact with transmembrane domains Ill, IV, V, VI and VII. 
The lack of an aromatic ring in the steroid and other mu opioid ligands, including the 
ozonolysis product of etorphine and certain cyclic tetrapeptides reported here, can be 
compensated for by the presence of a relatively planar, electron rich region in the 
appropriate position. Thus, the work reported here represents a significant advance 
upon the previous understanding of structure-activity relationships in mu opioid 
ligands, both peptide and alkaloid. Future ligand design initiatives will be able to 
further characterise the nature of the structural requirements for binding to the mu 
opioid receptor, although understanding the structural basis of efficacy is still 
problematic. 
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